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Abstract 
 
Streptococcus agalactiae is a common opportunistic pathogen, which, when transmitted 
to the immunocompromised, elderly or newborns, can cause complications such as sepsis, 
pneumonia, meningitis and can also be fatal. In screening programmes expectant mothers 
are typically sampled at 35-37 weeks gestation to ensure microbial culture results are 
available prior to labour. As levels of S. agalactiae rapidly fluctuate, premature testing 
results in antibiotic prescription being informed by outdated information. This project aimed 
to develop tools for use in a sensitive, specific, point-of-care diagnostic test able to detect 
all strains of S. agalactiae. Three detection strategies were pursued based on peptide 
aptamers, antibodies and DNA amplification. 
 
A bioluminescent protein, aequorin, was selected for use as a peptide aptamer scaffold in 
order to link epitope detection to reporter signal. Peptide insertion into aequorin eliminated 
expression of soluble protein, and therefore was deemed unsuitable for aptamer library 
construction. 
 
A novel computer programme, IDRIS, identified peptides conserved throughout all 
currently sequenced S. agalactiae strains, which are also unique to the species. Through 
further bioinformatic analysis, three peptide sequences from SAG1474 protein were 
selected for in-house murine monoclonal antibody production. Antibodies targeted against 
one peptide (CVNLEENSQV) exhibited sensitivity to all S. agalactiae serotypes. 
Antibodies exhibited species specificity when tested against Streptococcus pyogenes; 
future work will focus on extending specificity studies, including analysis of bacteria 
present in the vaginal flora. 
 
Recombinase polymerase amplification is a rapid, isothermal DNA amplification technique 
that may enable inexpensive point-of-care testing. Target-specific primers with single 
stranded overhang sequences allow amplified product to hybridise to a complementary 
capture probe and reporter-tagged detection probe. The plate-based system can detect 
3.8 x 104 copies of DNA and is able to specifically detect all S. agalactiae serotypes over 
S. pyogenes DNA. The test will be converted into a lateral flow assay in the future. 
ii 
 
Declaration  
 
I hereby declare that this thesis has been composed by myself and has not been 
submitted in any previous application for a degree. The work presented has been 
performed by myself, unless otherwise stated. All sources of information have been 
appropriately acknowledged by means of reference. 
  
iii 
 
Acknowledgements  
I am grateful to the EPSRC for funding this work. 
  
I would like to thank Neil Keegan, Chris Johnson and Calum McNeil for their continual 
support throughout the project. Their knowledge, help, ideas, guidance and 
encouragement have pushed me to become a better scientist. 
 
Thanks to Julia Spoors and Rob Bolt for countless reasons, most significantly in all 
their work in antibody development. Thanks to Beth Lawry for her advice in every 
aspect of the project. I’d like to thank Keith Flanagan, Elisa Anastasi and Anil Wipat for 
their help using the IDRIS system, Helen Glenwright and Wendy Smith for their support 
whilst working in the Centre for Bacterial Cell Biology and Nicholas Jakubovics for 
kindly donating S. pyogenes strains. 
 
Special thanks to Cara, Emily, Gina, Katie, Suzie, Carl, Phil, Chen and all those 
mentioned above for their friendship; it has made the past three years wonderful. 
iv 
 
Contents 
Chapter 1 Streptococcus agalactiae: Bacteria, Disease and Diagnostics .................. 1 
1.1 Streptococcus agalactiae bacterium .................................................................. 1 
1.1.1 Streptococcus agalactiae ............................................................................ 1 
1.1.2 Serotypes .................................................................................................... 3 
1.1.3 Related bacteria belonging to the genus streptococcus .............................. 3 
1.1.4 Virulence factors.......................................................................................... 6 
1.2 Group B streptococcal disease .......................................................................... 8 
1.2.1 Early onset disease ..................................................................................... 8 
1.2.2 Late onset disease .................................................................................... 10 
1.2.3 Immunocompromised ................................................................................ 11 
1.2.4 Elderly ....................................................................................................... 12 
1.2.5 Worldwide disease .................................................................................... 13 
1.3 Treating and preventing GBS disease ............................................................. 13 
1.3.1 GBS vaccine development ........................................................................ 13 
1.3.2 Antibiotic treatment .................................................................................... 14 
1.3.3 Maternal screening/risk- based treatment ................................................. 16 
1.4 Diagnosis of S. agalactiae infection ................................................................. 18 
1.4.1 Current GBS diagnostic tests .................................................................... 18 
1.4.2 Rapid test .................................................................................................. 24 
1.5 Project aims ..................................................................................................... 26 
Chapter 2 Methods ................................................................................................... 28 
2.1 Materials .......................................................................................................... 28 
2.2 General techniques .......................................................................................... 29 
2.2.1 Bacterial cell growth .................................................................................. 29 
2.2.2 Bacterial cell storage ................................................................................. 30 
2.2.3 SDS-PAGE ................................................................................................ 30 
v 
 
2.2.4 Western blotting ........................................................................................ 31 
2.2.5 Indirect enzyme linked immunosorbent assay (ELISA) ............................. 32 
2.2.6 Protein concentration determination – BCA assay .................................... 33 
2.2.7 Protein concentration determination – spectrophotometry ........................ 33 
2.2.8 RNA extraction .......................................................................................... 33 
2.2.9 cDNA synthesis ......................................................................................... 33 
2.2.10 DNA extraction ........................................................................................ 34 
2.2.11 Polymerase chain reaction ...................................................................... 34 
2.2.12 Agarose gel ............................................................................................. 34 
2.2.13 Nucleic acid concentration determination - spectrophotometry ............... 35 
2.2.14 DNA purification ...................................................................................... 35 
2.2.15 Statistics .................................................................................................. 35 
2.3 Computing ....................................................................................................... 36 
2.3.1 IDRIS ......................................................................................................... 36 
2.3.2 PSORTb .................................................................................................... 37 
2.3.3 SignalP ...................................................................................................... 37 
2.3.4 LipoP ......................................................................................................... 37 
2.3.5 TMHMM .................................................................................................... 38 
2.3.6 I-TASSER .................................................................................................. 38 
2.3.7 PSIPRED .................................................................................................. 38 
2.3.8 Prodepth .................................................................................................... 39 
2.3.9 Bcepred ..................................................................................................... 39 
2.3.10 Microarray data analysis ......................................................................... 39 
2.3.11 Protein BLAST (Basic local alignment tool) search ................................. 40 
2.3.12 DNA alignment ........................................................................................ 40 
2.3.13 Primer design: PCR and RPA ................................................................. 40 
2.3.14 Band densitometry .................................................................................. 41 
vi 
 
2.4 Recombinant protein expression and purification ............................................ 41 
2.4.1 Overview ................................................................................................... 41 
2.4.2 Competent cells......................................................................................... 41 
2.4.3 Transformation .......................................................................................... 42 
2.4.4 Induction growth tests ............................................................................... 42 
2.4.5 Cell lysis .................................................................................................... 43 
2.4.6 Periplasmic extraction ............................................................................... 43 
2.4.7 Protease cleavage..................................................................................... 43 
2.4.8 Protein purification - chromatography ........................................................ 44 
2.4.9 Nickel-affinity chromatography .................................................................. 44 
2.4.10 GST-affinity chromatography .................................................................. 44 
2.4.11 Ion exchange chromatography ................................................................ 45 
2.4.12 Size exclusion chromatography .............................................................. 45 
2.4.13 Circular dichroism .................................................................................... 46 
2.4.14 Liquid chromatography mass spectrometry ............................................. 46 
2.5 Antibody production ......................................................................................... 47 
2.5.1 Overview ................................................................................................... 47 
2.5.2 Peptide - carrier protein conjugation .......................................................... 47 
2.5.3 Ellman’s test .............................................................................................. 47 
2.5.4 Mouse immunisation ................................................................................. 48 
2.5.5 Cell culture ................................................................................................ 49 
2.5.6 Viable cell count ........................................................................................ 49 
2.5.7 Freezing cells ............................................................................................ 49 
2.5.8 Thawing frozen cells .................................................................................. 50 
2.5.9 Fusion ....................................................................................................... 50 
2.5.10 Cloning .................................................................................................... 50 
2.5.11 Antibody purification ................................................................................ 51 
vii 
 
2.6 Recombinase Polymerase Amplification (RPA) ............................................... 51 
2.6.1 RPA assay ................................................................................................ 51 
2.6.2 Enzyme linked oligonucleotide assay ........................................................ 52 
Chapter 3 Protein target selection ............................................................................ 53 
3.1 Introduction ...................................................................................................... 53 
3.2 GBS specific peptides ...................................................................................... 53 
3.3 Protein localisation ........................................................................................... 58 
3.3.1 PSORTb .................................................................................................... 58 
3.3.2 SignalP ...................................................................................................... 59 
3.3.3 LipoP ......................................................................................................... 59 
3.3.4 TMHMM .................................................................................................... 60 
3.3.5 Surface exposure ...................................................................................... 61 
3.3.6 Protein localisation consensus .................................................................. 61 
3.4 Protein selection .............................................................................................. 62 
3.4.1 Experimental analysis of protein expression in 10 serotypes .................... 62 
3.4.2 Microarray data from previous literature .................................................... 64 
3.4.2.1 pH ........................................................................................................ 64 
3.4.2.2 Temperature ........................................................................................ 65 
3.4.2.3 Oxygen concentration .......................................................................... 66 
3.4.3 Structure prediction ................................................................................... 67 
3.4.4 Evaluation of expression and structural modelling data ............................ 68 
3.5 Token selection ................................................................................................ 70 
3.5.1 Unique peptides ........................................................................................ 70 
3.5.2 Polarity ...................................................................................................... 71 
3.5.3 Secondary structure .................................................................................. 71 
3.5.4 Surface exposure ...................................................................................... 72 
3.5.5 Combination of predictive tools ................................................................. 72 
viii 
 
3.5.6 Conclusion ................................................................................................ 75 
Chapter 4 Antibody generation against S. agalactiae biomarkers ............................ 76 
4.1 Introduction ...................................................................................................... 76 
4.1.1 Immunoassays in diagnostic tests ............................................................. 76 
4.1.2 In vivo antibody production ........................................................................ 76 
4.2 Antibody production ......................................................................................... 76 
4.3 Antibody characterisation against linear peptide .............................................. 84 
4.4 Production of recombinant SAG1474............................................................... 86 
4.4.1 Design of SAG1474 construct ................................................................... 86 
4.4.2 Induction of SAG1474 ............................................................................... 88 
4.4.3 Design of a SAG1474 fusion protein ......................................................... 92 
4.4.4 Induction of SAG1474-MBP ...................................................................... 94 
4.4.5 SAG1474-MBP purification ....................................................................... 97 
4.4.6 Structural characterisation of SAG1474-MBP ......................................... 101 
4.4.6.1 Far UV circular dichroism .................................................................. 101 
4.4.6.2 Near UV circular dichroism ................................................................ 102 
4.4.6.3 Melting temperature circular dichroism .............................................. 103 
4.5 Antibody characterisation against folded protein ........................................... 104 
4.6 Antibody characterisation against bacterial cells ........................................... 107 
4.6.1 Comparison of antibodies ........................................................................ 109 
4.6.2 Antibody characterisation against S. agalactiae serotypes ..................... 110 
4.7 Conclusions and future work .......................................................................... 112 
Chapter 5 RPA DNA amplification .......................................................................... 114 
5.1 Introduction .................................................................................................... 114 
5.1.1 DNA amplification in diagnostic tests ...................................................... 114 
5.1.2 Isothermal DNA amplification .................................................................. 115 
5.1.3 Recombinase polymerase amplification .................................................. 116 
ix 
 
5.1.4 Hybridisation-based detection of RPA amplicon ..................................... 119 
5.2 Recombinase polymerase amplification for the detection of S. agalactiae .... 121 
5.2.1 Analysis of primers .................................................................................. 122 
5.2.2 Tailed-primer DNA amplification .............................................................. 130 
5.2.3 Strain sensitivity and specificity ............................................................... 133 
5.3 Conclusions and future work .......................................................................... 136 
Chapter 6 Peptide aptamer .................................................................................... 137 
6.1 Introduction .................................................................................................... 137 
6.2 Aptamers ....................................................................................................... 137 
6.2.1 Peptide aptamers .................................................................................... 137 
6.2.2 Nucleic acid aptamers ............................................................................. 138 
6.2.3 Designing a scaffold ................................................................................ 139 
6.2.3.1 Peptide aptamer constraint ................................................................ 139 
6.2.3.2 Functional or non-functional scaffolds ............................................... 140 
6.2.4 Aptamer scaffolds as diagnostic tools ..................................................... 141 
6.2.4.1 Surface adsorption ............................................................................ 141 
6.2.4.2 Specificity .......................................................................................... 141 
6.2.4.3 Compatible with label-free detection techniques ............................... 142 
6.2.4.4 The need for additional antigen detection molecules in diagnostics .. 142 
6.2.5 Production and screening of a peptide aptamer library ........................... 142 
6.3 Design of a reporter-based peptide aptamer ................................................. 145 
6.3.1 Selection of reporter scaffold ................................................................... 145 
6.3.2 Aequorin .................................................................................................. 145 
6.4 Sequence design of peptide aptamer scaffold ............................................... 148 
6.4.1 Site of aptamer insertion ......................................................................... 148 
6.4.2 Sequence optimisation ............................................................................ 151 
6.5 Induction of aequorin WT* ............................................................................. 154 
x 
 
6.6 Purification of aequorin WT* .......................................................................... 158 
6.7 Induction of aequorin FLAG ........................................................................... 160 
6.8 Conclusion ..................................................................................................... 162 
Chapter 7 Discussion ............................................................................................. 163 
7.1 Recent research in GBS diagnostics ............................................................. 163 
7.1.1 Optimisation of PCR ................................................................................ 163 
7.1.2 Other methods of detection ..................................................................... 163 
7.1.3 Alternative detection strategies ............................................................... 164 
7.1.4 Sample preparation ................................................................................. 164 
7.1.5 Antibiotic susceptibility ............................................................................ 165 
7.1.6 Identification of multiple pathogens ......................................................... 165 
7.1.7 Comparison to current work .................................................................... 165 
7.2 IDRIS as a useful tool .................................................................................... 166 
7.3 ASSURED Diagnostics .................................................................................. 166 
7.3.1 Antibody for application to GBS diagnostics ............................................ 167 
7.3.2 RPA for application to GBS diagnostics .................................................. 167 
7.3.3 Aequorin as a peptide aptamer scaffold for application to GBS diagnostics
 ......................................................................................................................... 168 
7.4 Conclusion ..................................................................................................... 168 
Chapter 8 References ............................................................................................ 170 
 
xi 
 
List of figures 
Figure 1.1 Schematic of gram positive bacteria........................................................... 2 
Figure 1.2 Phylogenetic tree of streptococcal species ................................................ 5 
Figure 1.3 Worldwide approach to early onset GBS prevention ................................ 17 
Figure 3.1 IDRIS selection of unique and conserved peptides .................................. 55 
Figure 3.2 Transcript expression in 10 serotypes of GBS ......................................... 63 
Figure 3.3 The effect of pH on gene transcript expression ........................................ 65 
Figure 3.4 The effect of temperature on gene transcript expression ......................... 66 
Figure 3.5 Structure of three candidate proteins with IDRIS tokens mapped on ....... 68 
Figure 3.6 Structure of SAG1474 with selected peptides mapped on ....................... 75 
Figure 4.1 Binding of murine test bleeds to peptide .................................................. 79 
Figure 4.2 Mechanism of HAT selection .................................................................... 81 
Figure 4.3 Peptide affinity screening programme of hybridoma fusions to cloned cells
 .................................................................................................................................. 83 
Figure 4.4 Antibody naming convention .................................................................... 84 
Figure 4.5 Antibody binding to peptide ...................................................................... 85 
Figure 4.6 Recombinant SAG1474 construct DNA sequence ................................... 87 
Figure 4.7 Recombinant SAG1474 protein ................................................................ 88 
Figure 4.8 Induction of SAG1474: western blots ....................................................... 89 
Figure 4.9 Growth curve following induction of SAG1474 with IPTG ......................... 91 
Figure 4.10 Recombinant SAG1474-MBP construct DNA sequence ........................ 93 
Figure 4.11 Recombinant SAG1474-MBP construct protein ..................................... 94 
Figure 4.12 Induction of SAG1474-MBP: western blots ............................................ 95 
Figure 4.13 Growth curve following induction of SAG1474-MBP with IPTG .............. 97 
Figure 4.14 Purification of recombinant SAG1474-MBP ........................................... 99 
Figure 4.15 TEV protease cleavage of SAG1474-MBP ........................................... 100 
Figure 4.16 Circular dichroism study of SAG1474: Far UV ..................................... 102 
Figure 4.17 Circular dichroism study of SAG1474: Near UV ................................... 103 
Figure 4.18 Circular dichroism study of SAG1474: Melting temperature ................. 104 
Figure 4.19 Antibody binding to recombinant SAG1474-MBP protein ..................... 106 
Figure 4.20 Antibody binding to lysed and whole cell S. agalactiae and S. pyogenes
 ................................................................................................................................ 108 
Figure 4.21 Assessment of antibody sensitivity and specificity ............................... 111 
Figure 5.1 Diagrammatic representation of recombinase polymerase amplification 118 
xii 
 
Figure 5.2 Visualisation of tailed RPA detection ...................................................... 121 
Figure 5.3 RPA of GBS DNA using primer pair E .................................................... 125 
Figure 5.4 RPA of GBS DNA using primer pair F .................................................... 126 
Figure 5.5 RPA of GBS DNA using primer pair F in 10 serotypes at 37 °C ............. 128 
Figure 5.6 RPA of GBS DNA using primer pair F in all 10 serotypes at 25 °C ........ 129 
Figure 5.7 Concentration curve of RPA performed at 37 °C for 10 minutes ............ 131 
Figure 5.8 Concentration curve of RPA performed at 37 °C for 20 minutes ............ 132 
Figure 5.9 Concentration curve of RPA performed at 25 °C for 20 minutes ............ 133 
Figure 5.10 RPA of DNA extracted from bacterial cell cultures ............................... 134 
Figure 5.11 RPA directly from lysed cell cultures .................................................... 135 
Figure 6.1 Nucleic acid structures ........................................................................... 139 
Figure 6.2 Selection of peptide aptamers exhibiting target affinity .......................... 144 
Figure 6.3 Mechanism of aequorin light emission and regeneration ....................... 147 
Figure 6.4 Structure of aequorin .............................................................................. 151 
Figure 6.5 Recombinant aequorin (WT* and FLAG) construct DNA and protein 
sequence. ................................................................................................................ 153 
Figure 6.6 Induction and solubility test for Aequorin WT*: comparison of lysis protocols
 ................................................................................................................................ 155 
Figure 6.7 Induction and solubility test for Aequorin WT*: comparison of time points
 ................................................................................................................................ 156 
Figure 6.8 Induction and solubility test for Aequorin WT*: comparison of induction 
temperatures ........................................................................................................... 157 
Figure 6.9 Confirmation induced protein is aequorin. .............................................. 158 
Figure 6.10 Purification of Aequorin WT* ................................................................ 159 
Figure 6.11 Induction and solubility test for Aequorin FLAG ................................... 160 
Figure 6.12 Growth curve of cells expressing aequorin FLAG ................................ 161 
 
xiii 
 
List of tables 
Table 1.1 Examples of Streptococcal species belonging to various Lancefield groups
 .................................................................................................................................... 4 
Table 1.2 Early onset GBS disease ............................................................................. 9 
Table 1.3 Late onset GBS disease ............................................................................ 10 
Table 1.4 Types of diagnostic tests for S. agalactiae detection ................................. 20 
Table 1.5 FDA approved NAAT-based GBS diagnostic tests .................................... 23 
Table 1.6 The use of a rapid GBS test in various clinical scenarios .......................... 25 
Table 2.1 Origin of E. coli and streptococcal strains .................................................. 29 
Table 2.2 Antibiotic concentrations ............................................................................ 30 
Table 2.3 Details on PCR experiments ..................................................................... 34 
Table 2.4 Recombinant proteins and associated parameters ................................... 41 
Table 2.5 E coli strains for production of recombinant protein ................................... 42 
Table 2.6 Experimental details for circular dichroism ................................................ 46 
Table 2.7 Sequences for use in RPA assay .............................................................. 52 
Table 3.1 IDRIS generated report listing proteins containing peptides distinctive to GBS
 .................................................................................................................................. 57 
Table 3.2 Cellular location as predicted by PSORTb ................................................ 58 
Table 3.3 Signal P results for SAG0771, SAG1473 and SAG1474. .......................... 59 
Table 3.4 LipoP results for SAG0771, SAG1473 and SAG1474. .............................. 60 
Table 3.5 TMHMM results for SAG0771, SAG1473 and SAG1474. .......................... 61 
Table 3.6 Summary of results, collated to inform protein target selection ................. 69 
Table 3.7 Analysis of token suitability for use as immunogenic peptides. ................. 74 
Table 4.1 Conjugation of peptide to carrier protein. ................................................... 77 
Table 4.2 Comparison of antibody binding to S. agalactiae and S. pyogenes ......... 109 
Table 5.1 Properties of isothermal DNA amplification techniques ........................... 116 
Table 5.2 Analysis of primer properties for amplification of GBS DNA .................... 123 
Table 5.3 Analysis of tailed primer properties.......................................................... 130 
Table 6.1 Analysis of sites in aequorin in which to insert a peptide aptamer. .......... 149 
 
 
 
xiv 
 
List of abbreviations 
 
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
ASSURED Affordable, sensitive, specific, user-friendly, rapid and robust, 
equipment free, deliverable to the people in need  
ATP Adenosine triphosphate 
BM Basic media 
bp Base pair 
BSA Bovine serum albumin 
C3 3 carbon spacer 
CBC Comparative Biology Centre 
CD Circular dichroism 
cDNA Complementary deoxyribonucleic acid  
CE Conformité Européenne 
cfu Colony forming unit 
dH2O Highly purified water 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid  
dNTPs Deoxynucleotide triphosphate 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme linked immunosorbent assay 
ELONA Enzyme linked oligonucleotide assay 
ESDA Exponential strand displacement amplification 
FBS Foetal bovine serum 
FDA US Food and Drug Administration 
GAS Group A streptococcus / Group A streptococcal 
GBS Group B streptococcus / Group B streptococcal 
GEO Gene Expression Omnibus 
GFP Green fluorescent protein 
GMP Guanosine monophosphate  
GST Glutathione S transferase 
xv 
 
HDA Helicase dependent amplification 
HAT Hypoxanthine, aminopterin, thymidine 
HGRPT Hypoxanthine guanine phosphoribosyltransferase 
HIV Human immunodeficiency virus 
HRCA Hyper branched rolling circle amplification 
HRP Horseradish peroxidase 
HT Hypoxanthine, thymidine (respect to antibody production) 
HT Feedback voltage (respect to circular dichroism) 
IAP Intrapartum antibiotic prophylaxis 
Ig Immunoglobulin 
IL-6 Interleukin 6 
IMP Inosine monophosphate 
IPTG Isopropyl β-D-1 thiogalactopyranoside 
KLH Keyhole limpet haemocyanin 
LAMP Loop mediated isothermal amplification 
LB Luria-Bertani broth 
LRCA Linear rolling circle amplification 
LSDA Linear strand displacement amplification 
MBP Maltose binding protein 
NAAT Nucleic acid amplification test 
NASBA Nucleic acid sequence based amplification 
NC Negative control 
NICE National Institute for Health and Care Excellence 
NPV Negative predictive value 
NRAMP Natural resistance-associated macrophage protein 
OD Optical density 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline, 0.05% tween 20 
PC Positive control 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
PGRCA Primer generation rolling circle amplification 
pI Isoelectric point 
xvi 
 
PMNL Polymorphonuclear leukocytes 
PPV Positive predictive value 
qPCR Quantitative polymerase chain reaction 
RNA Ribonucleic acid 
RPA Recombinase polymerase amplification 
RT-PCR Reverse transcriptase polymerase chain reaction 
S. species Streptococcus species 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SELEX Systematic evolution of ligands by exponential enrichment 
SrtA Sortase A 
SSB Single stranded binding protein 
TBE Tris-boric acid-EDTA buffer 
TCEP Tris(2-carboxyethyl)phosphine hydrochloride 
TEV protease Protease from the tobacco etch virus 
TK Thymidine kinase 
TM Transmembrane 
TMB 3, 3’, 5, 5’-tetramethylbenzidine 
TMP Thymidine monophosphate 
UMP Uridine monophosphate 
UTI Urinary tract infection 
UV Ultraviolet 
1 
 
Chapter 1 Streptococcus agalactiae: Bacteria, Disease and Diagnostics 
 
1.1 Streptococcus agalactiae bacterium 
 
1.1.1 Streptococcus agalactiae  
Streptococcus agalactiae is the causative agent of group B streptococcal (GBS) 
disease. In healthy individuals it acts as a commensal bacteria and a constituent of the 
normal vaginal and intestinal microbiota. However the bacterium causes severe 
symptoms, such as pneumonia, meningitis and sepsis, in infants, 
immunocompromised patients and the elderly and is a leading cause of neonatal death. 
(Heath et al., 2004; Edwards and Baker, 2005; Skoff et al., 2009) S. agalactiae is a 
facultative anaerobe, (Johri et al., 2007) and is therefore able to survive in a variety of 
environments. S. agalactiae has been isolated from the rectum, (Platt et al., 1995) 
throat, vagina, wounds, blood, cerebrospinal fluid and urine. (Mhalu, 1976) 
 
As well as a human pathogen, S. agalactiae is also a leading cause of bovine mastitis 
(Keefe, 1997) and is known to be pathogenic in cats, dogs, monkeys, (Lammler et al., 
1998) fish, seals, dolphins, bullfrogs (Delannoy et al., 2013) and crocodiles. (Bishop et 
al., 2007) 
 
Streptococci are gram positive bacteria; the plasma membrane is surrounded by a 
peptidoglycan cell wall which consists of glucosamine and muramic acid sugars. A 
polysaccharide capsule envelopes the bacterial cells, made up of repeating sugar 
groups. Although surrounded by the capsule, cell wall associated proteins may be 
exposed to the outer surface of the bacteria. Early experiments showed antisera 
produced in response to injection with a single serotype of GBS, protected mice against 
infection with a second serotype of GBS. As these strains of GBS did not share the 
same capsule type, the antigen must have been a non-capsular component, shared 
by the two strains and exposed to the bacterial surface. (Lancefield et al., 1975) More 
recently antibodies raised against cell wall associated Sip protein were shown to be 
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immunoprotective against GBS challenge across multiple serotypes. (Brodeur et al., 
2000) This is significant as the capsule does not block antibody binding to surface 
proteins. This may be because the capsule is narrow in vivo, because there is a degree 
of flexibility and mobility or because it is only present at particular stages of bacterial 
cell growth. (Lindahl et al., 2005) A schematic of a gram positive bacterial cell is shown 
in figure 1.1. 
 
 
 
 
Figure 1.1 Schematic of gram positive bacteria 
The figure shows the structure of a gram positive bacteria consisting of a cytoplasmic 
membrane, cell wall and capsule. Based on figures from (Fischetti, 2006) and (Murphy, 
2011). 
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1.1.2 Serotypes 
Most clinically isolated strains of S. agalactiae are encapsulated. (Benson et al., 2002) 
S. agalactiae strains are classified into serotypes, the polysaccharide capsule of each 
serotype consists of a distinct monosaccharide. These are composed of galactose, 
glucose and N-acetylneuraminic acid in various conformations, with some 
monosaccharides containing N-acetylglucosamine or rhamnose. (Cieslewicz et al., 
2005) There are 10 variations, all of which have been isolated in human disease. 
(Cieslewicz et al., 2005; Slotved et al., 2007) The genetic variation between strains 
has been analysed through comparative genome hybridisation using 20 S. agalactiae 
strains. 18% of genes found in strain 2603 V/R, serotype V, were not found in all strains. 
This figure increased to 38% when only the genes unique to GBS were considered. 
(Tettelin et al., 2002) There is evidence to suggest the expression of certain surface 
proteins is associated with particular serotypes. (Johnson and Ferrieri, 1984; Hauge et 
al., 1996; Areschoug et al., 1999; Lindahl et al., 2005) This linkage can also be 
observed at the DNA (deoxyribonucleic acid) level. (Creti et al., 2004; Shabayek et al., 
2014) In a study of the relationships between strains, profile clustering based on the 
sequences of 19 genes from 11 strains of GBS was performed. The results showed 
both serotype-dependent and -independent gene clustering. Three strains of serotype 
III were found to exhibit similar DNA sequences, whilst two strains within serotype Ia 
showed differential gene sequence patterns. The latter may be due to horizontal gene 
transfer. (Tettelin et al., 2002) This partial correlation between serotype and DNA 
sequence was also observed in other studies. (Creti et al., 2004; Shabayek et al., 2014) 
The most common serotypes isolated from human infections are III, Ia, V, Ib and II, 
prevalence of each varies globally and over time. (Berg et al., 2000; Ippolito et al., 2010; 
Soares et al., 2013; Vinnemeier et al., 2015) 
 
1.1.3 Related bacteria belonging to the genus streptococcus 
Streptococci can be divided into pyogenic, and non-pyogenic streptococci. The former 
group mainly comprises β-haemolytic bacteria, whilst the latter consists of α- and non-
haemolytic bacteria. Pyogenic bacteria can be further classified by the presence of 
Lancefield antigens, see table 1.1. Streptococcus agalactiae is the only species to 
contain type B antigen, and this can therefore be used to identify the species. The 
group A antigen is found in S. pyogenes, S. dysgalactiae subspecies equisimilis, and 
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S. anginosus group. The group C antigen is predominantly found in zoonotic species 
but can also be found in S. dysgalactiae subspecies equisimilis. There are many more 
Lancefield antigens. (Spellerberg and Brandt, 2011) 
 
 
There are several pathogenic species of significance within the Streptococcal genus. 
S. pyogenes causes group A streptococcal (GAS) disease which can lead to 
complications such as rheumatic fever (Bessen et al., 1989) or acute 
glomerulonephritis. (Rodriguez-Iturbe and Batsford, 2007; Cunningham, 2008) 
Pneumonia, sepsis and meningitis can all result from infection with S. pneumonia. 
Studies report 11-86% of the population to be infected with S. pneumonia in the nasal 
cavity. (Bogaert et al., 2004) S. mutans is a major cause of dental decay in humans, 
comprising 22-40% of the microbial flora found on carious teeth. (Loesche, 1986) S. 
suis is primarily a porcine pathogen, (Staats et al., 1997) but human infections are 
rising following consumption of diseased meat. (Wertheim et al., 2009) 
 
138 streptococcal strains were analysed for the presence or absence of certain genes. 
A gene content matrix was used to calculate phylogenetic distances between each 
Lancefield 
antigen 
Species 
A S. pyogenes, S. dysgalactiae subspecies equisimilis, S. anginosus group 
B S. agalactiae 
C S. dysgalactiae subspecies dysgalactiae, S. dysgalactiae subspecies 
equisimilis, S. equi subspecies equi, S. equi subspecies zooepidemicus, 
S. anginosus group 
E S. porcinus 
F S. anginosus group 
G S. dysgalactiae subspecies equisimilis, S. canis, S. anginosus group 
L S. dysgalactiae subspecies equisimilis 
P S. porcinus 
U S. porcinus 
V S. porcinus 
None S. anginosus group, S. porcinus 
Table 1.1 Examples of Streptococcal species belonging to various Lancefield groups 
Information obtained from (Spellerberg and Brandt, 2011). 
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species, and hierarchical clustering was used to create a phylogenetic tree, shown in 
figure 1.2. S. agalactiae was found to be most closely related to S. parauberis, S. uberis, 
S. iniae, S. porcinus, and S. pseudoporcinus. (Gao et al., 2014) 
 
 
Figure 1.2 Phylogenetic tree of streptococcal species 
Phylogenetic tree reproduced from (Gao et al., 2014). Differences in gene content were 
analysed and hierarchical clustering utilised to construct the dendrogram. Branches are 
colour coded based on species allocation. Species are assigned to a group type, e.g. 
pyogenic. 
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1.1.4 Virulence factors 
Streptococcus agalactiae contains many virulence factors acting to evade the host’s 
immune system, maximise dissemination, promote cell adhesion, adapt to alternative 
environments and function in several pathogenic pathways. Virulence factors include 
hyaluronidase, β-haemolysin, C5a peptidase, natural resistance-associated 
macrophage protein (NRAMP) homologues, sialic acid, D-alanylated lipoteichoic acids 
and CAMP factor, with some virulence factors performing multiple functions. 
(Landwehr-Kenzel and Henneke, 2014) 
 
Hyaluronidase degrades the extracellular matrix of the host, clearing a path to enable 
the pathogen to spread. (Li and Jedrzejas, 2001) It also aids survival within phagocytes, 
which may be exploited as a transport system allowing rapid dissemination through the 
body. Hyaluronidase can act to reduce proinflammatory cytokine production. (Wang et 
al., 2014b) A reduced inflammatory response in the vaginal tract of pregnant women, 
can allow the infection to ascend to the uterine tissue and increase the likelihood of 
preterm birth. (Vornhagen et al., 2016)  
 
β-haemolysin is a pore-forming cytotoxin which causes damage to lung tissue. (Nizet 
et al., 1996; Pritzlaff et al., 2001) Septic shock, a condition in which an infection causes 
blood pressure to drop to a critical level, is dependent on nitric oxide production. β-
haemolysin activates inducible nitric oxide synthase in murine macrophages, (Ring et 
al., 2000) it can also initiate apoptosis in hepatocytes and may be responsible for liver 
failure. (Ring et al., 2002) 
 
C5a is a chemoattractant which draws polymorphonuclear leukocytes (PMNL) to the 
site of infection. C5a peptidase cleaves C5a at the PMNL binding site, reducing the 
chemotactic gradient. C5a peptidase is highly conserved between group A and group 
B streptococci, illustrating its essential role. In S. pyogenes, C5a peptidase deficient 
mutants were cleared from the air sac more efficiently than wild-type variants; 
indicating the role of C5a peptidase in immune evasion. (Ji et al., 1996) C5a peptidase 
has also been proposed to act as an invasin. C5a peptidase deficient mutants were 
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able to invade an epithelial cell line to half the extent that wild-type GBS cells were 
capable of. (Cheng et al., 2002b) 
 
To survive the acidic environment of the vaginal tract, S. agalactiae contain pH-
dependent NRAMP homologues which transport iron and manganese ions. 
Phagosomes employ reactive oxygen species to kill pathogenic bacteria; the removal 
of these toxic reactive oxygen species by superoxide dismutase is dependent on its 
cofactor, manganese. Iron is an essential cofactor in many enzymes. (Lisher and 
Giedroc, 2013) Therefore control of iron and manganese is essential for bacterial 
survival. A deletion mutant of the NRAMP mntH, resulted in reduced resistance to 
reactive oxygen species. This mutant also showed a reduced ability to adhere to the 
extracellular matrix at low pH. It is likely that this is dependent on the intracellular metal 
concentration, as adherence is recovered when the system is supplemented with 
manganese. (Shabayek et al., 2016) Lactobacilli are the dominant genus found in the 
vaginal flora, they produce lactic acid, hydrogen peroxide and bacteriocin-like 
substances to restrict the growth of neighbouring bacteria. (Boris and Barbes, 2000) 
The NRAMP mntH- mutant exhibited increased susceptibility to the anti-microbial 
agents produced by lactobacilli. This study has indicated the role of NRAMP 
homologues in pH-dependent host adhesion, resistance to oxidative stress and 
survival in the presence of bacteria found in the vaginal microbiome. (Shabayek et al., 
2016) 
 
Sialic acid, D-alanylated lipoteichoic acid and CAMP factor function as virulence 
factors. Sialic acid is a component of the polysaccharide capsule, which inhibits the 
host’s alternative complement pathway. (Edwards et al., 1982) D-alanylation of 
lipoteichoic acids in the cell wall decreases cell wall flexibility and permeability, which 
in turn increases protection from the host cationic antimicrobial peptide response. 
(Saar-Dover et al., 2012) CAMP factor is a toxin which causes the formation of 
transmembrane pores in erythrocyte membranes, (Lang and Palmer, 2003) via 
interaction with host glycosylphosphatidylinositol anchored proteins. (Lang et al., 2007) 
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Several virulence factors, although not well studied in S. agalactiae, have homologues 
in other bacterial species. (Tettelin et al., 2002) α-enolase of S. pyogenes binds 
plasminogen, and is proposed to aid in tissue invasion. (Pancholi and Fischetti, 1998) 
In gram negative bacteria, such as Pseudomonas aeruginosa, secreted adenylate 
kinase induces macrophage cell death. Adenylate kinase catalyses the reversible 
formation of ADP (adenoside monophosphate) from ATP (adenosine triphosphate) and 
AMP (adenosine monophosphate). It is predicted that adenylate kinase binds to the 
macrophage cell surface and controls the levels of AMP, ADP and ATP to create a 
combination which is toxic to macrophages. (Markaryan et al., 2001) Although 
streptococcal adenylate kinase functions as an ATPase, it is not known if it also acts 
as a virulence factor to induce macrophage cell death. (Thach et al., 2014) 
 
1.2 Group B streptococcal disease 
 
19-28% of the population is colonised with S. agalactiae at any one time. (Benitz et al., 
1999) These commensal bacteria contain virulence genes (Otaguiri et al., 2013) and 
therefore have the capability of causing severe or fatal infections within vulnerable 
patients. The large-scale colonisation of the population acts as a substantial reservoir 
of disease. This, coupled with the asymptomatic state of carriers, means it is difficult 
to prevent transmission. S. agalactiae can cause GBS disease in a variety of patient 
groups: neonatal infants, the elderly and the immunocompromised. Each is 
characterised by different methods of transmission, risk factors and clinical outcomes. 
 
1.2.1 Early onset disease 
Early onset GBS disease is defined as infection occurring within the first six days of 
life. Early onset GBS is caused by the transmission of bacteria from the mother to the 
infant prior to, or during delivery. During delivery neonates are colonised with maternal 
flora, the microbiota of an infant delivered vaginally and by caesarean differ 
considerably, with the dominant colonising bacteria being lactobacilli and staphylococci 
respectively. (Dominguez-Bello et al., 2010) Streptococcus agalactiae is a resident of 
the vaginal flora, therefore vaginally born infants are at most risk of early onset GBS 
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disease. Risk factors for early onset disease include preterm birth, prolonged rupture 
of membranes, chorioamnionitis, maternal pyrexia during labour, maternal GBS 
vaginal or rectal colonisation or urinary tract infection (UTI) during pregnancy and the 
mother having had a previous child with neonatal GBS disease. (Hughes et al., 2017) 
The mothers of 58% of infants who developed early onset GBS disease experienced 
prolonged membrane rupture, GBS carriage during pregnancy or preterm delivery. 
This figure increased to 73% of mother’s whose infants died of GBS. (Heath et al., 
2004) 
 
In recent years, incidence rates for early onset GBS disease of 0.37- 0.98 per 1000 
live births have been reported. (Heath et al., 2004; Puopolo et al., 2005; Stoll et al., 
2011)) This is significantly reduced from rates observed prior to the recommendation 
of intrapartum antibiotic treatment, up to 5.46 per 1000 live births. (Benitz et al., 1999) 
Early onset group B streptococcal disease can present in many ways, see table 1.2. 
When discharged from hospital, 7% of babies had a developed a disability or possible 
disability. (Heath et al., 2004) The mortality rate associated with full term babies is 2%, 
(Schrag et al., 2000) this increases to 23-30% for premature babies. (Schrag et al., 
2000; Brooks et al., 2006) 
 
 Prevalence 
Incidence 0.37-0.98 per 1000 live births a, b, c 
Mortality 2% (23-30% for premature babies)d, e 
Disability 7%a 
Sepsis 63% a 
Pneumonia 26% a 
Meningitis 11% a 
Focal infections 0.6% a 
 
 
Table 1.2 Early onset GBS disease 
The table states the prevalence of early onset GBS disease and the likelihood of the 
conditions it causes. a (Heath et al., 2004), b (Puopolo et al., 2005), c (Stoll et al., 2011), d 
(Schrag et al., 2000) e (Brooks et al., 2006) 
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1.2.2 Late onset disease 
Infection of infants aged one week to three months is classified as late onset GBS. 
Late onset disease has a lower incidence rate, of 0.24 per 1000 live births, (Heath et 
al., 2004) and the disease presents differently to early onset disease, with more cases 
of meningitis and focal infections, and fewer cases of sepsis and pneumonia, (Heath 
et al., 2004) see table 1.3. A large nation-wide study of bacterial meningitis conducted 
in France was carried out over six years. Late onset GBS patients experienced a range 
of complications; 30% underwent shock, whilst 14% and 34% experienced seizures, 
prior to and during treatment. 32% required mechanical ventilation, 22% entered a 
coma and 17% of patients died from the infection. (Guilbert et al., 2010) Other studies 
found late onset fatality to be 8% in the UK, (Heath et al., 2004) and 2.8% in the US. 
(Schrag et al., 2000) Bacteria were isolated from infected patients and analysed for 
serotype. 81% of isolated bacteria were found to be serotype III, (Guilbert et al., 2010) 
in comparison to 38% for early onset disease. (Weisner et al., 2004) 
 
 Prevalence 
Incidence 0.24 per 1000 live births a 
Mortality 2.8-17%a, b, c 
Sepsis 41%a 
Pneumonia 8%a 
Meningitis 43%a 
Focal infections 7%a 
 
 
In contrast to early onset disease which is vertically transmitted during delivery, late 
onset disease may derive from a number of sources. Environmental sources have 
been implicated in cases of nosocomial infections. (Al-Maani et al., 2014) In around 
50% of cases, the serotype of the neonatal infectious agent matches that of the 
intrapartum maternal coloniser. (Dillon et al., 1987) However it is not definitive that the 
mother is the source of transmission. 
Table 1.3 Late onset GBS disease 
The table states the prevalence of late onset GBS disease and the likelihood of the 
conditions it causes. a (Heath et al., 2004) b (Guilbert et al., 2010) c (Schrag et al., 2000) 
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In identifying methods of transmission that occur following birth, infants delivered by 
caesarean are particularly useful to study as colonisation with vaginal bacteria is 
unlikely. An association between late onset disease and breast milk infection has been 
suggested. S. agalactiae infection of breast milk was found in 25% of mothers with 
infants with late onset disease, both in those presenting with mastitis and those not. 
(Berardi et al., 2013) Infants born to human immunodeficiency virus (HIV)-positive 
mothers have increased risk of contracting late onset disease. Reasons for this may 
include placental transfer of drugs to treat the maternal HIV infection, reduced 
placental transfer of maternal antibodies, reduced socioeconomic status or lack of 
breastfeeding. (Epalza et al., 2010) Neonatal viral infection has been proposed to be 
associated with late onset disease. In one study, all GBS positive infants had viral 
symptoms, or confirmed viral infection, determined by virus isolation or detection of 
viral induced cytokines. (Raymond et al., 2007) 
 
Premature birth is a significant risk factor. Ultra-late onset GBS is the infection of 
infants over three months of age, and is extremely rare. 32% of infants who contracted 
ultra-late onset GBS were born under 32 weeks gestation, in comparison to 7% of 
those who developed late onset disease. It has been suggested that levels of maternal 
antibodies are responsible. (Guilbert et al., 2010) Placental transfer of maternal 
antibodies that are capable of protecting against disease starts from 28-32 weeks 
gestation. Premature birth results in lower antibody transfer and reduced protection 
against disease. Antibody titres decrease following birth, according to their specific 
half-lives, (van den Berg et al., 2011) therefore preterm infants with low GBS antibody 
levels at birth become increasingly more susceptible to GBS disease. 
 
1.2.3 Immunocompromised 
Prevalence of group B streptococcal disease in adults is increasing. In one study, the 
incidence rate increased from 3.6 to 7.3 cases per 100,000 people from 1990 to 2007. 
In patients under 65 years old, skin and soft tissue infections are the most common 
presentation. (Skoff et al., 2009) Wounds and ulcers present easy routes of entry as 
the skin is broken, severe infections can lead to necrotizing fasciitis and toxic shock 
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syndrome. Other presentations include respiratory infections, genitourinary infections 
and joint and bone infections. (Sendi et al., 2008) 
 
Adult GBS infection is heavily associated with pre-existing conditions, such as diabetes 
mellitus, obesity, cancer, cardiovascular disease, renal disease, liver disease, chronic 
obstructive pulmonary disease, neurological diseases and immunosuppression. 
Previous studies of invasive GBS infection have found between 88% (Skoff et al., 2009) 
and 100% (Edwards et al., 2016) of patients to exhibit one or more of these conditions. 
 
44-59% of GBS infected adults have diabetes. (Skoff et al., 2009; Edwards et al., 2016) 
Diabetic patients are more susceptible to microbial infections as a hyperglycaemic 
environment promotes disruption of the immune system. There is a reduction in 
inflammatory cytokine secretion, antioxidant response, leucocyte mobility and 
phagocytosis of infectious organisms. Treatment of diabetic complications adds to this 
as the number of medical interventions a patient experiences also increases the risk 
of acquiring infectious disease. (Casqueiro et al., 2012) Commonly, diabetic patients 
with GBS disease present with skin, soft tissue or bone infection, with foot infections 
being particularly common. (Yanai et al., 2012) Rare complications within diabetic 
patients include necrotising pneumonia, (Pacha et al., 2017) skeletal muscle 
abscesses (Panikkath et al., 2016) and abdominopelvic abscesses. (Ulett et al., 2012) 
 
1.2.4 Elderly 
Bacteremia is the most common presentation of GBS disease in patients over 65. 
(Skoff et al., 2009) In comparison with infections of younger adults, elderly patients 
have an increased likelihood to present with urinary tract infections or pneumonia. The 
fatality rate of elderly patients diagnosed with GBS was 14-15% between 1997 and 
2003. Risk factors include being a nursing or care home resident, being bedridden, or 
possessing a catheter. Infections are often diagnosed later in elderly patients partly 
due to a decreased ability to initiate a fever. Dementia decreases the capability of the 
individual to recognise symptoms of infectious diseases, and patients are therefore 
unable to report these to clinicians. In the elderly population there is also an increased 
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prevalence of underlying medical conditions in comparison to the general adult 
population. (Edwards and Baker, 2005) As previously discussed these play a 
significant role in susceptibility to GBS disease. 
 
1.2.5 Worldwide disease 
Most GBS studies have been carried out in developed countries; GBS disease is three 
times as fatal in low income countries. (Edmond et al., 2012) Similar rates of maternal 
S. agalactiae carriage are reported in developing countries such as North Africa, India, 
Pakistan and Saudi Arabia, (World Health Organization, 2006) however fewer cases 
of GBS disease are reported. This may be due to differences in transmission 
frequencies or a reduced ability to monitor infection on account of insufficient 
diagnostic techniques, undiagnosed causes of early death, or the larger number of 
births occurring away from healthcare sites. (Johri et al., 2006) The true burden of 
global GBS disease is unknown.  
 
1.3 Treating and preventing GBS disease 
 
1.3.1 GBS vaccine development 
Early onset GBS disease can be prevented by administering antibiotics intravenously 
to the mother at the onset of labour, thus reducing the likelihood of transmission to the 
neonate. (Hughes et al., 2017) However this is only capable of preventing early onset 
GBS disease. A vaccination programme may also be able to prevent late onset disease 
and disease in adults. 
 
The outermost layer of the S. agalactiae bacterium is a polysaccharide capsule. 
Serotype-specific capsular polysaccharides, conjugated to carrier proteins for 
increased immunogenicity, have been used to confer protection to GBS challenge in 
animal models. (Wessels et al., 1990; Paoletti et al., 1992; Paoletti et al., 1994; Paoletti 
and Kasper, 2002) In clinical trials, vaccination caused a rise in serum Ig 
(immunoglobulin) G levels and in vitro opsonophagocytosis of S. agalactiae. (Baker et 
al., 1999; Baker et al., 2000; Baker et al., 2004; Baker et al., 2007) This effect was 
14 
 
serotype specific, therefore a multivalent vaccine would be required for sufficient 
coverage of clinical isolates. A clinical trial performed in South Africa investigating the 
effect of multivalent immunisation (serotypes: Ia, Ib and III) in pregnant women resulted 
in raised antibody levels against all three serotypes in the mother and infant. (Madhi et 
al., 2016) In the UK 85% of colonising S. agalactiae strains are serotype III, Ia or V. 
(Weisner et al., 2004) As serotype distribution varies geographically, different 
combinations of vaccines may be required to the cover the majority of strains found in 
different areas. (World Health Organization, 2006) 
 
To eliminate serotype-specificity, an S. agalactiae protein could function as the 
immunogen. To be effective as an S. agalactiae specific vaccine target, the protein 
would need to be conserved in all strains, surface exposed and be immunogenic. 
(Nuccitelli et al., 2015) Proteins such as Sip and C5a peptidase have been investigated 
as vaccine targets. The Sip protein was conserved and expressed in all serotypes 
tested, and when injected into mice was protective against multiple serotypes of GBS. 
(Brodeur et al., 2000) C5a peptidase vaccination also gave protection against GBS 
challenge, independent of serotype. (Cheng et al., 2002a) Surface exposed proteins 
can be identified by surfome protease digestion followed by mass spectrometry. In the 
study of S. agalactiae, both Sip and C5a peptidase were found to be surface exposed. 
(Doro et al., 2009) It is likely that bioinformatic techniques able to screen multiple 
genomes will direct the discovery of vaccine targets. (Johri et al., 2006) 
 
1.3.2 Antibiotic treatment 
As there is no currently available vaccine, the strategy for early onset GBS disease 
prevention is maternal antibiotic treatment. Repeat doses are given during labour until 
the infant is delivered. (Hughes et al., 2017) Since intrapartum antibiotic prophylaxis 
(IAP) became the recommended treatment in the US in the 1990s, mortality due to 
GBS disease decreased at a faster rate (5% per year) than previously (3% per year). 
(Lukacs et al., 2004) The efficacy of IAP treatment, if given more than two hours prior 
to delivery, is 89%. (Lin et al., 2001) The advised minimal treatment period is four hours. 
Antibiotic treatment of mothers during pregnancy causes no reduction in GBS 
colonisation at the time of delivery. (Hughes et al., 2017) 
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If an infant presents with early onset symptoms, penicillin and gentamicin should be 
administered. (Hughes et al., 2017) Antibiotics are also prescribed for treatment of 
adult GBS disease. Additional treatments such as surgery may be necessary in cases 
of skin or bone infection. (Farley, 2001) 
 
Benzylpenicillin is the first choice antibiotic. There are no reports of penicillin resistance 
in the UK, (Lamagni et al., 2013) however decreased susceptibility has been reported 
in the US (Dahesh et al., 2008) and East Asia. (Hsueh et al., 2001; Chu et al., 2007; 
Kimura et al., 2008) 0.7-4% of penicillin treatments result in allergic reactions, with 
anaphylaxis being a rare but severe side effect. (Petri, 2011) In cases of penicillin 
allergy, clindamycin or erythromycin are often administered. Clindamycin resistance 
rose from a frequency of 3% to 9% from 1998 to 2010; erythromycin resistance 
increased from <3% to 15% from 1991 to 2010. (Lamagni et al., 2013) An association 
between antibiotic treatment and infant colonisation with antibiotic resistant bacteria  
has been suggested, (Terrone et al., 1999), however statistical significance was not  
observed by other groups. (Jaureguy et al., 2004; Nogacka et al., 2017) 
 
There are some concerns over the danger of intrapartum antibiotic treatment to the 
long term health of the infant. A study concluded there was a marked increase in the 
percentage of children with functional impairments and cerebral palsy at seven years 
of age, born to mothers treated with erythromycin during labour, in comparison to those 
who were given a placebo. In this study mothers were treated with a low dosage of 
oral, broad spectrum antibiotics over 10 days (or until delivery). (Kenyon et al., 2008) 
This contrasts the strategy to prevent GBS transmission where high dosage, targeted 
antibiotics are administered intravenously over a short period of time. The findings of 
the study may not be applicable to alternative antibiotic treatment programmes, and 
do not impact the recommendation for antibiotics to be used in GBS prevention. 
(McCartney et al., 2002) 
 
16 
 
1.3.3 Maternal screening/risk- based treatment 
In the US, Canada, Japan and many European counties, an antenatal screening 
programme is offered at 35-37 weeks gestation. (Burns and Plumb, 2013) However, 
countries such as the United Kingdom, Denmark, the Netherlands and New Zealand 
do not recommend universal screening, (Melin and Efstratiou, 2013) see figure 1.3. 
The UK National Screening Committee (2017) recently concluded that universal 
screening would not be appropriate for several reasons. There is no technique to 
identify which infants would be severely affected by GBS. The maternal GBS status 
fluctuates, therefore mothers who are colonised with S. agalactiae at the time of 
screening may not be positive during delivery and vice versa. Screening may increase 
unnecessary antibiotic treatment, which may be harmful to the infant, mother or to 
antibiotic stewardship. (UK National Screening Committee, 2012) 
 
The UK follows a risk factor-based treatment plan; risk factors include preterm birth, 
maternal pyrexia in labour and prolonged membrane rupture. (UK National Screening 
Committee, 2017) However 33-42% of infants who present with early onset GBS 
disease are born to mothers who present no risk factors, (Heath et al., 2004; Vergnano 
et al., 2010) therefore the opportunity to prevent these infections is missed. In a 
screening trial conducted in the UK, cases of early onset disease fell by 84% in 
comparison to the pre-screening period, (Rao et al., 2017) supporting the development 
of a universal screening programme. 
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The selection of treatment plans is heavily influenced by the cost of screening and 
preventative maternal treatment balanced with the potential savings associated with 
reduced time in hospital and lower costs of infant treatment. Costs outside of the health 
system should also be considered, such as loss of parental productivity, and therefore 
tax, and future schooling requirements associated with disability. Any scheme which 
reduced costs to a larger extent than the increase in diagnostic expenditure would be 
deemed economically viable, and may be suitable for use in the NHS. The current 
practice of treating women exhibiting risk factors is considered to not be cost effective. 
(Colbourn et al., 2007; Kaambwa et al., 2010) In one study, the most economically 
favourable strategy was determined to be universal treatment for all women. 
(Kaambwa et al., 2010) This directly opposes a Public Health England campaign to 
decrease unnecessary antibiotic usage in order to combat antibiotic resistance. (Public 
Health England, 2017) Eliminating this option, the most cost viable strategy is the use 
Figure 1.3 Worldwide approach to early onset GBS prevention 
Countries which conduct routine screening for GBS disease are shown in red, those which 
treat based on risk factors are shown in blue. In Australia prevention differs between 
states, shown in green. Information from: (Burns and Plumb, 2013; Melin and Efstratiou, 
2013; Homer et al., 2014; Cho et al., 2017) Map template from: (mapchart.net, 2017). 
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of enriched culture media for screening. (Kaambwa et al., 2010) An alternative study 
suggested the treatment of women with preterm or high risk conditions coupled with 
screening of women at low risk of the disease to be the most cost effective approach. 
(Colbourn et al., 2007) 
 
1.4 Diagnosis of S. agalactiae infection 
 
The UK does not support specific GBS testing, however if there are symptoms of 
bacterial infection a standard direct plate test is often carried out. This non-specific test 
enables the identification of a number of bacterial species, however is associated with 
a high rate of false negative results, with 50% of infected samples reported as negative. 
(Centers for Disease Control and Prevention, 1999) Diagnostic tests with the aim of 
specific detection of S. agalactiae infections are described below. 
 
1.4.1 Current GBS diagnostic tests 
S. agalactiae colonisation or infection is most commonly diagnosed by growth on blood 
agar plates, the CAMP test, or more recently with chromogenic media. As S. agalactiae 
strains are β-haemolytic, colonies form a small area of haemolysis on blood agar plates, 
characterised by a transparent zone of complete lysis. This differs from α-haemolytic 
species which exhibit partial haemolysis, producing a green zone. (Wannamaker, 1965) 
Microbial culture techniques still dominates the field of infectious disease diagnostics, 
despite the lengthy process of 24-72 hours. 
 
The sensitivity and specificity of these techniques can be enhanced by S. agalactiae 
enrichment. Incubation for 18-24 hours in selective medias such as TransVag (Todd-
Hewitt broth supplemented with gentamicin and nalidixic acid) and Lim broth (Todd-
Hewitt broth supplemented with colistin and nalidixic acid) promotes the growth of 
S. agalactiae in preference to other bacterial species. (Verani et al., 2010) Subsequent 
tests are performed on specimens with an enhanced S. agalactiae content. In 
comparison to direct culture, prior enrichment in selective broth increased the number 
of positive samples detected in one study by 105%. (Platt et al., 1995) The major 
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disadvantage of enrichment is the additional time required until results become 
available. 
 
S. agalactiae haemolysis can be enhanced by incubation with Staphylococcus aureus 
β-haemolysin through interaction with S. agalactiae CAMP factor. The interaction 
between S. aureus and S. agalactiae was first discovered by Christie, Atkins and 
Munch-Petersen (Christie et al., 1944) and the resulting test is named after them. β-
haemolysin can be supplied in a disc or through incubation with S. aureus. (Wilkinson, 
1977) This method is able to detect non-haemolytic strains; 5% of strains isolated from 
colonising bacteria are non-haemolytic. (Rodriguez-Granger et al., 2015) Microbial 
culture of enriched samples, and the CAMP test are considered gold standard 
diagnostic tests to which new diagnostic tests are measured against to determine test 
accuracy. (de-Paris et al., 2011) 
 
Various diagnostic tests for GBS detection are described below, with key features 
summarised in table 1.4. Results were compared to a gold standard technique for 
calculation of test sensitivities and specificities. The sensitivity of a diagnostic test is 
the fraction of individuals with a disease that are identified by the test. The specificity 
of a diagnostic test is the probability that the diagnostic test will produce a negative 
result for individuals who do not have the disease. The positive predictive value (PPV) 
determines the likelihood of a patient having the disease if the test result is positive. 
The negative predictive value (NPV) states the likelihood of a negative result arising 
from a true lack of disease. Predictive values of diagnostic tests are dependent on 
disease prevalence in the sample population. In populations of high disease 
prevalence, the NPV is low and diagnostic tests with high specificities are required. 
Conversely, at low disease prevalence PPV is low, and diagnostic tests with increased 
sensitivities are needed. (Wong and Lim, 2011) As clinical validation tests were not 
performed in the same population, predictive values cannot be directly compared, and 
therefore are not reported below. 
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𝑇𝑇𝑇𝑇𝑇𝑇𝑆𝑆 𝑃𝑃𝑃𝑃𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐹𝐹𝐹𝐹𝐹𝐹𝑆𝑆𝑆𝑆 𝑁𝑁𝑆𝑆𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑇𝑇𝑇𝑇𝑇𝑇𝑆𝑆 𝑁𝑁𝑆𝑆𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆
𝐹𝐹𝐹𝐹𝐹𝐹𝑆𝑆𝑆𝑆 𝑃𝑃𝑃𝑃𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝑇𝑇𝑇𝑇𝑇𝑇𝑆𝑆 𝑁𝑁𝑆𝑆𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 
𝑃𝑃𝑃𝑃𝑃𝑃 = 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝜋𝜋
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝜋𝜋 + (1 − 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆)(1 − 𝜋𝜋) 
𝑁𝑁𝑃𝑃𝑃𝑃 = 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (1 − 𝜋𝜋)
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (1 − 𝜋𝜋) + (1 − 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆)𝜋𝜋 
 
 
Method Enrichment Time Sensitivity 
/ % 
Specificity 
/ % 
Reference 
Pigmented 
agar / broth 
No 18-24 
hours 
(if positive), 
48 hours 
(if negative) 
94.1 - 97.8 
(agar), 
85.5 - 96.6 
(broth) 
100 (Votava et al., 2001; Tazi et 
al., 2008) 
Latex 
agglutination 
No 15 
minutes 
13.3-100 
(dependent 
on cfu 
number) 
100 (Xie et al., 2016) 
Optical 
immunoassay 
No 35 
minutes 
7.1 - 98.4 
(dependent 
on 
colonisation 
levels) 
41.5 - 98.1 
(dependent 
on 
colonisation 
levels) 
(Baker, 1996; Thinkhamrop 
et al., 2003; Aziz et al., 
2005; Daniels et al., 2009) 
Enzyme 
immunoassay 
No 10 
minutes 
16.1-20.7 98.8-99.8 (Baker, 1996) 
DNA probes Yes 120 
minutes 
90.1 - 97.4 97.5 - 100 (Williams-Bouyer et al., 
2000; Montague et al., 
2008; Peltroche-
Llacsahuanga et al., 2010; 
Wilson et al., 2010) 
Nucleic acid 
amplification 
tests 
No 
(Yes) 
80-210 
minutes 
90.3 
(92.5 -100) 
99 
(92.5 -99.3) 
(Goodrich and Miller, 
2007; Block et al., 2008; 
Ellem et al., 2017) 
Table 1.4 Types of diagnostic tests for S. agalactiae detection 
This table states the sensitivities, specificities, diagnosis time and requirement for enrichment 
for a variety of types of GBS diagnostic test. Abbreviation: cfu (colony forming unit) 
𝛑𝛑 is defined as the prevalence in the population. Equations from (Wong and Lim, 2011) 
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Chromogenic media or agar is used to facilitate easy identification of S. agalactiae. In 
a starch rich media under anaerobic conditions, S. agalactiae produces an orange 
coloured pigment, granadaene. (Votava et al., 2001; Tazi et al., 2008) A chromogenic 
media causes S. agalactiae to appear as pink colonies in an aerobic environment. 
Strains isolated from invasive disease were subjected to testing, 5.4% of these 
samples were found to be non-pigmented, however all strains were able to be detected 
by the observation of pink colonies in chromogenic media. (Votava et al., 2001) 
 
Latex agglutination is used in streptococcal serogrouping, and is based on detection 
of Lancefield carbohydrate antigens. (Davies et al., 2003) It can be performed directly 
from patient samples and takes around 15 minutes. Latex particle-conjugated 
antibodies bind to S. agalactiae-specific antigen, causing latex particles to agglutinate. 
(Ghaddar et al., 2014) This technique is highly sensitive in moderate-heavy 
colonisation (>50 colony forming units (cfu) per swab), however sensitivity drops to 
66.7% and 13.3% for samples with 10-50 cfu per swab and <10 cfu per swab 
respectively. (Xie et al., 2016) When implemented following enrichment, high 
sensitivities can be achieved. (Davies et al., 2003) Other polysaccharide antigen 
detection diagnostics, including optical and enzyme immunoassays, have been 
developed, however they lack the sensitivity and specificity to be used clinically. (Baker, 
1996; Thinkhamrop et al., 2003; Aziz et al., 2005; Daniels et al., 2009) Carbohydrate-
protein interactions are typically weak, (Fernandez-Alonso et al., 2012; De Schutter 
and Van Damme, 2015) which may explain the low sensitivities observed for patient 
samples with light colonisation. 
 
Further techniques include the use of nucleic acid probes which bind to specific regions 
within S. agalactiae ribosomal RNA (ribonucleic acid). The probes are labelled with 
fluorescent (Montague et al., 2008; Peltroche-Llacsahuanga et al., 2010; Wilson et al., 
2010) or chemiluminescent molecules. (Williams-Bouyer et al., 2000) Although probe 
diagnostics exhibit promising sensitivities and specificities, they are limited by the 
requirement for enrichment and long processing time of around two hours. 
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Nucleic acid amplification tests (NAATs) have been used for GBS diagnosis, often in 
the form of quantitative polymerase chain reaction (qPCR). The amplification of target 
specific DNA is measured in real time by the increase in fluorescent signal. NAATs are 
often associated with high sensitivities and specificities. In the 2000s, the use of DNA 
amplification directly from patient samples with no pre-enrichment stage was found to 
not be accurate enough for use in clinical practice. (Aziz et al., 2005; Daniels et al., 
2009) There have been several NAATs which have gained FDA (US Food and Drug 
Administration) approval, table 1.5 details those approved since 2002. 
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Device name 
(Company) 
Type Sensitivity 
/ % 
Specificity 
/ % 
Enrichment Time to 
result 
/ minutes 
Document 
number 
IDI-Strep B Assay 
(Infectio Diagnostic) 
qPCR 89-97.2 94-97.3 No Not 
specified 
K022504 
Xpert GeneXpert Dx 
System 
(Cepheid) 
qPCR 94.6 94.8 No 75 K060540 
Smart GBS, 
SmartCycle Dx System 
(Cepheid) 
qPCR 98.7 (81.6) 90.5 (96.4) Yes (No) 75 K062948 
HandyLab GBS Assay 
(HandyLab) 
qPCR 95 96.7 Yes 120 K090191 
Illumigene Group B 
Streptococcus 
(Meridian Bioscience) 
LAMP 97.4 92.3 Yes 60 K112125 
BD Max GBS Assay 
(Becton Dickinson) 
qPCR Not 
specified 
Not 
specified 
Yes Not 
specified 
K111860 
Illumigene Group B 
Streptococcus 
(Meridian Bioscience) 
LAMP 98.6 93.2 Yes 60 K121044 
XPERT GBS LB 
GeneXpert Dx 
Systems 
(Cepheid) 
qPCR 99 92.4 Yes 55 K121539 
AmpliVue GBS Assay 
(Quidel) 
HDA 99.5 92.7 Yes 75-90 K133503 
Portrait GBS Assay 
(Great Basin) 
PCR, 
chip 
97.9 96 Yes 90 K143312 
ARIES GBS Assay 
(Luminex) 
qPCR 96.1 91.4 Yes Not 
specified 
K162772 
GenePOC GBS LB 
(GenePOC) 
qPCR 95.9 95.5 Yes 120-180 K170557 
 
For marketing within Europe, diagnostic tests must comply by directive 98/79/EC (in 
vitro diagnostic medical devices) and carry a CE (Conformité Européenne) mark. (The 
European Parliament and the Council of the European Union, 1998) Several of the 
FDA approved tests detailed in table 1.5 are currently CE-marked, including the 
Illumigene Group B Streptococcus test, (Meridian Bioscience, 2018) GenePOC’s GBS 
Table 1.5 FDA approved NAAT-based GBS diagnostic tests 
FDA approved NAATs for GBS detection were evaluated for reported sensitivity, specificity, 
detection time and requirement for enrichment. Types of NAAT: qPCR (quantitative PCR); 
LAMP (loop mediated isothermal amplification); HDA (helicase dependent amplification). 
Document numbers from FDA premarket notification files, accessed from (US Food and Drug 
Administration, 2017). 
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LB test, (GenePOC, 2018) the Amplivue GBS Assay (Quidel, 2018) and the Xpert GBS 
test. (Cepheid, 2018) Currently there is no publically available database of CE-marked 
medical devices therefore the above list is non-exhaustive. However by 2022 EU 
directive 2017/746 will be instated, which requires certificates of devices to be 
registered on a publically accessible database. 
 
Cepheid’s GeneXpert GBS is an example of a state of the art NAAT for GBS diagnosis. 
Cells are captured on a filter and lysed by sonication. The DNA is eluted and this 
solution rehydrates the lyophilised PCR reagents. Real time PCR is performed and 
fluorescence is measured. (US Food and Drug Administration, 2017) In 2015, the 
National Institute for Health and Care Excellence (NICE) published an innovation 
briefing discussing the use of the Xpert GBS for intrapartum testing. (Jones et al., 2015) 
It reported that Xpert GBS is an accurate test able to provide results in 50 minutes, a 
vast improvement over microbial culture. The recommended minimal length of IAP 
treatment prior to delivery is four hours. This was achieved in 68% of cases diagnosed 
by Xpert GBS, an increase over the 64% treated successfully in cases diagnosed by 
antenatal microbial culture. In preterm births the GBS status of the mother was known 
at least four hours before delivery in 23% of cases diagnosed by bacterial culture, and 
in 74% of cases diagnosed by Cepheid’s Xpert GBS. (de Tejada et al., 2011) However, 
15% of diagnoses resulted in an invalid result, and required re-testing. (Hakansson et 
al., 2014) For intrapartum testing to be viable, diagnosis will have to be carried out at 
or close to the point of care, as transportation to a centralised test centre will reduce 
the number of patients able to receive timely results. The state of the art cartridge-
based system requires very little operator input therefore could be transitioned out of 
the laboratory and into a healthcare setting. However the high running cost and initial 
expense of the base station may prohibit use in public healthcare systems. There are 
no economic studies which show applicability for use across the NHS. 
 
1.4.2 Rapid test 
Current US guidelines advise maternal screening at 35-37 weeks gestation. (Verani et 
al., 2010) The GBS status of the vaginal flora rapidly fluctuates; 24-30% of women 
testing positive during pregnancy will not be during labour, and 5-6% of women testing 
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negative will be positive at the time of delivery. (Public Health England, 2015b) 
Outdated test results may misinform clinicians, leading to a lack of necessary treatment 
or inappropriate antibiotic usage. A rapid test would report the current state of maternal 
colonisation, and therefore accurate risk of transmission to the neonate. 
 
Although a screening programme is not currently recommended in the UK, Public 
Health England (2015a) has stated that a rapid point of care diagnostic test able to 
provide results in under two hours may be of interest. NICE has indicated the role of 
rapid GBS testing in antibiotic stewardship, reducing IAP prescriptions. (Jones et al., 
2015) Table 1.6 summarises in which clinical scenarios a rapid test may be useful. 
 
Clinical scenario Rapid test useful? 
No risk factors In screening programme 
GBS colonisation in previous 
pregnancy 
In screening programme 
Preterm delivery Yes; preterm delivery is a risk factor for neonatal GBS disease, 
conventional tests may not have been completed by this time 
point 
Preterm pre-labour rupture of 
membranes 
Yes; preterm delivery is a risk factor for neonatal GBS disease, 
conventional tests may not have been completed by this time 
point 
Symptoms of vaginal/ urinary 
infection during pregnancy 
Yes; rapid testing would allow earlier maternal treatment 
Caesarean section No; GBS transmission unlikely 
Previous infant with GBS disease No; antibiotics would be advised irrespective of results 
Prolonged rupture of 
membranes 
No; if evidence of infection broad spectrum antibiotics should 
be administered 
Pyrexia in labour No; broad spectrum antibiotics should be administered 
 
 
There are several scenarios in which testing would not influence treatment plans. In 
instances of maternal pyrexia, or when there is evidence of infection in cases of 
prolonged membrane rupture, broad spectrum antibiotics would be prescribed 
Table 1.6 The use of a rapid GBS test in various clinical scenarios 
Statements concerning preterm delivery, premature pre-labour rupture of membranes, 
caesarean section, previous infant with GBS disease, prolonged rupture of membrane 
and pyrexia in labour obtained from (Public Health England, 2015a). 
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regardless of GBS status. Targeted antibiotics would be prescribed in cases where a 
mother had previously had a baby infected with GBS infection. However a rapid test 
would be beneficial for preterm births, where results from a potential traditional 
screening programme at 35-37 weeks may not be available. In cases of preterm pre-
labour membrane rupture there is an increased association with early onset disease. 
Rapid testing of GBS status at the time of rupture would enable appropriate antibiotics 
to be given. A rapid test could be used in a universal screening programme or as a 
diagnostic test for specified clinical presentations. In countries that currently conduct a 
screening programme, replacement of traditional tests with a point of care test may 
provide a more accurate infection status, resulting in more appropriate care. 
 
Although a less strict timescale is applicable for detection of adult disease, point of 
care testing would allow diagnosis within a single clinic visit, therefore required 
treatment could start immediately. As S. agalactiae is a dominant cause of early onset 
sepsis and meningitis, neonates presenting with these symptoms are often prescribed 
a suitable treatment for GBS, ampicillin and gentamicin, prior to diagnosis. However, 
infants with late onset sepsis or meningitis are often prescribed gentamicin and 
cloxacillin. (Sivanandan et al., 2011) Once a GBS diagnosis is confirmed, treatment is 
altered to penicillin or ampicillin. Rapid diagnosis would allow for correct treatment to 
be administered initially. 
 
1.5 Project aims 
 
The aim of the project is to progress towards developing a rapid diagnostic test 
primarily for use in intrapartum diagnosis of maternal S. agalactiae colonisation. This 
would best inform clinical treatment of the mother and child to reduce the prevalence 
of early onset group B streptococcal disease. The project will investigate three 
methods of detecting S. agalactiae: using antibodies, isothermal DNA amplification and 
peptide aptamers. 
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1. Current enzyme- and optical-immunoassays based on the detection of 
S. agalactiae-specific polysaccharide are not sensitive enough to be used for 
clinical detection of GBS. Development of an immunoassay which recognises 
protein antigen may overcome the limitations associated with weak 
carbohydrate-protein affinity, and theoretically could exhibit increased 
sensitivity. This project looks to develop antibodies against S. agalactiae 
utilising a novel computer programme to identify peptide sequences unique to, 
and conserved within, S. agalactiae strains. The eventual aim would be to 
incorporate these antibodies into a diagnostic test able to detect all strains of 
S. agalactiae whilst exhibiting no cross-reactivity with other bacterial species. 
 
2. Cepheid’s GeneXpert GBS shows promising sensitivity and specificity whilst 
operating at a relatively fast turn-around time. However its high cost for the base 
station and cartridge replacements restricts its widespread use in healthcare. 
The use of isothermal DNA amplification for the detection of S. agalactiae will 
be considered. These tests have rapid turnaround times and do not require an 
expensive thermocycler, making them more amenable to point of care testing. 
 
3. Although antibodies are commonly used for antigen detection in diagnostics, 
there are several other types of detection molecule. A novel peptide aptamer 
scaffold which functions as a reporter protein whilst specifically recognising the 
target of interest will be considered. This would reduce the steps required in a 
detection assay, beneficial for a rapid point of care test for S. agalactiae 
diagnosis. 
 
The World Health Organisation created the term ASSURED, to describe the desired 
characteristics of a diagnostic test. An optimal diagnostic test would be affordable, 
sensitive, specific, user friendly, robust and rapid, equipment-free and deliverable to 
the point of need. (Mabey et al., 2004) These criteria will be considered in progressing 
towards a point of care GBS diagnostic tool. 
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Chapter 2 Methods 
 
2.1 Materials 
 
Escherichia coli BL21 pLysS DE3 and LMG194 strains were obtained from Novagen 
and ATCC respectively. S. agalactiae strains were obtained from the Statens Serum 
Institut, Copenhagen and S. pyogenes strains were kindly donated by Dr Nicholas 
Jakubovics. The NS-1 cell line was obtained from ATCC. BALB/c mice were obtained 
from Charles River. Custom ordered primers were purchased from Integrated DNA 
Technologies or Life Technologies. Capture and reporter nucleic acid probes were 
purchased from Biomers. Peptides were purchased from Biomatik, Aequorin WT*, 
Aequorin FLAG, SAG1474 and SAG1474-MBP encoding plasmids were manufactured 
by GeneArt, Life Technologies. pBADHisA was supplied by Invitrogen, pET28a by 
Novagen and pMAL p5x plasmid was purchased from New England Biolabs. Luria-
Bertani broth and Bacto Todd-Hewitt media were supplied by Melford and BD 
respectively. Bugbuster master mix for cell lysis was supplied by Novagen. Ellman’s 
reagent was purchased from Thermo Scientific. Maltose binding protein was produced 
by Acris, OriGene Technologies. GelRed nucleic acid stain was supplied by Biotium. 
UltraPure agarose 1000 was purchased from Invitrogen. Gel loading dye was supplied 
by Biorad, the 100 bp DNA ladder was purchased from Promega and the PageRuler 
prestained protein ladder, 10 to 180 kDa from Thermo Scientific. Mouse anti-histidine 
tag antibody was purchased from Abd serotec (MCA1396GA), horseradish peroxidase 
(HRP)-conjugated goat anti-mouse heavy and light chain specific secondary antibody 
was purchased from Abcam (ab97023). ECL western blotting substrate was supplied 
by Pierce, and TMB microwell peroxidase substrate by SureBlue. Maleimide activated 
96 well plates were supplied by Pierce. ISOLATE II RNA mini kit and Tetro cDNA 
synthesis kit were supplied by Bioline. Qiagen supplied the DNeasy blood & tissue kit 
and QIAquick PCR purification kit. Go TaqFlexi PCR kit was supplied by Promega. The 
Imject maleimide activated KLH and BSA conjugation kits were supplied by Thermo 
Scientific. Basic recombinase polymerase amplification kits were purchased from 
TwistDx. All other chemicals were provided by Sigma. 
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2.2 General techniques 
 
2.2.1 Bacterial cell growth 
Details of bacterial strains can be found in table 2.1. E. coli strains were cultured in 
Luria-Bertani broth (LB) (10 g l-1 tryptone, 5 g l-1 NaCl, 5 g l-1 yeast extract) at 37 ˚C. S. 
agalactiae and S. pyogenes strains were cultured in Todd-Hewitt media (3.1 g l-1 heart 
infusion, 20 g l-1 neopeptone, 2 g l-1 dextrose, 2 g l-1 NaCl, 0.4 g l-1 disodium phosphate, 
2.5 g l-1 sodium carbonate), and incubated at 37 ˚C, 5% CO2. Bacteria were grown on 
plates consisting of 7.5 g l-1 agar diluted in their respective medias. Bacterial cultures 
were supplemented with antibiotics if appropriate as detailed in table 2.2. 
Species Serotype Origin 
Escherichia coli BL21 Novagen 
Escherichia coli LMG194 ATCC, 47090 
Streptococcus agalactiae Ia Statens Serum Institut, Copenhagen, 
84902 
Streptococcus agalactiae Ib Statens Serum Institut, Copenhagen, 
84903 
Streptococcus agalactiae II Statens Serum Institut, Copenhagen, 
84904 
Streptococcus agalactiae III Statens Serum Institut, Copenhagen, 
84905 
Streptococcus agalactiae IV Statens Serum Institut, Copenhagen, 
84906 
Streptococcus agalactiae V Statens Serum Institut, Copenhagen, 
84907 
Streptococcus agalactiae VI Statens Serum Institut, Copenhagen, 
84913 
Streptococcus agalactiae VII Statens Serum Institut, Copenhagen, 
84908 
Streptococcus agalactiae VIII Statens Serum Institut, Copenhagen, 
84909 
Streptococcus agalactiae IX Statens Serum Institut, Copenhagen, 
84910 
Streptococcus pyogenes M1 SF370 ATCC, 700294. Donated by Dr Nicholas 
Jakubovics. 
Streptococcus pyogenes M2 75245 Clinical isolate, wound infection, 
Newcastle University. Donated by Dr 
Nicholas Jakubovics. 
Streptococcus pyogenes M5 Manfredo58 Donated by Dr Nicholas Jakubovics. 
Table 2.1 Origin of E. coli and streptococcal strains 
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2.2.2 Bacterial cell storage 
Bacterial cell stocks were frozen from cultures grown for 16-21 hours in a solution of 
50% cell culture, 25% glycerol, 25% dH2O, with stocks kept at -80 ˚C and in liquid 
nitrogen. Bacteria were resuscitated from these frozen stocks when required. 
 
2.2.3  SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate proteins based on molecular weight, as originally described by Laemmli. 
(Laemmli, 1970) In this technique SDS is added to the sample, linearising proteins and 
coating them in a uniform negative charge; the sample is then loaded onto a gel. An 
electric current is applied, attracting the negatively charged proteins to the base of the 
gel, towards the anode. The stacking gel acts to concentrate proteins in a small volume. 
The buffer contains glycine which, when it enters the gel, becomes dominated by its 
zwitterionic state and therefore moves slowly. The chloride ions within the gel move 
quickly, creating a strongly negatively charged band which is able to pull along the 
glycine band. When the differentially charged bands pass through the sample well, 
proteins accumulate within the narrow gap as proteins have an electrophoretic mobility 
which is intermediate to the two fronts. The proteins then enter the resolving gel, which 
consists of a less porous structure. Small proteins navigate easily through the gel 
structure, with large proteins impeded to a greater extent. 
 
Plasmid Antibiotic Working 
concentration 
/ µg ml-1 
Solvent 
pLysS Chloramphenicol 25 Ethanol 
pBAD HisA Ampicillin 100 dH2O 
pET28a Kanamycin 50 dH2O 
pMAL p5x Ampicillin 100 dH2O 
Table 2.2 Antibiotic concentrations 
Antibiotics were reconstituted in ethanol or dH2O (highly purified water), at the specified 
concentrations. 
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SDS-PAGE buffer was added to protein samples (final concentration 3.1 mM Tris HCl, 
0.4% SDS (w/v), 960 mM glycerol, 3.3 µM EDTA (ethylenediaminetetraacetic acid), 
300 nM bromophenol blue) and incubated at 95 °C for 5 minutes to disrupt the three-
dimensional structure. β-mercaptoethanol was added to samples that required 
disulphide bond disruption, at a final concentration of 2.5%. Samples were run on 
discontinuous gels consisting of a stacking gel (3.5% acrylamide (w/v), buffered with 
0.125 M Tris HCl, 0.1% SDS (w/v), pH 6.8) and a resolving gel (7.5-15% acrylamide, 
buffered with 0.375 M Tris HCl, 0.1% SDS (w/v), pH 8.8). The gels were catalysed with 
0.125% ammonium persulphate (w/v) and 0.0025% TEMED (v/v). The acrylamide 
percentage of the resolving gel was varied dependent on the molecular weight of the 
protein to be studied. Electrophoresis was performed at 120-200 V in running buffer 
(25 mM Tris, 192 mM glycine, 0.1% SDS (w/v), pH 8.3), until the dye front reached the 
end of the gel. Following gel electrophoresis, proteins were visualised by staining with 
Coomassie Brilliant Blue R for 1 hour, followed by background de-staining in 40% 
methanol, 10% acetic acid for 1 hour. Images were taken with a standard camera or 
LI-COR Odyssey Fc using the 700 nm channel. A protein ladder (PageRuler prestained 
protein ladder, 10 to 180 kDa) was used for protein size estimation. 
 
2.2.4 Western blotting 
Protein samples separated by gel electrophoresis were transferred to a polyvinylidene 
difluoride membrane (pore size 0.45 µm) via the wet electrophoretic transfer method. 
Membranes were activated by soaking in methanol for 15 seconds before incubation 
in transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol) for 15 minutes 
alongside the SDS PAGE gel. A sandwich of pad, filter paper, gel, membrane, filter 
paper, pad was constructed. The tank was filled with transfer buffer, and the system 
was kept at 4 °C. Proteins were transferred at a constant current, 200 mA, for 2 hours. 
The negatively charged proteins moved from the gel to the membrane towards the 
positively charged anode. 
 
Membranes were incubated overnight at 4 °C in blocking buffer (5% milk solution or 2% 
bovine serum albumin (BSA) in phosphate buffered saline (PBS) (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4)). Membranes were washed 
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three times in wash buffer (blocking buffer, 0.05% tween 20). Membranes were 
incubated in 1 µg ml-1 mouse anti-histidine tag primary antibody in wash buffer at room 
temperature for 2 hours. Membranes were washed in wash buffer three times before 
incubation with 100 ng ml-1 HRP-conjugated goat anti-mouse heavy and light chain 
specific secondary antibody in wash buffer at room temperature for 1 hour. Membranes 
were washed four times in wash buffer, three times in PBST (PBS, 0.05% tween 20) 
and twice in PBS. ECL western blotting substrate was added to the membrane, and 
the chemiluminescent signal detected using a LI-COR Odyssey Fc. ECL western 
blotting substrate contains luminol and a peroxide reagent. Luminol turnover is 
catalysed by HRP, producing a chemiluminescent signal. 
 
2.2.5 Indirect enzyme linked immunosorbent assay (ELISA) 
Antigen solutions were prepared in carbonate buffer (50 mM sodium carbonate, 
pH 9.6). Protein solutions were prepared at 2 µg ml-1. For whole cell antigen, bacterial 
cells were pelleted by centrifugation and re-suspended in carbonate buffer in the 
original volume. For lysed cell antigen, bacterial cells were pelleted by centrifugation 
and re-suspended in 1/10 volume of lysis buffer (Tris-EDTA, 2 mg ml-1 lysozyme, 
50 U ml-1 mutanolysin). The solutions were incubated at 37 °C for 1 hour. Carbonate 
buffer was added to the original bacterial cell culture volume. 
 
96 well plates were coated with 100 µl antigen, and incubated overnight at 4 °C. Wells 
were blocked with 200 µl 2% milk in carbonate buffer for 1 hour at room temperature 
or at 4 °C overnight. Wash steps consisted of a 5 minute incubation in PBST. Plates 
were washed 3 times and incubated with 100 µl primary antibody for 1 hour at room 
temperature, either in the form of purified antibody diluted in PBS, cell culture solution 
or murine sera. The plates were washed three times and incubated with 100 µl 
100 ng ml-1 HRP-conjugated goat anti-mouse IgG heavy and light chain specific 
secondary antibody diluted in PBS for 1 hour at room temperature. Plates were washed 
3 times and incubated with 100 µl TMB (3, 3’, 5, 5’-tetramethylbenzidine) for 30 minutes. 
The absorbance at 630 nm was read on a Tecan Infinite 200. 
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2.2.6 Protein concentration determination – BCA assay 
A BCA (bicinchoninic acid) assay was performed to determine protein concentration. 
A standard curve using known concentrations of BSA was produced. 10 µl sample or 
BSA standard and 200 µl of BCA reagent (0.08% (w/v) cupric sulphate in BCA) was 
added to each well, and the plate was incubated at 37 °C for 30 minutes. Absorbance 
was read at 562 nm on a Tecan Infinite 200. 
 
2.2.7 Protein concentration determination – spectrophotometry 
Protein concentration was determined by spectrophotometry (NanoVue Plus) through 
the absorbance of UV (ultraviolet) light by tryptophan, tyrosine and cysteine residues. 
The extinction coefficient values and molecular weights were estimated through use of 
ExPASy software (Gasteiger et al., 2005) see table 2.4 in section 2.4.1. Results were 
evaluated for the presence of a distinct peak at 280 nm. 
 
2.2.8 RNA extraction 
RNA was extracted from S. agalactiae strains using ISOLATE II RNA mini kit. The 
protocol for gram positive bacteria was followed, 3 mg ml-1 lysozyme and 60 U ml-1 
mutanolysin were utilised for enhanced cell lysis. RNA was eluted in 50 µl dH2O. 
 
2.2.9 cDNA synthesis 
Reverse transcription was performed to convert the RNA extracted from S. agalactiae 
to cDNA (complementary DNA) for use in PCR reactions. Tetro cDNA synthesis kit 
was utilised. Briefly, 5 µg RNA was added to 4 µl buffer, 1 µl RiboSafe RNase inhibitor, 
1 µl random hexamer primers, and 1 µl Tetro reverse transcriptase, the solution was 
made up to 20 µl with dH2O. The reaction mix was incubated for 10 minutes at 25 °C 
followed by 30 minutes at 45 °C. The reaction was terminated by incubation at 85 °C 
for 5 minutes. 
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2.2.10 DNA extraction 
DNA was extracted from S. agalactiae strains using Qiagen’s DNeasy blood & tissue 
kit. DNA extraction was performed according to the manufacturer’s protocol, 60 U ml-1 
mutanolysin was added to the lysis buffer immediately before use. DNA was eluted in 
200 µl elution buffer. 
 
2.2.11 Polymerase chain reaction 
DNA was amplified using GoTaq Flexi PCR kit. The reaction mix consisted of 20% (v/v) 
buffer, 2 mM MgCl2, 0.2 mM dNTPs (deoxynucleotide triphosphates), 1 µM forward 
primer, 1 µM reverse primer, 1.25 U GoTaq DNA polymerase and 0.5 µg DNA. PCR 
was performed using a MyCycler Biorad thermocycler. Samples were initially 
denatured at 95 °C for 2 minutes, followed by 25 cycles of denaturation (95 °C for 1 
minute), annealing (see table 2.3 for annealing temperature, for 1 minute) and 
extension (72 °C for 1 minute (if amplicon ~500 bp) or 3 minutes (if amplicon ~2500 bp)) 
and final extension at 72 °C for 5 minutes. The primers used and resulting amplicon 
lengths are detailed in table 2.3. 
 
Target Primer sequences Amplicon length / 
base pairs 
Annealing 
temperature / °C 
SAG0771 F:GTGTGAAAACGAATGATGCC 
R:GTGTGAAAACGAATGATGCC 
499 51 
SAG1473 F:GCACTTACTGTCTTAACATGTG 
R: ATAATCCCTCCCGTAGATGC 
500 51 
SAG1474 F: AGCCAACATGGTGAGAAGTG 
R:GGAATACGGATAGAACCACCAG 
498 50 
RPA template F:ATGGAGACGGCTAACAATAA 
R:TACCATCAGGCTTGTTCTCT 
2583 48 
 
2.2.12 Agarose gel 
DNA samples were analysed by electrophoretic separation on agarose gels. The 
percentage of agarose used was dependent on the size of DNA fragment to be 
analysed (3% for samples 100-200 bp, 2% for samples ~500 bp). Agarose was melted 
in 0.5X TBE (tris-boric acid-EDTA buffer) (47 mM Tris, 1.3 mM EDTA, 45 mM boric 
Table 2.3 Details on PCR experiments 
Annealing temperatures determined by Primer3Plus 
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acid). 0.01% (v/v) GelRed nucleic acid stain was added, and gels were cast. Gel 
loading dye was added to samples prior to loading onto the gel. DNA standards (PCR 
low ladder, 20 bp and 100bp DNA ladder) were used for molecular weight estimation. 
Electrophoresis was performed at 80 V in 0.5x TBE, until the dye front approached the 
end of the gel. Gels were imaged using a LI-COR Odyssey Fc. 
 
2.2.13 Nucleic acid concentration determination - spectrophotometry 
A spectrophotometer (NanoVue plus) was used to calculate nucleic acid concentration 
by exploiting its absorbance of UV light at 260 nm. An absorbance reading of 1 A (with 
a 1 cm pathlength) equates to 50 µg ml-1 DNA and 40 µg ml-1 RNA. An absorbance 
scan of wavelengths 220 nm to 325 nm was completed, allowing assessment of 
sample purity. 
 
DNA copy number was calculated using the equation below: 
 
𝐶𝐶𝑃𝑃𝑆𝑆𝑆𝑆 𝑆𝑆𝑇𝑇𝑛𝑛𝑛𝑛𝑆𝑆𝑇𝑇 (𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆𝑇𝑇𝐹𝐹𝑆𝑆𝑆𝑆) = mass (g) 𝑥𝑥 6.0221 𝑥𝑥 1023(𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆𝑇𝑇𝐹𝐹𝑆𝑆𝑆𝑆 𝑛𝑛𝑃𝑃𝐹𝐹−1)
𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆𝑇𝑇𝐹𝐹𝐹𝐹𝑇𝑇 𝑤𝑤𝑆𝑆𝑆𝑆𝑁𝑁ℎ𝑆𝑆 (𝑁𝑁 𝑛𝑛𝑃𝑃𝐹𝐹−1)  
 
2.2.14 DNA purification 
PCR product was purified for use in subsequent RPA reactions using Qiagen’s 
QIAquick PCR purification kit, following the centrifugation protocol. All centrifugations 
were performed at 13,000 g for 1 minute. DNA was eluted in 50 µl dH2O. 
 
2.2.15 Statistics 
Non-parametric Mann-Whitney U tests were performed to assess statistical 
significance between two groups, comparing median values. One assumption the 
Mann-Whitney U test requires is that groups have equal variances, this was validated 
using a Lavene’s test. A Kruskal-Wallis test was performed to extend the comparison 
to multiple groups. For analysis of data extracted by microarray studies, unpaired 
student t tests were performed, replicating the strategies followed by the authors of the 
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studies. (Klinzing et al., 2009; Santi et al., 2009) These tests were performed on 
Minitab. (Minitab Inc, 2014) 
 
2.3 Computing 
 
2.3.1 IDRIS 
IDRIS is a bespoke in-house computer system developed at Newcastle University 
within the i-sense project (www.i-sense.org.uk/). (Flanagan et al., 2014) IDRIS 
compares amino acid sequences to identify peptides which appear in a user defined 
group of bacteria, and in no other bacteria. The reported amino acid sequences are 
therefore conserved within and unique to the group of interest. IDRIS consists of two 
workflows: ApID1 and ApID2. Within ApID1, the translated protein sequences from all 
complete bacterial genomes in the RefSeq database are captured by IDRIS. IDRIS 
creates a database of 15-mer amino acid “tokens”, capturing each 15-amino acid run 
via a sliding window which moves across the sequence in single-step increments. Each 
peptide is annotated with the protein and species it belongs to, along with its predicted 
cellular localisation. Protein localisation is determined via PSORTb, SignalP and LipoP 
(discussed further in following sections). Within ApID2 a group of interest is designated, 
tokens which appear in each proteome in this group are selected. This group of tokens 
is compared to tokens from proteomes external to the group; tokens are eliminated if 
they also belong to any other proteome. The resulting IDRIS report lists group-
distinctive peptides, the protein they are found within and their predicted cellular 
localisations. 
 
IDRIS v1.0 was utilised for initial work within this project. Subsequent iterations (v1.5 
and v2.0) include updated RefSeq data and the capability to analyse protein 
localisation in gram negative bacteria. Currently the IDRIS token database comprises 
of 7.65 billion tokens from 7,059 organisms. 
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2.3.2 PSORTb 
PSORTb is a protein localisation prediction tool. (Yu et al., 2010) It was created on a 
dataset of 2652 gram positive proteins with known localisations. PSORTb v3.0 has a 
higher accuracy than competitor tools, but is less sensitive, therefore the frequency of 
unknown localisations is higher. PSORTb is able to identify 25 sequence motifs and 6 
profiles (sequence motifs with position specific weighting) for gram positive bacteria. 
The programme returns a localisation prediction score out of 10 for 4 locations: 
extracellular, cell wall, cytoplasmic membrane and cytoplasmic. PSORTb was used to 
confirm IDRIS localisation predictions of SAG0771, SAG1473 and SAG1474. 
 
2.3.3 SignalP 
SignalP predicts the presence of and cleavage site of a signal peptide within a protein 
sequence. (Petersen et al., 2011) A large C-score is found in the first residue of the 
mature protein following signal peptide cleavage. The S-score discriminates residues 
in a signal peptide from those in a mature protein or protein with no signal peptide. The 
Y-score is derived from the C-score and the gradient of the S-score to report a more 
precise prediction of the cleavage site. The mean S-score is an average of the S-
scores of all amino acids up to the residue before the maximum Y-score. The D-score 
is determined by a weighted combination of the mean S-score and maximum Y-score. 
A D-score over 0.45 (range: 0-1) represents the presence of a signal peptide. The 
probability of a false positive result is 0.001. SignalP was used to confirm IDRIS 
localisation predictions of SAG0771, SAG1473 and SAG1474. 
 
2.3.4 LipoP 
LipoP is a prediction tool which distinguishes lipoprotein signal peptides from 
alternative signal peptides, N-terminal membrane helices and other proteins. (Juncker 
et al., 2003) LipoP predicts cleavage sites for signal peptides and lipoprotein signal 
peptides if appropriate. The highest scoring protein class is returned as the best fitting 
prediction. Although the server was created for use in gram negative bacteria, it has 
been found to be applicable to gram positive bacteria also. (Rahman et al., 2008) LipoP 
was used to confirm IDRIS localisation predictions of SAG0771, SAG1473 and 
SAG1474. 
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2.3.5 TMHMM 
TMHMM predicts the presence, length and orientation of transmembrane helices within 
a protein sequence. (Krogh et al., 2001) A probability plot is created using an average 
score, from all potential structure models, of the probability of each amino acid to exist 
in a transmembrane helix, intracellular or extracellular environment. TMHMM was used 
to confirm IDRIS localisation predictions of SAG0771, SAG1473 and SAG1474. 
 
2.3.6 I-TASSER 
I-TASSER is a server which predicts structural models based on a protein sequence. 
(Roy et al., 2010) Secondary structural templates are assembled into full length models 
that are iteratively threaded through homology models to improve the prediction. 
Models are refined to minimise steric hindrance and optimise hydrogen bonding. A 
confidence score (C-score) is calculated from the convergence parameters of models 
and the significance of alignment with templates. In validation studies TM-scores were 
determined by analysing structural similarity between a predicted structure and its 
empirically determined structure. A strong correlation was found between C-score and 
TM-score. A predicted TM-score is calculated for each predicted structure. A TM-score 
(range: 0-1) of ≥0.5 is considered a correct fold. I-TASSER was used to visualise the 
structure of SAG0771, SAG1473 and SAG1474. I-TASSER was also used in the 
analysis of peptide secondary structure and surface exposure with the SAG1474 
protein. 
 
2.3.7 PSIPRED 
PSIPRED v3.3 is a tool for the prediction of secondary structure. (Jones, 1999) The 
server utilises evolutionarily related sequences, determined by position specific 
iterated BLAST, (Altschul et al., 1997) to train a machine learning algorithm to predict 
the secondary structure of each amino acid residue. PSIPRED was used in analysing 
the secondary structure of SAG1474 for antigen selection. 
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2.3.8 Prodepth 
Prodepth is used to predict surface accessible amino acids within a protein sequence. 
(Song et al., 2009) The server predicts the distance between each residue and its 
nearest water molecule. The larger the length, the deeper the residue is buried. The 
threshold for exposure is set to 3.0 Å. Prodepth combines data on solvent accessibility 
(SCRATCH), secondary structure (PSIPRED), disordered regions (DISOPRED) and 
sequence alignments (PSI-BLAST) to generate its output. Input programmes shown in 
brackets. Prodepth was used for analysis of SAG1474 peptide surface exposure for 
antigen selection. 
 
2.3.9 Bcepred 
Bcepred is a tool to predict linear B-cell epitopes from a protein sequence. (Saha and 
Raghava, 2004) The server allows threshold values for various parameters 
(hydrophilicity, flexibility/mobility, accessibility, polarity, surface exposure and turns) to 
be set as desired. A study into optimal epitope prediction determined that using 
hydrophilicity, flexibility, polarity and surface exposure with threshold values 2.0, 1.9, 
2.3 and 2.4 respectively, and an overall threshold of 2.38 enabled 58.7% accuracy. 
These parameters and threshold values were utilised for the study of SAG1474 tokens. 
 
2.3.10 Microarray data analysis 
The Gene Expression Omnibus (GEO) and ArrayExpress are public repository 
databases consisting of gene expression studies including microarray studies. These 
databases were searched to investigate changes in gene expression in response to 
temperature (GEO: GSE14573) and pH (ArrayExpress: E-TABM-708). Data from the 
two microarray studies were extracted and expressed as the average normalised 
fluorescent signal of the test condition as a ratio to the control condition. Values were 
considered to be statistically different from the control if ratios were <0.5 or >2 and had 
a p value ≤0.01. 
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2.3.11 Protein BLAST (Basic local alignment tool) search 
Protein BLAST searches (Altschul et al., 1990) were performed to analyse similarity 
between query proteins and sequenced proteins within the specified dataset. Specific 
organisms can be included or excluded from the search criteria. Results showed 
peptide sequences with the highest similarity to the query, the alignment between 
these sequences, and the percentage of amino acid similarity and identity. 
 
2.3.12 DNA alignment 
DNA encoding for the S. agalactiae SAG1474 protein was inputted to a standard 
nucleotide BLAST to find all variants of the sequence within the NCBI GenBank. The 
aligned sequences (Zhang et al., 2000) were exported and visualised using Jalview. 
(Waterhouse et al., 2009) DNA alignments were manually adjusted to allow analysis 
of the number of base mismatches found in each prospective RPA primer. 
 
2.3.13 Primer design: PCR and RPA 
Primers were designed using Primer3Plus. (Untergasser et al., 2007) For primers for 
use in PCR, the following parameters were set: primer size: 18-22 bp, primer Tm: 52-
63 °C, maximum primer Tm difference: 10 °C, primer GC content: 40-60%, maximum 
3’ self-complementarity: 3, maximum self-complementarity: 8, optimal amplicon length: 
500 bp (base pairs) or 2500 bp, and all penalties: 1. For use in RPA, primers were 
designed using the following parameters: primer size: 18-35 bp, optimal amplicon 
length: 80-275 bp and all penalties: 1. Potential primers were evaluated using IDT 
OligoAnalyzer 3.1, to predict melting temperatures of hairpin structures and the change 
in Gibbs’ free energy (ΔG) associated with primer self-dimers and hetero-dimers. For 
PCR primers thermal properties were calculated using the following conditions: 0.5 µM 
oligo, 50 mM Na+, 2 mM Mg2+, 0.2 mM dNTPs and at the primers’ annealing 
temperature. For RPA primers thermal properties were calculated using the following 
conditions: 0.5 µM oligo, 0 mM Na+, 14 mM Mg2+, 0.24 mM dNTPs and at 25 °C. 
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2.3.14 Band densitometry 
LI-COR Image Studio was used to analyse SDS-PAGE and agarose gel images. Band 
densities were calculated for comparison of protein levels. Background levels (median 
values surrounding the bands, with a border width of 3) were subtracted from protein 
signals. 
 
2.4 Recombinant protein expression and purification 
 
2.4.1 Overview 
Table 2.4 shows the recombinant proteins made in this work and several predicted 
parameters. 
 
Protein Molecular weight / 
kDa 
Extinction coefficient 
/M-1 cm-1 
Isoelectric point 
(pI) 
Aequorin- WT* 22.6 43.4 5.2 
Aequorin-FLAG 23.6 44.9 5.0 
SAG1474 69.4 65.3 8.5 
SAG1474-MBP 115 133 6.5 
 
2.4.2 Competent cells 
Competent cells are permeable to accept horizontally transferred DNA. Chemically 
competent E. coli cells were created by the addition of positively charged cations to 
minimise electrostatic repulsion between the bacterial cell and external DNA. 500 µl 
cell suspension from an overnight culture was added to 50 ml LB broth and grown to 
an OD (optical density) 600 nm of 0.35-0.45. Further steps were carried out at 4 °C or on 
ice. Cells were centrifuged at 700 g for 10 minutes. The pellet was re-suspended in 
5 ml filter-sterilised (0.22 µm pore size) transformation and storage buffer (12.5 mM 
PEG (polyethylene glycol) 8000, 30 mM MgCl2, 5% dimethyl sulphoxide (DMSO) in LB 
media). 100 µl aliquots were frozen at -80 °C. 
Table 2.4 Recombinant proteins and associated parameters 
Protein parameters were calculated using ExPASy. (Gasteiger et al., 2005) 
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2.4.3 Transformation 
Plasmid DNA was transformed into competent E. coli cells. 50 ng of plasmid DNA was 
added to 500 µl of thawed competent cells and incubated on ice for 30 minutes. Cells 
were heatshocked at 42 °C for 45 seconds and transferred to an ice bath for 1-2 
minutes. 800 µl of LB media was added and cells were incubated at 37 °C for 90 
minutes. Cells were centrifuged at 14,000 g for 1 minute, and 800 µl of supernatant 
was removed. Cell suspensions were cultured on antibiotic selective media to select 
for transformants that had received the plasmid-derived antibiotic resistance. Table 2.5 
details the E. coli strains used in the production of recombinant proteins. 
 
Name Genotype Recombinant protein 
BL21 BL21 pLysS DE3 N/A 
LMG194 LMG194 N/A 
Aeq-WT*(BL21) BL21 pLysS DE3 
pBADHisA:Aeq-WT* 
Aequorin WT* 
Aeq-FLAG(BL21) BL21 pLysS DE3 
pBADHisA:Aeq-FLAG 
Aequorin FLAG 
Aeq-WT*(LMG194) LMG194 
pBADHisA:Aeq-WT* 
Aequorin WT* 
Aeq-FLAG(LMG194) LMG194 
pBADHisA:Aeq-FLAG 
Aequorin FLAG 
SAG1474(BL21) BL21 pLysS DE3 pET:SAG1474 SAG1474 
SAG1474-MBP(BL21) BL21 pLysS DE3 
pMALp5x:SAG1474-MBP 
SAG1474-MBP 
 
2.4.4 Induction growth tests 
Growth tests were performed to assess the optimum conditions for protein 
expression. E. coli cells were grown to an OD 600 nm of 0.5 and induced with the 
appropriate compound: isopropyl β-D-1 thiogalactopyranoside (IPTG) for genes 
located in pET28a and pMAL p5x plasmids and arabinose for pBADHisA plasmids. 
Several parameters were investigated: cell type (BL21, LMG194), temperature (37 °C, 
Table 2.5 E coli strains for production of recombinant protein 
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30 °C, 25 °C and 20 °C), concentration of inducer (IPTG: 0 mM – 2 mM, arabinose: 
0%-0.2%) and time of induction (1-16 hours). Cells were pelleted by centrifugation. 
 
2.4.5 Cell lysis  
Cells were lysed by sonication or chemical lysis. For sonication, cells were 
re-suspended in 20 mM sodium phosphate buffer, pH 7.4 with 150 or 500 mM NaCl. 
Cell suspensions were sonicated on ice with six 15-second bursts. Cells were 
chemically lysed by re-suspension in Bugbuster protein extraction reagent followed by 
incubation at room temperature for 20 minutes whilst shaking. Lysed cells were 
centrifuged to separate the soluble and insoluble fractions. 
 
2.4.6 Periplasmic extraction 
The periplasmic fraction was extracted as per pMAL guidelines. (New England BioLabs, 
2017b) Cells were re-suspended in 400 µl 30 mM Tris-HCl, pH 8.0, 20% sucrose. 
EDTA was added to 1 mM, and the solution was shaken for 10 minutes at room 
temperature. All further steps were completed at 4 °C. Cells were pelleted at 8000 g 
for 10 minutes, and re-suspended in 400 µl ice cold 5 mM MgSO4. The solution was 
shaken for 10 minutes and centrifuged at 8000 g for 10 minutes. The periplasmic 
fraction was found in the supernatant. 
 
2.4.7 Protease cleavage 
SAG1474-MBP was cleaved at the TEV protease (protease from the Tobacco Etch 
Virus) cleavage site to separate SAG1474 from the MBP binding protein. The protein 
sample was dialysed overnight at 4 °C into 25 mM Tris-HCl, pH 8.0, 500 mM NaCl, 
14 mM β-mercaptoethanol, with one buffer change. TEV protease was added to 1% 
(w/w). The sample was incubated at 4 °C for 16 hours. TEV protease was removed via 
chromatography. 
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2.4.8 Protein purification - chromatography 
Large scale bacterial culture was performed using the induction, cell lysis and protein 
extraction conditions previously determined. Proteins were purified from the crude 
cellular protein mixture using nickel-affinity, ion-exchange, GST (glutathione S 
transferase)-affinity and size exclusion chromatography using an Åkta start system. All 
buffers were filtered (0.22 µm) and degassed prior to use. Samples were filtered (0.22 
µm) prior to addition to the column. All purification steps were performed at a speed of 
1 ml min-1. 
 
2.4.9 Nickel-affinity chromatography 
Proteins containing a polyhistidine tag can be purified by exploiting the affinity for nickel. 
Proteins are eluted by raising the imidazole concentration of the buffer, which has a 
higher affinity for nickel and therefore outcompetes the protein. (Bornhorst and Falke, 
2000) His-tagged proteins were purified using a HisTrap HP column. 20 mM sodium 
phosphate buffer, pH 7.6, 500 mM NaCl was used for column buffers. Imidazole was 
added to the loading, wash and elution buffers at final concentrations of 10 mM, 20 mM 
and 250 mM respectively. The system was equilibriated with loading buffer. Sample 
was added to an equal volume of wash buffer and loaded onto the column. The column 
was flushed with wash buffer until there was no change in absorbance spectra. Elution 
buffer was added to the system at a concentration gradient of 5% per 1 ml eluted. 1 ml 
fractions were collected. 
 
2.4.10 GST-affinity chromatography 
The GST-tagged protein TEV protease was purified using a GSTrap FF column. GST 
binds to its substrate glutathione, immobilised onto a column. The tagged protein is 
eluted by addition of an excess of free glutathione to the system. Briefly, the sample 
was dialysed in PBS overnight at 4 °C with one buffer change. The column was 
equilibriated with PBS, the sample was added and the column was washed with 5 
column volumes of PBS. GST-affinity chromatography was performed to remove a 
GST-tagged contaminant (TEV protease), therefore flow through was collected. The 
column was cleaned by addition of elution buffer (50 mM Tris HCl, pH 8.0, 10 mM 
reduced glutathione). 
45 
 
2.4.11 Ion exchange chromatography 
Proteins were purified by ion exchange chromatography using HiTrap CM FF (cationic 
exchanger) and HiTrap DEAE FF (anionic exchanger) columns. Proteins with a higher 
pI than the pH of the buffer are positively charged, and are able to bind to a cationic 
exchange column. Proteins with a lower pI than the pH of the buffer are negatively 
charged, and therefore bind to an anionic exchange column. Proteins are eluted by 
increasing the salt concentration, with the higher concentration of ions outcompeting 
the affinity of the protein for the column. (Selkirk, 2004) For cationic exchange 
chromatography, the protein sample was dialysed overnight at 4 °C into loading buffer 
(50 mM sodium phosphate, pH 7.5, 50 mM NaCl), with one buffer change. The column 
was equilibriated with loading buffer and the sample was loaded onto the column. The 
column was washed with 5 column volumes of loading buffer. Protein was eluted with 
10 column volumes of elution buffer (50 mM sodium phosphate, pH 7.5, 1 M NaCl). 1 
ml fractions were collected. For anionic exchange chromatography, the protein sample 
was dialysed overnight at 4 °C into loading buffer (50 mM sodium phosphate buffer, 
pH 7.2, 50 mM NaCl) with one buffer change. The column was equilibriated with 
loading buffer and the sample was loaded onto the column. The column was washed 
with 5 column volumes of loading buffer. Elution buffer (50 mM sodium phosphate 
buffer, pH 7.2, 1 M NaCl) was added to the system at a concentration gradient of 2% 
per 1 ml eluted, until elution buffer was at 50%. 100% elution buffer was used to wash 
remaining protein from the column. 1 ml fractions were collected. 
 
2.4.12 Size exclusion chromatography 
Proteins were separated by size using a HiLoad 16/600 Superdex 200 prep grade 
column. Large proteins cannot enter the pores within the beads which form the 
chromatography column, and therefore flow through the column quickly. Smaller 
proteins enter the pores and their progress through the column is slowed. Thus 
proteins are separated based on their molecular size. The column was equilibriated 
with PBS, and the sample was loaded onto the column in 1 or 2 ml volumes. Samples 
were concentrated using a vivaspin column to reduce buffer volume if necessary. The 
column was washed with PBS until the desired protein was eluted. 1 ml fractions were 
collected. 
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2.4.13 Circular dichroism 
Circular dichroism (CD) is a technique utilised to study protein structure, based on the 
differential absorbance of right handed, and left handed, circularly polarised light. 
Further explanation can be found in section 4.4.6. Circular dichroism (CD) was 
performed to analyse the secondary and tertiary structure of proteins, using far and 
near UV respectively. The melting temperature of protein secondary structure was also 
analysed. These experiments were performed using a JASCO J-810. Protein samples 
were dialysed into 20 mM potassium phosphate, pH 7.5, 50 mM NaCl. Background 
scans were performed using buffer and subtracted from far and near UV scans. The 
following table, table 2.6, shows experiments details. HT (feedback voltage) values 
were monitored to ensure they did not exceed 800 V. 
 Far UV Near UV Thermal melt 
Varied parameter 190-250 nm 250-320 nm 10-95 °C 
Measurement 
increment 
0.2 nm 0.2 nm 0.2 °C 
Protein concentration 
/ µM 
9.9 9.9 2.4 
Cuvette path length 0.2 mm 1 cm 1 cm 
Number of scans 9 9 1 
Number of 
background scans 
3 3 0 
 
 
2.4.14 Liquid chromatography mass spectrometry 
Liquid chromatography mass spectrometry was performed by Newcastle University 
Protein and Proteome Analysis. The protein sample was extracted from an SDS-PAGE 
gel, protease digested and peptides were separated by liquid chromatography. The 
mass:charge ratios of ionised peptides were determined by mass spectrometry. A 
reference data set comprising of proteins from E. coli, S. agalactiae and the 
recombinant SAG1474-MBP sequence was utilised to determine protein identity. 
 
 
Table 2.6 Experimental details for circular dichroism 
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2.5 Antibody production 
 
2.5.1 Overview 
Murine antibodies were raised in house against three peptides CVQTNDSNPT, 
CVNLEENSQV and CNMENLSQEERI. This work was performed in combination with 
Julia Spoors and Robert Bolt. 
 
2.5.2 Peptide - carrier protein conjugation 
Peptides were conjugated to maleimide activated keyhole limpet haemocyanin (KLH) 
for murine immunisation. Each peptide contained an N-terminal cysteine residue to 
enable directed conjugation. Peptides were also conjugated to maleimide activated 
BSA for use in antibody screening for target affinity. Peptides were conjugated to their 
carrier proteins using Imject maleimide activated KLH and BSA conjugation kits, 
according to the manufacturer’s protocol. Briefly, 2 mg carrier protein was reconstituted 
in dH2O to 10 mg ml-1 and added to 2 mg peptide dissolved in conjugation buffer. 
Conjugation mix was incubated at room temperature for 2 hours. Conjugated peptide 
was purified using a desalting column to remove EDTA prior to injection into mice. 
 
2.5.3 Ellman’s test 
An Ellman’s test was carried out to estimate the coupling efficiency of peptide to KLH 
and BSA and to estimate the average number of peptide molecules attached to the 
carrier protein. Cysteine standards (0-5 mM) were used to create a standard curve, 
from this, the concentration of free cysteine residues in the unconjugated peptide and 
the peptide after conjugation were interpolated. 
 
200 µl Ellman’s buffer (0.2 M sodium phosphate buffer, pH 8.0, 0.15 M NaCl, 0.1 M 
EDTA) was loaded into each well. 20 µl of Ellman’s reagent 
(5,5’dithio-bis-(2-nitrobenzoic acid) at 1 mg ml-1 diluted in Ellman’s buffer, and 10 µl of 
cysteine standards or sample was added to wells. The plate was incubated at room 
temperature for 15 minutes, and the absorbance was read at 412 nm on a Tecan 
Infinite 200. 
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The following calculations were performed: 
 
𝐶𝐶𝑃𝑃𝑆𝑆𝐶𝐶𝑇𝑇𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝐶𝐶 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑆𝑆𝑃𝑃𝑆𝑆𝐹𝐹𝐹𝐹 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆) ∗ −𝑇𝑇𝑆𝑆𝑆𝑆𝑃𝑃𝑆𝑆𝐶𝐶𝑇𝑇𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝐶𝐶 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆) ∗∗ 
 
𝐶𝐶𝑃𝑃𝑆𝑆𝐶𝐶𝑇𝑇𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝑃𝑃𝑆𝑆 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑆𝑆𝑃𝑃𝑆𝑆𝐶𝐶𝑇𝑇𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝐶𝐶 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆)
𝑆𝑆𝑃𝑃𝑆𝑆𝐹𝐹𝐹𝐹 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆)  
 
𝑁𝑁𝑇𝑇𝑛𝑛𝑛𝑛𝑆𝑆𝑇𝑇 𝑃𝑃𝑆𝑆 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐶𝐶𝑆𝑆𝑆𝑆 𝑆𝑆𝑆𝑆𝑇𝑇 𝑆𝑆𝑇𝑇𝑃𝑃𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑇𝑇𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐶𝐶𝑆𝑆 (𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆) 𝑥𝑥 𝑆𝑆𝑃𝑃𝑆𝑆𝐶𝐶𝑇𝑇𝑁𝑁𝐹𝐹𝑆𝑆𝑆𝑆𝑃𝑃𝑆𝑆 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆
𝑆𝑆𝐹𝐹𝑇𝑇𝑇𝑇𝑆𝑆𝑆𝑆𝑇𝑇 𝑆𝑆𝑇𝑇𝑃𝑃𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (𝑛𝑛𝑃𝑃𝐹𝐹𝑆𝑆𝑆𝑆)  
 
* Determined by the number of free cysteine residues in the peptide sample prior to 
conjugation. 
** Determined by the number of free cysteine residues in the protein-peptide sample 
following conjugation. 
 
2.5.4 Mouse immunisation 
6-8 week old female BALB/c mice were immunised with KLH-conjugated peptide. Two 
week intervals were scheduled between the first four immunisations. The time between 
the penultimate immunisation and pre-immune boost varied from 14 days to 98 days. 
The final pre-immune boost was performed four days prior to spleen harvest. Each 
mouse received a total of five immunisations. For each immunisation mice received 
two 50 µl subcutaneous injections of 1 mg ml-1 total protein, one into each flank. 
Peptide solutions were mixed 1:1 with Freund’s adjuvant to create an emulsion in order 
to minimise dispersion of solution following injection. This decreases degradation and 
elimination from the body and promotes prolonged antibody generation. (Stills, 2005) 
Initial immunisation was carried out with Freund’s complete adjuvant, the following 
three immunisations contained Freund’s incomplete adjuvant. The final pre-immune 
boost was diluted in PBS. 50-60 µl tail bleeds were taken from each mouse prior to the 
immunisation programme and again following the 4th immunisation. Serum was 
isolated from whole blood samples via centrifugation at 12,000 g for 10 minutes at 
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room temperature. All murine work was carried out at the Comparative Biology Centre 
(CBC), Newcastle University under licence number: PCEAA8B1B. 
 
2.5.5 Cell culture 
NS-1 cells (P3/NSI/1-Ag4-1), which produce but do not secrete kappa chain antibodies, 
were utilised as the myeloma fusion partner. NS-1 and hybridoma cells were grown in 
a 5% CO2 incubator at 37 ˚C. Cells were grown in various medias. Basic media (BM) 
consisted of 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U ml-1 penicillin 
and 100 µg ml-1 streptomycin in RPMI 1640 medium. HAT-selective media consisted 
of 20% FBS, 2 mM L-glutamine, 100 U ml-1 penicillin, 100 µg ml-1 streptomycin and 
HAT supplement (final concentration 0.1 mM sodium hypoxanthine, 0.4 µM 
aminopterin, 1.6 µM thymidine) in RPMI 1640 medium. HT media consisted of BM with 
HT supplement (final concentration 0.1 mM sodium hypoxanthine, 1.6 µM thymidine).  
BM condimed media consisted of 10% condimed in BM. Serum-free media consisted 
of 100 U ml-1 penicillin and 100 µg ml-1 streptomycin in EX-CELL 610-HSF serum-free 
medium for hybridoma cells. Freezing media contained 10% FBS, 10% DMSO in BM. 
All media was pre-warmed before addition to cells, unless otherwise specified. All 
centrifugation steps were performed at 400 g for 5 minutes unless otherwise specified. 
 
2.5.6 Viable cell count 
A viable cell count was completed by adding equal volume of 0.4% trypan blue to a 
cell culture sample. Cells were transferred to a haemocytometer and visualised 
microscopically at 100x magnification. Viable cells resisted staining, showing as clear 
spherical cells. Non-viable cells stained blue and often had rough edges. Viable cells 
within four squares of the haemocytometer were counted and the average value was 
taken. This was multiplied by 104 and doubled (to account for the 1:1 dilution in trypan 
blue) to calculate the number of viable cells per ml. 
 
2.5.7 Freezing cells 
Cells were grown to confluence and collected by centrifugation. The cell pellet was re-
suspended gently in freezing media at approximately 106 cells ml-1 and transferred to 
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a cryovial. Vials were placed in a freezing container, which controlled the rate of cooling 
at 1 °C per minute until -80 °C was reached. Cells were stored in liquid nitrogen. 
 
2.5.8 Thawing frozen cells 
Cells were thawed rapidly by incubation of cryovials in a 37 °C water bath. Media was 
added to cell solutions to dilute the DMSO and cell solutions were centrifuged. The cell 
pellet was re-suspended in BM and transferred to the appropriately sized well or flask, 
dependent on cell number and viability. 
 
2.5.9 Fusion 
2 x 107 NS-1 cells were pelleted and re-suspended in 50 ml RPMI 1640 medium in 
preparation for fusion. Mice were sacrificed by the CBC and spleens were harvested 
and kept in RPMI 1640 medium on ice. A small incision was made in the spleen and 
cells were gently pressed out into 50 ml RPMI 1640 medium. The culture fluid was 
pipetted up and down several times using a 10 ml serological pipette to create a single 
cell suspension, and passed through a sieve. Spleen and NS-1 cells were pelleted and 
re-suspended in 50 ml RPMI 1640 medium and pelleted again. Each pellet was re-
suspended in 25 ml RPMI 1640 medium and the cell solutions were combined and 
pelleted. 1 ml PEG-DMSO was added slowly over one minute and this was stirred for 
an additional one minute. 1 ml RPMI 1640 medium was added over one minute, and 
9 ml added over the following two minutes. Cells were pelleted and re-suspended in 
HAT selective media. 50 µl of this cell suspension was added to each well of eight 96 
well plates pre-charged with 150 µl HAT selective media. The plates were incubated 
until sufficient growth had occurred before screening. 
 
2.5.10 Cloning 
Fusion wells were screened for antibody binding to the BSA-conjugated peptide. 
ELISA screens were completed using the protocol described in section 2.2.5. Cells 
with positive binding were cultured and expanded into 24-well and 12-well plates in HT 
media. Following sufficient growth, these cells were used to seed 96-well subcloning 
plates. A series of six-fold dilutions was set up with wells seeded at a range of 600-0.1 
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cells per well. Viable cell counts were performed as described in section 2.5.6. Cells 
were diluted in BM-condimed media to support the growth of low cell numbers. Target-
binding wells which derived from one cell per well were deemed to be monoclonal cell 
lines. Those wells which exhibited target binding and were derived from more than one 
cell per well were used to seed further subcloning plates. 
 
2.5.11 Antibody purification 
Hybridoma cell lines were grown in serum free media for 10-14 days until cells were 
overgrown and 50% of cells were visibly dead. Cell culture fluid was centrifuged at 
700 g for 10 minutes to remove hybridoma cells. Antibodies were purified through 
addition of ammonium sulphate. Interactions between antibodies and water molecules 
are disrupted as water molecules show affinity for the added ammonium sulphate. This 
effectively reduces the availability of water, causing antibodies to precipitate. (Grodzki 
et al., 2010) Ammonium sulphate was slowly added to the cell culture supernatant at 
a final concentration of 2.05 M (50% saturation). The solution was incubated overnight 
at 4 °C whilst stirring constantly. The precipitated protein collected in the pellet 
following centrifugation at 3000 g for 30 minutes. The pellet was re-suspended in PBS 
and dialysed overnight at 4 °C. The solution was centrifuged at 14000 g for 5 minutes 
to remove any insoluble fraction and the supernatant was collected. 
 
2.6 Recombinase Polymerase Amplification (RPA) 
 
2.6.1 RPA assay 
RPA is an isothermal DNA amplification technique. RPA kits were used according to 
manufacturer instructions. Briefly, 2.4 µl 10 µM forward primer, 2.4 µl 10 µM reverse 
primer, 29.5 µl rehydration buffer and template DNA was combined. dH2O was added 
to give a total volume of 47.5 µl. The solution was vortexed, briefly centrifuged, added 
to the RPA enzyme pellet. The mixture was pipetted up and down 20 times until fully 
reconstituted. 2.5 µl 280 mM magnesium acetate was added to the curved lids. The 
reaction was initiated by centrifuging the RPA tube, causing magnesium to be drawn 
into the RPA reaction solution. Tubes were vortexed and re-centrifuged before 
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incubating in a PCR block at the desired temperature. Reactions were stopped by 
transferring samples to a -80°C freezer. Negative controls which contained no template 
DNA or with an incubation time of 0 minutes were used. A positive control was provided 
by the manufacturers. 
 
2.6.2 Enzyme linked oligonucleotide assay 
An enzyme linked oligonucleotide assay (ELONA) was performed to analyse the 
amplification using tailed-primers, as previously described by Jauset-Rubio et al., 2016. 
 
50 µM capture probe was reduced in an equal volume of 10 mM TCEP HCl (Tris(2-
carboxyethyl)phosphine hydrochloride) by incubation for 1 hour at room temperature. 
Reduction solution was added to PBS in a 0.4% solution (v/v). Maleimide plates were 
washed three times with PBST. 100 µl capture probe solution was added to each well 
and the plate was incubated overnight at 4 °C. The plate was washed three times in 
PBST and blocked with 200 µl 100 µM 6-mercaptohexanol. This was incubated at room 
temperature for 40 minutes. The plate was washed three times with PBST. 35 µl of 
RPA product was added to each well, and the plate was incubated for 30 minutes at 
room temperature whilst shaking. The plate was washed three times in PBST and 
100 µl 10 nM reporter probe was added. This was incubated for 30 minutes at room 
temperature whilst shaking. The plate was washed three times in PBST prior to the 
addition of 100 µl TMB. The plate was read at 630 nm every 5 minutes on a Tecan 
Infinite 200. See table 2.7 for primer and probe sequences. 
 
Name Sequence 
Capture probe GGCATGTCTGTGATTACTTTTTTTTTTTTTTT-C6 Thiol 
Reporter probe HRP-AGTGGTCGTCGTTTTACA 
Forward primer GTAATCACAGACATGCC-C3-ACTACTAGACGCCAAGAAGCTATTGAAGAGG 
Reverse primer TGTAAAACGACGACCACT-C3-TCACCACCTTTAATACTGTGCCCTAACC 
 
Table 2.7 Sequences for use in RPA assay 
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Chapter 3 Protein target selection 
 
3.1 Introduction 
 
Diagnostic molecules for the detection of infectious disease are often generated 
against proteins or bacterial cells and may exhibit binding affinity to any epitope within 
the target. Many of these epitopes will not be unique to the desired organism, therefore 
cross-reactivity is likely. By raising an antibody against a specified peptide, proteins 
with similar amino acid sequences can be identified bioinformatically and cross-
reactivity can be studied. This targeted approach can result in an increased confidence 
of specificity. Within a bacterial species there are often multiple serotypes and strains, 
which may contain significant sequence variability within their proteomes. Antibodies 
generated against regions of diversity would have a decreased ability to detect certain 
strains. Peptides found in all strains of interest can be selected as antibody targets to 
maximise sensitivity. 
 
One limitation of peptide-raised antibodies is that for the generation of a successful 
antibody, the peptide sequence must hold the same shape in the complex three-
dimensional structure of the native protein as it does in solution. Therefore the antibody 
epitope must be linear rather than discontinuous. 
 
3.2 GBS specific peptides 
 
IDRIS v1.0 is a bespoke in-house computer system developed at Newcastle University 
within the i-sense project (www.i-sense.org.uk), created to identify sequences of amino 
acids, which are unique to, and conserved throughout, a user-defined group of interest. 
(Flanagan et al., 2014) The programme has been utilised to identify potential protein 
targets for diagnostic molecules. The IDRIS system translates every bacterial genome 
sequence found in NCBI RefSeq into all possible reading frames, and then splits the 
protein sequences into tokens, which are sequences of 15 amino acids. Tokens are 
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analysed for their uniqueness to a selected group of bacterial strains and their 
conservation within the bacterial group. The proteins that these tokens belong to are 
analysed to predict protein location in the cell. A diagrammatic representation can be 
seen in figure 3.1. A diagnostic target would ideally be surface exposed to enable 
molecular detection with minimal sample processing required, possibly utilising whole 
cell detection. IDRIS uses SignalP, (Petersen et al., 2011) LipoP (Juncker et al., 2003) 
and PSORTb (Yu et al., 2010) to assess protein location. 
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Figure 3.1 IDRIS selection of unique and conserved peptides 
A: Protein sequences are broken up into tokens and compared to tokens from all strains 
within the bacterial group of interest. Conserved peptides are selected. Tokens are also 
compared with tokens from other bacteria. Unique peptides are selected. Peptides which 
appear in both of these groups are reported as tokens distinctive to the bacterial group of 
interest. B: Tokens found in all GBS strains and no other bacterial strains are reported. 
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All Streptococcus agalactiae strains found in the NCBI RefSeq database (as of 
18/06/2015) were used as the group of interest. The resulting IDRIS report listed all 
tokens found in every GBS proteome in the database that were also not found in any 
proteomes outside of this group. Table 3.1 shows the proteins from this report which 
are predicted to contain a signal peptide, as determined by SignalP. PSORTb 
categorised three of the returned proteins as cell wall associated proteins, these have 
the highest likelihood of all returned proteins of being surface exposed, as the cell wall 
is the most exterior layer of gram positive cells, excluding the polysaccharide capsule. 
(Shockman and Barrett, 1983) Cell wall associated proteins of S. agalactiae have been 
reported to be exposed to surface (Lancefield et al., 1975; Brodeur et al., 2000) 
possibly due to the capsule being narrow or flexible, or not being present at certain 
phases of bacterial growth. (Lindahl et al., 2005) The proteins considered further were 
SAG0771 (NP_687786.1), SAG1473 (NP_688467.1) and SAG1474 (NP_688468.1) 
(locus tag (protein ID)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
 
 
 
Locus tag Protein ID Protein name / function Localisation 
SAG0032 NP_687068.1 Group B streptococcal surface immunogenic protein 
(Sip) 
Ex 
SAG0017 NP_687053.1 Peptidoglycan hydrolase (PcsB) Ex 
SAG1197 NP_688206.1 Hyaluronate lyase Ex 
SAG0031 NP_687067.1 M24/M37 family peptidase Ex 
SAG0771 NP_687786.1 Cell wall surface anchor family protein CW 
SAG1473 NP_688467.1 Cell wall surface anchor family protein CW 
SAG1474 NP_688468.1 Amidase CW 
SAG0147 NP_687183.1 D-alanyl-D-alanine carboxypeptidase CM 
SAG0146 NP_687182.1 Penicillin-binding protein 4 CM 
SAG1466 NP_688460.1 Glutamine ABC transporter CM 
SAG0136 NP_687172.1 Amino acid ABC transporter CM 
SAG0535 NP_687564.1 Zinc ABC transporter substrate-binding protein CM 
SAG1007 NP_688018.1 Iron-compound ABC transporter U 
SAG2174 NP_689159.1 Serine protease U 
SAG0034 NP_687070.1 Sugar ABC transporter sugar-binding protein U 
SAG1441 NP_688438.1 Maltose/maltodextrin ABC transporter protein U 
SAG2148 NP_689133.1 LysM domain-containing protein U 
SAG0290 NP_687325.1 ABC transporter substrate-binding protein U 
SAG0963 NP_687975.1 Hypothetical protein U 
SAG0886 NP_687900.1 Hypothetical protein U 
SAG0833 NP_687848.1 Hypothetical protein U 
SAG0451 NP_687482.1 Hypothetical protein CM 
SAG2056 NP_689042.1 Hypothetical protein U 
SAG1491 NP_688485.1 Hypothetical protein U 
SAG1762 NP_688752.1 Hypothetical protein Ex 
SAG0013 NP_687049.1 Hypothetical protein U 
SAG1227 NP_688234.1 Hypothetical protein U 
SAG1214 NP_688223.1 Hypothetical protein CM 
Table 3.1 IDRIS generated report listing proteins containing peptides distinctive to GBS  
This report, generated by IDRIS, lists all the proteins containing peptides specific to 
Streptococcus agalactiae that are conserved across all sequenced strains, and are also 
predicted to have a signal peptide (SignalP score of over 0.45). The table details the 
protein name or putative function and the PSORTb predicted localisation 
(Ex=extracellular, CW=cell wall, CM=cytoplasmic membrane, U=unknown). 
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The IDRIS report is limited by the quality and quantity of data and annotations inputted 
into RefSeq. The IDRIS report is subject to change in later versions as the database is 
populated with updated RefSeq data. IDRIS v1.0 comprised of 2.5 billion tokens from 
2,764 organisms. In the most recent update the dataset consisted of 7.65 billion tokens 
from 7,059 organisms. 
 
3.3 Protein localisation 
 
Minimal research has been conducted on SAG0771, SAG1473 and SAG1474 proteins, 
therefore bioinformatic tools are essential to determine protein localisation. IDRIS 
utilises the programmes PSORTb, SignalP and LipoP to provide information on the 
proteins it returns. These tools, alongside TMHMM, were repeated manually on several 
proteins to gain a clear insight into the protein localisation. 
 
3.3.1 PSORTb 
PSORTb v3.0 recognises 25 protein sequence motifs and six profiles for gram positive 
bacteria to categorise proteins into four locations: extracellular, cell wall, cytoplasmic 
membrane and cytoplasmic. Profiles are similar to sequence motifs but also 
incorporate position specific weighting into the criteria. (Yu et al., 2010) PSORTb 
classifies SAG0071, SAG1473 and SAG1474 as cell wall associated proteins, see 
table 3.2, based on the identification of the LPXTG profile; there were no sequence 
motifs detected. 
 
 SAG0771 SAG1473 SAG1474 
Extracellular 0.01 0.01 0.01 
Cell wall 9.98 9.98 9.99 
Cytoplasmic 
membrane 
0.01 0.01 0.00 
Cytoplasmic 0.00 0.00 0.00 
 
Table 3.2 Cellular location as predicted by PSORTb 
Localisation scores out of a total value of 10.00. SAG0771, SAG1473 and SAG1474 are 
predicted to be cell wall associated proteins. 
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3.3.2 SignalP 
Signal peptides direct proteins to their destination within the cell or to the secretory 
pathway. Signal peptides share several common features: an N-terminal positively 
charged region, a hydrophobic region and a C-terminal protease cleavage site. (Jain 
et al., 1994) There are several computer programmes designed to predict the presence 
of, and the site of, signal peptides from an amino acid sequence; SignalP 4.0 is 
reported to be the best prediction tool. (Petersen et al., 2011) The SignalP D-score is 
calculated from a combination of scores representing the prediction of cleavage sites 
and the likelihood of residues forming a signal peptide. Positive results are reported if 
the D-score is over 0.45 (range: 0-1). Using this cut off point, the probability of a false 
positive result is 0.001. (Petersen et al., 2011) The proteins investigated were all found 
to have a signal peptide, see figure 3.3. 
 
Protein D-score Signal 
peptide? 
Cleavage site - 
sequence position 
Cleavage site - 
amino acids 
SAG0771 0.750 Yes 32-33 AKA-ET 
SAG1473 0.731 Yes 27-28 GYA-DT 
SAG1474 0.696 Yes 27-28 IYA-NS 
 
 
3.3.3 LipoP 
Similarly to signal peptides, lipoprotein signal peptides have recognisable N-terminal 
motifs. These are composed of an N-terminal positively charged region, a short 
hydrophobic region and a C-terminal polar region adjacent to the protease cleavage 
site, called a lipobox. (Juncker et al., 2003) LipoP distinguishes between four classes 
of protein sequences: signal peptides, lipoprotein signal peptides, N-terminal 
transmembrane helices and cytoplasmic regions. Scores for each classification are 
reported and represented graphically. Cleavage sites for signal peptides and 
lipoprotein signal peptides are also predicted. (Juncker et al., 2003) Although 
developed for predicting lipoprotein sequences in gram-negative bacteria, there have 
also been reports of success in gram-positive bacteria. The probability of a false result 
Table 3.3 Signal P results for SAG0771, SAG1473 and SAG1474. 
Proteins with D-scores above 0.45 are reported as containing a signal peptide. It is 
predicted that SAG0771, SAG1473 and SAG1474 have signal peptides with cleavage 
following residue 32, 27 and 27 respectively. 
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is 0.048. (Rahman et al., 2008) LipoP did not classify any of the proteins tested as 
lipoproteins, see figure 3.4. 
 
Protein Signal 
peptide 
score  
Lipoprotein 
signal 
peptide 
score 
N-terminal 
transmembrane 
helices score 
Cytoplasmic 
region 
score 
Result Site of signal 
peptide cleavage 
Sequence 
position 
SAG0771 10.65 < -3 -0.39 -0.20 Signal 
peptide 
30-31 
SAG1473 17.96 13.32 < -3 -0.20 Signal 
peptide 
27-28 
SAG1474 16.24 < -3 -2.57 -0.20 Signal 
peptide 
27-28 
 
 
3.3.4 TMHMM 
Cellular membranes are lipophilic environments where charged or polar amino acids 
are not tolerated well, therefore transmembrane (TM) helices generally consist of non-
polar amino acid sequences. They can also be characterised by their length, around 
17 amino acids, to span the membrane. (Hildebrand et al., 2004) TMHMM 2.0 is 
reported to be the best computational programme to predict TM helices, with 82.7% of 
membrane spanning regions predicted correctly. (Moller et al., 2001) This decreases 
when signal peptides are considered, with 60% of these peptides incorrectly identified 
as TM helices. (Krogh et al., 2001) This statistic is reflected in the TMHMM output of 
the three selected proteins, SAG0771, SAG1473 and SAG1474. Two out of three 
signal peptides previously identified by SignalP and LipoP were predicted to be 
transmembrane helices by TMHMM. It is predicted that SAG0771 and SAG1473 have 
C-terminal TM helices, however as a cleavage event is likely to occur at the LPXTG 
motifs during anchorage to the cell wall, (Navarre and Schneewind, 1994) this region 
would not be present in the mature protein, see figure 3.5. 
 
 
Table 3.4 LipoP results for SAG0771, SAG1473 and SAG1474. 
The highest scoring class of protein type is reported as the predicted result. It is 
predicted that SAG0771, SAG1473 and SAG1474 have signal peptides with cleavage 
following residue 30, 27 and 27 respectively. 
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Protein Inside TM helix Outside TM helix Inside 
 Start End Start End Start End Start End Start End 
SAG0771     1 483 484 506 507 512 
SAG1473 1 6 7 26 27 168 169 186 187 192 
SAG1474 1 4 5 27 28 680     
 
 
3.3.5 Surface exposure 
Cell wall association of proteins does not guarantee surface exposure. A study 
investigating cell surface exposed proteins incubated S. agalactiae cells with proteases 
trypsin and protease K, and the resulting peptide sequences were analysed by mass 
spectroscopy. To identify the origin of each peptide, sequences were compared to 
genome data. Of the 22 proteins predicted by PSORTb to be cell wall associated, nine 
were found to be surface exposed. SAG1473 and SAG1474 were established as being 
surface exposed; SAG0771 was not. (Doro et al., 2009) Additionally the protease-
released peptide from SAG1474 was identified as an IDRIS token, supporting the 
selection of this peptide as a promising target for antibody production. 
 
3.3.6 Protein localisation consensus 
In a previous study SAG0771 expression was found to be dependent on sortase A 
(SrtA), an enzyme which anchors proteins to the cell wall via cleavage of the LPXTG 
motif. Western blotting experiments showed a reduction in SAG0771 concentration in 
SrtA knockout strains compared to wild type. (Nobbs et al., 2008) SAG1473 and 
SAG1474 also contain LPXTG motifs, and are therefore likely to be under similar 
control. Manual inspection of IDRIS data and previous literature supported the three 
candidates for further work as they are predicted to be cell wall associated proteins. 
 
Table 3.5 TMHMM results for SAG0771, SAG1473 and SAG1474.  
TMHMM predicts which regions within a protein sequence are internal, external 
and transmembrane. The N- and C-terminal regions are likely not to be present in 
the processed protein due to removal of the signal sequence and cleavage at the 
LPXTG motif. The remainder of peptide sequences in the three proteins, SAG0771, 
SAG1473 and SAG1474, are predicted to be external to the membrane. 
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3.4 Protein selection 
 
IDRIS identifies promising targets using sequencing data. As these proteins have not 
necessarily been empirically observed previously, there is no assurance that proteins 
are expressed at all, or at levels feasible for diagnostic detection. Proteins should be 
studied experimentally prior to selection. The optimal protein would be highly 
expressed in all strains under varying conditions. 
 
3.4.1 Experimental analysis of protein expression in 10 serotypes 
As protein expression profiles vary across serotypes, (Lindahl et al., 2005) it is 
important to select diagnostic targets contained within all strains. Although the link 
between protein expression and serotype is not complete, (Tettelin et al., 2002; Creti 
et al., 2004; Shabayek et al., 2014) if a protein target is found within an example of 
each of the 10 different serotypes, there is a considerable likelihood that it will be found 
in all strains. 
 
To estimate protein expression levels, reverse transcription PCR (RT-PCR) was 
performed in 10 strains of GBS representing different serotypes: 1A, 1B, 2-9. RNA was 
purified from cultures grown at 37 °C in 5% CO2 to a mid-log phase (OD 600 nm 0.5). 
Contaminating DNA was removed via DNase treatment and reverse transcription was 
performed to produce cDNA. PCR amplification of 500 bp fragments using primers 
specific to SAG0771, SAG1473 and SAG1474 was completed. PCR products were 
imaged following electrophoresis on an agarose gel, see figure 3.2. 
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Figure 3.2 Transcript expression in 10 serotypes of GBS 
Extracted RNA was reverse transcribed to cDNA and amplified by PCR to analyse 
transcript presence in the 10 serotypes of GBS (1A, 1B, 2-9). Negative control PCR 
experiments containing RNA without a reverse transcription step were used to validate 
each sample. An additional negative control (NC) contained no nucleic acid. Extracted 
DNA was amplified as a positive control (PC). Representative agarose gels are shown. 
Presence of SAG0771, SAG1473 and SAG1474 transcripts was studied. Results show 
SAG1473 and SAG1474 transcripts are expressed across all 10 serotypes, SAG0771 
transcript expression is reduced to a large extent in serotype 8. 
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In summary, SAG1473 transcripts were consistently expressed across all strains 
tested. SAG1474 transcripts were expressed across all strains with serotype 8 showing 
reduced expression. Levels of SAG0771 expression varied across strains with 
serotype 8 showing minimal or no expression. As RT-PCR is a crude method of 
analysing protein levels, the reduced levels of SAG1474 transcript may or may not be 
significant. 
 
Contaminating DNA is a common problem associated with RT-PCR assays in which 
you cannot differentially amplify cDNA. In some cases primers can be designed which 
span exon-exon boundaries, however this is not possible when studying bacterial 
samples. Contaminating DNA was examined by amplifying extracted RNA without prior 
conversion to cDNA. As contaminating DNA was found to contribute between 0.1-10.6% 
of the signal of the test samples, it was considered acceptable. This was determined 
by calculating and comparing the band density of the images produced. 
 
RNA transcript analysis is a crude indicator of protein expression as it is not influenced 
by RNA stability, ribosome binding site accessibility, translation rate or protein 
degradation. (Cham et al., 2003; Van Assche et al., 2015) Previous studies have 
identified peptides specific to SAG1473 and SAG1474, (Doro et al., 2009) indicating 
that transcripts are then translated. 
 
3.4.2 Microarray data from previous literature 
Streptococcus agalactiae is present at many locations within the human body, 
including the vagina, rectum, blood, brain and lungs. (Heath et al., 2004) The optimum 
protein target would be expressed at comparable levels under the diverse conditions 
found at these sites, thus increasing the chances that a diagnostic test could be 
adapted for multiple sample types for multiple patient groups. 
 
3.4.2.1 pH 
Vaginal and rectal swabs are commonly used in combination for GBS diagnostics, 
(Public Health England, 2015b) these sites vary in pH significantly from pH 3.8-4.0 to 
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7.0-8.0 respectively. (Jantzen et al., 1989; Riedewald et al., 1990) The study of low pH 
values is problematic due to slow growth under laboratory conditions (Yang, 2011) 
therefore the effect of pH on the GBS transcriptome has been studied by culturing cells 
at pH 5.5 and pH 7.0. (Santi et al., 2009) There were no significant changes in 
transcriptome expression across the three proteins that were identified as potential 
targets, see figure 3.3. 
 
 
 
3.4.2.2 Temperature 
GBS infection is often associated with a fever. The effect on the transcriptome of 
incubation at 42 °C, to emulate fever, was compared to S. agalactiae incubated at 
37 °C, simulating normal body temperature. (Klinzing et al., 2009) SAG0771 showed 
a significant rise in transcript expression at increased temperature, however there was 
no significant change observed in SAG1473 or SAG1474, see figure 3.4. 
Figure 3.3 The effect of pH on gene transcript expression 
Changes in GBS gene expression in response to changes in pH were analysed by 
microarray. (Santi et al., 2009) P values were calculated by an unpaired 2 tailed 
student’s t test. A two-fold difference of expression with a p value of ≤0.01 is reported 
as a statistically significant change of expression. No transcripts exhibit significant 
differential expression at pH 5.0 and pH 7.0. Data accessible at ArrayExpress database 
at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-TABM-708. 
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3.4.2.3 Oxygen concentration 
Streptococcus agalactiae is a facultative anaerobe, therefore can exist in varying 
concentrations of oxygen. To evaluate the effect of oxygen concentration on the 
transcriptome, a previous study compared cultures after incubation at 0% and 12% 
oxygen. No microarray data has been published, however the paper lists all surface 
exposed proteins which were downregulated at 0% oxygen. SAG0771, SAG1473 and 
SAG1474 do not feature on this list. (Johri et al., 2007) 
 
The data collected both experimentally and through study of microarray data supports 
the use of SAG1473 or SAG1474 as tools to generate antibodies against, as they are 
transcribed consistently under varying conditions and across all GBS serotypes. 
 
Figure 3.4 The effect of temperature on gene transcript expression 
Ratio of gene transcript expression at 42 °C compared to 37 °C (Klinzing et al., 2009) P 
values were calculated by an unpaired 2 tailed student’s t test. A two-fold difference of 
expression with a p value of ≤0.01 is reported as a statistically significant change of 
expression. SAG0771 is significantly upregulated at 42 °C in comparison to 37 °C. Data 
accessible at NCBI GEO, (Edgar et al., 2002) accession GSE14573. 
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3.4.3 Structure prediction 
Knowing the correct structure of each protein would enable epitopes to be selected 
based on their exposure to the protein surface, and their position relative to other 
potential epitopes and the cell wall binding region. Antibodies against two spatially 
distinct sites would enable the generation of a capture and detection-based diagnostic 
test against a single protein. As the protein structures are unknown, predicted models 
are the most suitable alternative, but must be considered with their associated 
confidence levels. I-TASSER is a computational tool that uses amino acid sequences 
to predict protein structure. (Roy et al., 2010) I-TASSER was used to provide five 
predicted structures for each protein, figure 3.5 shows the structures with the highest 
C-scores, and therefore the models with highest confidence. In validation studies, 
known protein structures were compared to their I-TASSER prediction. TM-scores 
were assigned to these comparisons with a score of 1 representing a perfect match. A 
TM-score of ≥0.5 is considered a correct fold, and a TM-score of <0.17 is considered 
a random pairing. A correlation between C-score and TM-score was observed; 
therefore C-score is able to predict matching to the true structure. A C-score of ≥-1.5 
equates to a likely correct fold. (Roy et al., 2010) SAG0771 was the only sequence to 
return a reliable structure, however the structure for SAG1474 does approach reliability 
(TM=0.44). Using SAG0771 as the antibody target would enable informed epitope 
selection. The model confidence is decreased in SAG1474 and further in SAG1473. 
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3.4.4 Evaluation of expression and structural modelling data 
Table 3.6 outlines data collected to inform the decision of which protein to raise 
antibodies against. Despite the reduced reliability in the proposed structure in 
comparison to SAG0771, SAG1474 was selected for antibody generation, largely due 
to its surface exposure. SAG1473 was not selected as it only contains two IDRIS 
Figure 3.5 Structure of three candidate proteins with IDRIS tokens mapped on 
The structures of SAG0771, SAG1473 and SAG1474 were predicted by I-TASSER, and 
visualised by PyMOL. (Schrodinger, 2015) IDRIS tokens are coloured. The cell wall 
anchoring motif is coloured in green. Structures are reported as reliable if the TM score is 
≥ 0.5, a TM score < 0.17 is considered a random prediction.  
SAG0771: C-score: -1.28, TM-score: 0.544, 8 tokens covering 218 amino acids. 
SAG1473: C-score: -3.29, TM-score: 0.289, 2 tokens covering 42 amino acids. 
SAG1474: C-score: -2.08, TM-score 0.440, 13 tokens covering 335 amino acids.  
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tokens. If antibodies were not able to be created against either token, the project would 
be limited to whole-cell diagnostics. Selecting SAG1474 with multiple tokens increases 
the likelihood of developing a system which can detect proteins. 
 
In a previous study, the genomes of Streptococcal agalactiae, Streptococcus 
pyogenes and Streptococcus pneumoniae were compared and several cell-wall 
associated proteins were identified as being unique to S. agalactiae, these being 
SAG0677, SAG0771, SAG1052, SAG1331, SAG1473 and SAG1996. SAG1474 was 
SAG0771 SAG1473 SAG1474 
Cell wall associated 
 
 
Cell wall associated Cell wall associated 
Large reduction in transcript 
expression in serotype 8 
 
Transcript expressed across 
all serotypes 
 
Transcript expressed across 
all serotypes, small reduction 
in transcript expression in 
serotype 8 
 
No significant change in 
transcript expression at 
decreased pH 
No significant change in 
transcript expression at 
decreased pH 
No significant change in 
transcript expression at 
decreased pH 
Significant increase in 
transcript expression at 
elevated temperature 
No significant change in 
transcript expression at 
elevated temperature 
No significant change in 
transcript expression at 
elevated temperature 
Protein: Not proven to be 
surface exposed 
 
Protein: Surface exposed 
 
Protein: Surface exposed 
 
Token: Not proven to be 
surface exposed 
 
Token: Not proven to be 
surface exposed 
 
Token: Surface exposed 
 
High confidence in predicted 
structure 
Low confidence in predicted 
structure 
Intermediate confidence in 
predicted structure 
Multiple tokens 2 tokens; would need both 
regions to be antigenic to 
develop non-whole cell test 
Multiple tokens 
 
Table 3.6 Summary of results, collated to inform protein target selection 
A series of experiments and computational predictions are summarised in the table. 
These form the basis of the discussion of which protein target to select for antibody 
generation. SAG1474 was selected as it has given the most favourable results. 
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not identified as unique. (Tettelin et al., 2002) Identifying peptides within SAG1474 as 
unique, indicates the significance of IDRIS. 
 
3.5 Token selection 
 
There are 13 IDRIS tokens within SAG1474, covering 328 amino acids of the sequence. 
Peptides for antibody production are typically between 10 and 20 amino acids in length, 
(Hancock and O'Reilly, 2004) therefore sequences of this length were selected for 
antibody production. Residue polarity and predicted secondary structure, surface 
exposure and a combined prediction of antigenicity were used to estimate which 
peptides would generate successful antibodies. 
 
3.5.1 Unique peptides 
IDRIS identifies stretches of 15-mer amino acids which are unique to Streptococcus 
agalactiae. If there are peptide sequences within other organisms which differ by a 
single amino acid IDRIS will not report these, however the specificity of any resulting 
antibodies may be compromised. Using BLAST to check for similar sequences allows 
uniqueness to be evaluated. 
 
Similarity matches to proteins found in organisms which would not be present in a 
patient sample can be disregarded. For whole-cell diagnostics only cell surface 
proteins need to be considered; for lysed cell diagnostics, proteins would have to 
contain sequences matching both the capture and detection epitopes to pose a 
specificity problem. The likelihood of cross-reactivity of the resulting diagnostic is 
limited, and for the final peptides selected for antibody production, no substantial 
matches have been identified. 
 
An additional use for BLAST results is to confirm that peptides do not match proteins 
found within mice. For antibody production, the selected peptides must be capable of 
evoking a murine immune response. Cells expressing antibodies which exhibit binding 
to a self-protein would be eliminated during clonal deletion. (Rose, 2015) If there is 
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similarity between a selected sequence and a self-protein, the ability to produce 
antibodies against it may be compromised. No murine proteins with high similarity to 
the selected peptides were identified. 
 
3.5.2 Polarity 
Antibody-antigen interactions are dominated by Van der Waals forces and polar 
attractions. When designing an antigenic peptide, regions with high charge should be 
avoided. (Hancock and O'Reilly, 2004) An additional consideration is that peptides 
must be soluble in order to conjugate to a carrier protein prior to immunisation. The 
inclusion of polar and charged residues facilitates solubility. Amino acids were 
classified into three groups: non-polar (neutral (G, A, V, I, L, M, F, Y, W)), polar (neutral 
with electron dense regions (S, T, N, Q, C, P)), and charged amino acids (R, H, K, D, 
E), shown in table 3.7. Within the tokens no regions of high charge were identified. 
Peptide sequences with a distribution of non-polar, polar and charged residues were 
selected for antibody production. 
 
3.5.3 Secondary structure 
For a peptide-generated antibody to be functional in binding a protein, the three-
dimensional conformation of the epitope must be identical in both formats. Secondary 
structure can be used to determine whether this will be likely. β-sheets are often formed 
with distant regions of protein sequence, (Baldi et al., 2000) therefore a peptide that 
resides in this structure cannot be held in the same conformation without the support 
of the rest of the protein. α-helical peptides which are long enough to form the complete 
helix may display the same shape as in the protein. (Hancock and O'Reilly, 2004) 
Unstructured loops may not be influenced by adjacent sequences within the protein, 
therefore holding the same conformation in its free and constrained form. Alternatively 
loops may lack a consistent structure, and therefore be unable to bind antibodies. 
Secondary structure was analysed by combining results from the prediction tools 
I-TASSER and PSIPRED, results can be found in table 3.7. The position specific 
iterated BLAST tool identifies sequences similar to the input. PSIPRED is a machine 
learning programme which uses this data to predict secondary structure. (Jones, 1999) 
PSIPRED 3.2 is able to correctly predict the secondary structure for 81.6% of residues. 
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(Bloomsbury Centre for Bioinformatics, n.d.) In peptide selection, regions of β-strand 
structure were avoided. 
 
3.5.4 Surface exposure 
Exposure of peptides to the protein surface is essential for antibody binding, the 
computing tools I-TASSER and prodepth were used to predict the likelihood of this. 
Prodepth estimates the distance from each residue to the nearest water molecule, with 
distances over 3.0 Å suggesting that the amino acid is buried within the protein, and 
distances of under 3.0 Å suggesting that residues are exposed. Prodepth has an 
accuracy of 78.2%. (Song et al., 2009) I-TASSER results were visualised with PyMOL 
(Schrodinger, 2015) and manually inspected for surface exposure, the results can be 
seen in table 3.7. 
 
3.5.5 Combination of predictive tools 
Polarity, surface exposure and secondary structure are useful tools to predict whether 
a peptide sequence will be antigenic. In previous studies, flexibility, hydrophilicity and 
the presence of certain amino acids at numbered positions within turns have also been 
used to inform antigenic predictions. (Karplus and Schulz, 1985; Parker et al., 1986; 
Pellequer et al., 1993) The programme Bcepred predicts whether peptides are likely B 
cell epitopes by consolidating a selection of these results and reporting an overall 
positive or negative prediction. A study has found the optimal combination of features 
to be hydrophilicity, flexibility, surface accessibility and polarity. Under these settings 
Bcepred was able to correctly identify antigenic regions with an efficiency of 58.70%. 
(Saha and Raghava, 2004) These properties were used in the study of SAG1474 
IDRIS tokens and data can be found in table 3.7. 
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Token 1  Token 4  Token 6  
P N E L N  V N U H N  M N B LS N  
T P E L N  N P U H N  T P B LS N  
T P U L N  M N E H N  P N B LS N  
N P E L N  A N U H N  I N B LS N  
T P E LH N  Y P U H N  A N B LS Y  
I N U LH N  D C U H N  S P B LS Y  
V N E LH Y  I N U H N  G N B L Y  
Q P E LH Y  I N U H N  S P B L Y  
T P E L Y  A N U H N  D C B L Y  
N P E L Y  K C E H N  A N B L Y  
D C E L Y  E C E H N  G N B L Y  
S P E L Y  N P U LH N  G N B LH Y  
N P E L Y  P N U LH N  S P B LH Y  
P N E L Y  S P E LH N  I N B LH N  
T P E LH Y  L N E LH N  R C B LH N  
A N U LH Y  N P U LH N  I N B LH N  
K C U LH Y  A N B LS N  P N B LH N  
F N U LH N  V N U LS N  S P B LH N  
Token 2  I N U S N  S P B LH N  
L N B LH N  T P U LS Y  W P B LH N  
F N U LH N  T P U LS Y  T P B LH N  
K C U LH N  R C U L Y  G N B L N  
A N U LH N  R C E H Y  L N U L N  
H C B LH N  Q P U H Y  V N B L N  
S P E LH N  E C E H Y  G N B LS N  
S P U LH N  A N E H Y  L N B LS N  
L N U LH N  I N U H N  K C B LS N  
V N U L Y  E C U H N  P N B L N  
N P U L Y  E C E H N  T P B L N  
L N U L Y  A N U H N   Token 7  
E C U L Y  R C U H N  V N B L Y  
E C E L Y  K C E LH N  S P B L Y  
N P E L Y  L N U L N  N P B L Y  
S P U L Y  K C U L N  E C B L Y  
Q P E L Y  D C E L N  K C B L Y  
V N U L Y  T P E L N  P N B L Y  
Token 3  N P E L N  D C B L Y  
D C E LH Y  Q P E L N  S P B L Y  
K C E LH Y  P N B L N  Y P B L Y  
R C U LH Y  F N B L N  S P U LH Y  
A N E LH Y  L N B L N  T P U LH Y  
I N E LH N  Token 5  Token 8  
Y P U LH N  F N U L N  F N U L N  
N P E LH N  D C U L N  P N B L N  
M N E LH N  S P U LH N  L N B L N  
E C U L Y  S P U H N  T P B L Y  
N P E L Y  Y P U H N  K C B L Y  
L N E L Y  V N U H N  S P U L Y  
S P E LH Y  K C U H N  S P B H Y  
Q P E LH Y  K C U H N  R C B H Y  
E C E LH Y  Y P B H N  D C B H Y  
E C E LH Y  K C U H N  A N B H Y  
R C E LH N  D C E H N  E C B H Y  
I N E LH N  L N U LH N  T P B H Y  
A N B LH N  G N B L N  L N B H N  
L N U LH N  F N B L N  L N B H N  
F N B LH N  I N B LS N  T P B H N  
N P B LH N  I N B LS N  Y P U LH N  
R C E LH N  L N B LS N  L N B LH N  
Q P U LH N  G N B LS N  K C B L N  
W P B H N  Q P B LS N  K C U L N  
E C B H N  T P B LS N  S P U L N  
P N U H N        D C U L N  
M N B H N        Q P E L N  
L N B LH N        T P B L N  
R C B LH N        L N B L N  
R C B LH N        V N B L N  
T P B LH N        S P B L N  
            V N B L N  
            N P B L N  
            D C U L N  
            L N U L N  
            K C B L N  
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 Token 9  Token 10  Token 11 
 L N U L N  F N E H N  L N U H N 
 P N U LS N  L N U H N  H C U H N 
 I N B LS N  R C U LH N  K C U LH N 
 A N B LS N  K C E LH N  Q P E LH N 
 Y P B LS N  Q P U L N  F N E LH N 
 T P B LS N  G N E L N  P N B LH N 
 L N U L N  F N E L N  I N U LS N 
 K C U L N  K C U LS N  F N B S N 
 S P U LH N  V N E LS N  L N B S N 
 P N E LH N  T P U LS N  S P B LS N 
 M N E LH N  E C U LS N  P N B LS N 
 G N U L Y  I N U LS N  T P U L N 
 T P U L Y  D C U L N  T P B L N 
 E C E L Y  L N U L N  A N B L N 
 V N B L Y  P N U LH N  S P B L N 
 S P B L Y  I N U LH N  L N U L N 
 Q P E H Y  D C U LH N  A N U L N 
 D C E H Y  G N U H N  Token 12 
 A N U H Y  R C U H N  I N B LH N 
 K C U H Y  A N U H N  A N B LH N 
 N P U H Y  L N U H N  N P B LH N 
 A N E H Y  M N U H N  M N B L N 
 I N B H N  R C U H N  T P B L N 
 M N B H N  D C B LH N  G N U L N 
 D C E H N  Y P B LH N  L N U L N 
 N P E H N  S P B LH N  P N U L N 
 V N B H N  T P B LH N  A N B LS N 
   L N B LH N  N B LH N N 
       A N B LH N  S P B LS N 
       I N B H N  I N B LS N 
       G N B H N  P N B LS N 
       M N B H N  T P B LS N 
       G N B H N  Y P B LS N 
       G N B H N  L N B LS N 
       A N B H N  S P B LS N 
       F N U H N  E C E L N 
       S P U H N  S P E L N 
       T P U H N  G N U LS N 
       I N U H N  L N U LS N 
       E C U H N  P N B LS N 
       K C U H N  I N B U N 
       D C U H N  G N B U N 
       L N U H N  Token 13 
       K C U H N  K C U LH Y 
       K C U LH N  S P B LH Y 
             S P U LH Y 
             V N E LH Y 
             K C U LH Y 
             N P B LH Y 
             K C E LH Y 
             P N E LH N 
             S P U LH N 
             V N B H N 
             M N U H N 
             A N E H N 
             Y P U LH N 
             Q P U LH N 
             K C U LH N 
  
 
 
 
           A N E LH N 
             L N U LH N 
                  
Table 3.7 Analysis of token suitability for use as immunogenic peptides. 
The table assesses the suitability of each residue in each token. Column 1: amino acid 
code for each residue; column 2: residues are classified as charged (C), polar (P) or non-
polar/hydrophobic (N); column 3: residues are classified as exposed (E), buried (B) or 
unknown (U) i.e. methods give opposing predictions, based on predictions from I-TASSER 
and prodepth; column 4: residues are classified as having loop (L), helix (H), sheet (S), or 
unknown structure (U) i.e. methods give opposing predictions, based on predictions 
from I-TASSER and PSIPRED; column 5: Residues are classified as being antigenic (Y) or 
non-antigenic (N), based on Bcepred prediction. Green denotes favourable, orange 
intermediate, and red undesirable qualities for selection as an immunogenic peptide. 
Peptides selected to raise antibodies against are coloured grey. 
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3.5.6 Conclusion 
Three peptides were chosen for antibody production: Peptide A (VQTNDSNPT), 
Peptide B (VNLEENSQV) and Peptide C (NMENLSQEERI). Each peptide derives from 
an IDRIS token, found in all Streptococcus agalactiae strains, and in no other bacteria. 
They all contain a combination of polar, charged and hydrophobic residues, exist as a 
loop or helix structure, are predicted to be surface exposed by at least one method, 
and give a positive antigenic combination score, as judged by Bcepred. Peptide A was 
previously identified as being exposed to the bacterial surface by protease degradation. 
(Doro et al., 2009) The selected tokens have been mapped onto the predicted structure 
of SAG1474, see figure 3.6. The spatially distinct sites may allow the binding of two 
antibodies simultaneously, leaving open the possibility for a capture and detection 
antibody pair to recognise the same protein, which would be required for lysed-cell or 
protein detection. 
 
Figure 3.6 Structure of SAG1474 with selected peptides mapped on 
The structure of SAG1474 was predicted by I-TASSER (C-score: -2.08; TM score: 0.440), 
and visualised by PyMOL. (Schrodinger, 2015) The three peptides selected to raise 
antibodies against are coloured (peptide A red, peptide B blue, peptide C yellow). The cell 
wall anchoring motif is coloured in green. 
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Chapter 4 Antibody generation against S. agalactiae biomarkers 
 
4.1 Introduction 
 
4.1.1 Immunoassays in diagnostic tests 
Since the development of hybridoma technology, (Kohler and Milstein, 1975) 
monoclonal antibodies have become a significant tool in disease detection. Antibodies 
have been employed to detect streptococcal infections using various techniques such 
as latex agglutination, (Ascher et al., 1991; Greenberg et al., 1995) lateral flow tests, 
(Jorgensen et al., 2015) ELISAs,  (Egger et al., 1990) and electrochemical tests. (Wang 
et al., 2017) 
 
4.1.2 In vivo antibody production 
Antibodies are made by exploiting an animal’s immune system. Naïve antibody-
producing B lymphocytes, expressing IgM and IgD, are produced in the bone marrow. 
(Chaplin, 2010) During initial antigen exposure, the antibody immune response is 
dominated by IgM molecules, which exhibit polyspecificity and weak affinity to the 
target. (Boes, 2000) Naïve B cells migrate to the spleen and lymph nodes. Upon 
pathogen exposure, antigen-specific B cells are activated by clonal selection and these 
cells multiply. During proliferation, B cells undergo isotype switching to IgG, IgA and 
IgE, and experience somatic hyper-mutation. Errors are introduced at an increased 
rate in comparison to typical cell replication, thus enabling the production of antibodies 
exhibiting stronger antigen binding. Mature B lymphocytes become memory B cells or 
short-lived plasma cells which attack and eliminate the threat. (Chaplin, 2010) 
 
4.2 Antibody production 
 
Short peptide sequences are not able to evoke an immune response in mice, (Hancock 
and O'Reilly, 2004) and are susceptible to proteolytic cleavage in vivo. (Vlieghe et al., 
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2010) Peptides were conjugated to a carrier protein as larger structures are more 
immunogenic. BSA and KLH are commonly used as conjugation proteins. (Lateef et 
al., 2007) KLH was selected, as use of BSA as an immunogen can cause problems in 
cross-reactivity with FBS whilst culturing hybridoma cells (Hancock and O'Reilly, 2004) 
and in downstream applications as BSA is commonly used in protein blocking. A 
cysteine residue was added to the N-terminus of each peptide to facilitate maleimide 
conjugation. This ensured all peptides were displayed in the same orientation. The 
immune system was presented with limited immunogen conformations, therefore the 
effective concentrations were high. Peptides were also conjugated to BSA to assess 
peptide affinity in antibody screening assays. Peptide-BSA conjugates were utilised, 
opposed to free peptide, so peptides were presented in a similar orientation as in 
antibody production in vivo. BSA was utilised as the carrier protein to ensure selected 
antibodies showed affinity to the peptide rather than the KLH moiety. 
 
The number of free cysteine residues was determined before and after conjugation to 
calculate the number of peptides which had successfully bound to the carrier protein. 
The reduction in free cysteines represents the fraction of total peptide bound to the 
carrier protein. Table 4.1 shows example data from peptide conjugation to KLH. 
 
Peptide Conjugation 
efficiency / % 
Number of peptides per 
KLH subunit 
Concentration / 
mg ml-1 
A 75 250-275 2.95 
B 94 290-330 2.45 
C 83 200-220 4.13 
Table 4.1 Conjugation of peptide to carrier protein. 
An Ellman’s assay was performed to assess conjugation efficiency to the carrier protein 
KLH. A standard curve using known concentrations of reduced cysteine was created. The 
numbers of free cysteine residues within the peptide sample before and after conjugation 
were interpolated from the standard curve. The conjugation efficiency of the Ellman’s 
assay was calculated and used to estimate the number of peptide molecules attached to 
each KLH subunit. The peptide number per KLH subunit is expressed as a range as KLH is 
formed of 350-390 kDa subunits. A BCA assay was performed using known BSA 
concentrations to create a standard curve; conjugated peptide-protein concentration was 
interpolated from the data, which was used to determine the dilution required for murine 
immunisations and screening assays. The data shown is a representative example from 
one round of peptide conjugation to KLH; peptide conjugation was performed several 
times, to KLH and BSA. 
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To create monoclonal murine antibodies, 15 mice were injected with immunogen, five 
mice for each peptide. On repeated exposure to the same antigen, memory B cells are 
converted to plasma cells and these circulate around the body, lowering the 
concentration of antigen available to induce the immune response. In mice, levels of 
circulating plasma cells decrease after two weeks, (Greenfield, 2014) therefore 
immunisations were separated by this time period. Four immunisations were 
performed, followed by a test bleed to assess if target-binding antibodies were being 
produced, see figure 4.1. 13 of the 15 mice established a strong immune response to 
their immunogen and were therefore suitable for antibody production. A pre-immune 
antigen boost was performed to cause a large amount of B lymphocytes to accumulate 
in the lymph nodes and spleen. (Greenfield, 2014) 
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Harvested spleen cells were fused with a myeloma cell line, NS-1; (Kohler et al., 1976) 
this process combines the immortal properties from the myeloma cell line to the 
antibody-producing properties of the spleen cell. Hybridomas were then selectively 
cultured. Cells extracted from the spleen cannot survive indefinitely, so died over time. 
Growth of the myeloma cell line was prohibited as it contains the deletion of a protein 
which is essential when cultured under certain conditions. The growth of hybridomas 
Figure 4.1 Binding of murine test bleeds to peptide 
Affinity of murine serum to the respective peptide antigens was assessed via ELISA. A 
serum sample was extracted prior to immunisation to assess any background signal, 
these results have been subtracted from the test bleed data post immunisation. All 
background signals < 0.06. Error bars show standard deviation of the data, n=3. Mice 
are named NN, LN, RN, BN and 2RN in each cage. A: Test bleeds from mice injected 
with peptide A. B: Test bleeds from mice injected with peptide B. C: Test bleeds from 
mice injected with peptide C. All mice responded well to the immunisation except 
mouse A-RN and B-BN; these were not used for antibody production. 
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was permitted as they contain the essential protein from the spleen cell, and 
immortality from the myeloma cell. 
 
In hypoxanthine-aminopterin-thymidine media, cells are unable to utilise de novo DNA 
synthesis as it is blocked by aminopterin. Cells must utilise the salvage pathway, which 
is enabled as the precursors hypoxanthine and thymidine are present in the media. 
The enzyme thymidine kinase (TK) phosphorylates thymidine, forming thymidine 
monophosphate (TMP), a precursor for one of the four nucleotides required for DNA 
and RNA formation. The enzyme hypoxanthine guanine phosphoribosyltransferase 
(HGRPT) converts hypoxanthine to inosine monophosphate (IMP), which is a 
precursor for guanosine triphosphate and adenosine triphosphate, a further two 
nucleotides essential for DNA and RNA synthesis. Myeloma cell lines used for 
hybridoma creation contain deletions in one of two proteins, HGRPT or TK, and are 
therefore unable to utilise the salvage pathway to synthesise DNA, so are unable to 
survive in HAT (hypoxanthine, aminopterin, thymidine) media. (Shay, 1987) NS-1 cells 
are deficient in HGPRT. (Cammack et al., 2006) The mechanism of HAT selection is 
shown in figure 4.2. The wildtype phenotype is recovered through fusion of the 
myeloma cell with a spleen cell, and therefore hybridomas are capable of proliferating. 
(Greenfield, 2014) 
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Following cell fusion, hybridomas were seeded at low density. Cells grow optimally in 
response to growth factors expressed by neighbouring cells. To create a more 
favourable environment, hybridomas can be cultured onto a feeder layer of cells, 
macrophages are often used, however this can restrict the hybridoma yield (Greenfield, 
2014) as cells must compete for nutrients, oxygen and space. Alternative strategies 
include incubation with conditioned media, the addition of interleukin 6 (IL-6), 
oxaloacetate pyruvate insulin, or hybridoma cloning factors. IL-6 and oxaloacetate 
pyruvate insulin promote cell growth, whilst IL-6 also increases antibody production. 
(Greenfield, 2014) Condimed, a hybridoma cloning supplement containing growth 
factors and cytokines, was added to low cell density cultures. 
Figure 4.2 Mechanism of HAT selection 
De novo synthesis of DNA is blocked in the presence of aminopterin (green pathways). Cells 
must utilise the salvage pathways (red) using the enzymes HGPRT and TK to synthesise 
precursors for DNA synthesis (common pathways shown in blue). Myeloma cell lines 
containing HGPRT or TK deletions are unable to utilise these salvage pathways, and in the 
presence of HAT media are unable to proliferate, and therefore die. Information of the 
de novo and salvage pathways from (Mofatt and Ashiharab, 2002). Abbreviations: HGPRT 
(hypoxanthine guanine phosphoribosyltransferase), IMP (inosine monophosphate), GMP 
(guanosine monophosphate), AMP (adenosine monophosphate), TK (thymidine kinase), UMP 
(uridine monophosphate), TMP (thymidine monophosphate). 
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At this stage cultures were likely to comprise of a mixed population of cells. Limiting 
dilution screening was carried out in order to create monoclonal cell lines, in which all 
cells were statistically likely to be derived from a single clone, and therefore produce a 
uniform antibody population. Hybridomas secrete antibody into the supernatant. Once 
cell growth reached a sufficient level, the culture media was screened for antigen-
binding antibodies. Cell cultures associated with positive binding were selected for 
expansion. These cells were re-seeded at a range of dilutions, spanning 600-0.1 cells 
per well. Wells that exhibited positive target binding which originated from more than 
one cell per well were re-seeded in further rounds of subcloning, until a monoclonal 
cell line was obtained. Figure 4.3 shows the path taken to select and clone cell line B4-
3-6-B12. The naming convention for the initial term is derived from the immunising 
peptide (A, B or C) and which spleen was used for fusion (1-5). The subsequent 
naming pattern follows the number associated with the positively binding well for each 
round of subcloning. In this example three rounds of sub cloning were completed (3, 6, 
B12), see figure 4.4 for details. The cell line B4-3-6-C10 follows the same pathway of 
cloning, deviating only in the final positively binding well selected. 
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Figure 4.3 Peptide affinity screening programme of hybridoma fusions to cloned cells 
A: All cell growth positive wells from hybridoma fusion plates were assessed for binding 
to their peptide antigen via ELISA. B: The target-affinity positive wells were seeded into a 
cloning plate. Cloning plates were set up at a cell density of 600 cells per well in the first 
16 wells, with 6-fold serial dilutions across the plate. The final wells statistically held less 
than one cell each so any growth positive wells were likely to be cloned. C: The cloning 
process was continued until positive ELISA results were obtained from cloned cells. 
D: The cells were then checked for clonality by seeding a plate at one cell per well, and 
assessing target binding via ELISA. Graphs show the signal obtained for each well tested 
as a proportion to that obtained for the negative control (incubation with cell culture 
fluid in comparison to PBS). From each round of screening, multiple wells which 
produced a higher signal than the negative control were selected for subcloning. In this 
figure the process to obtain the clone B4-3-6-B12 is shown in blue. The final graph shows 
that all growth positive wells, which were statistically derived from a single cell, had 
affinity for the peptide, therefore a monoclonal cell line with target affinity was 
produced. 
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A final catalogue of 17 antibodies was created, consisting of five antibodies binding 
peptide A, seven antibodies against peptide B and five antibodies raised against 
peptide C. 
 
4.3 Antibody characterisation against linear peptide 
 
ELISAs were performed to assess the ability of each antibody to bind their respective 
peptide across a range of concentrations (0-10 µg ml-1), see figure 4.5. Antibodies 
raised against peptide B exhibited the strongest binding, producing an absorbance 
signal at 630 nm around twice as high as that of the two strongest binding antibodies 
generated against peptide A. The remaining peptide A antibodies and all peptide C 
antibodies displayed minimal binding. During clonal selection these antibodies did 
exhibit target-binding properties, it is possible that the cultures were not fully cloned, 
and during the scale up process cultures became dominated by a clone which did not 
produce antigen-binding antibodies. Results support the further investigation of two 
peptide A antibodies (A1-69B-9-1-18 and A1-69B-9-2-5) and seven peptide B 
antibodies. 
Figure 4.4 Antibody naming convention 
The antibody naming convention is shown using the cell line B4-3-6-B12 as an exemplar. 
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Figure 4.5 Antibody binding to peptide 
Antibody binding to peptide was analysed via ELISA. Concentrations of antibody in the 
range 0-10 µg ml-1 were used for primary incubation onto peptide-coated ELISA plates. 
Plates were incubated with TMB for 30 minutes. Peptide A and B antibodies were fitted 
to logarithmic lines of best fit with R2 values ranging from 0.87-0.97 for peptide A 
antibodies and 0.97-0.99 for peptide B antibodies. Antibodies raised against peptide C 
fitted to a quadratic equation with R2 values ranging from 0.87 – 1.00. Lines of best fit 
were determined by SigmaPlot. Error bars show standard deviation, n=2. 
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4.4 Production of recombinant SAG1474 
 
Antibodies were raised, and initially screened against peptides. For use in a diagnostic 
test, the antibodies will have to bind the folded-protein form, in which the peptide 
sequence may hold an alternative conformation, or may be buried within the protein. 
A recombinant version of the protein SAG1474 was made to assess binding in the 
native form. 
 
4.4.1 Design of SAG1474 construct 
For recombinant protein production, the amino acid sequence of SAG1474 was edited 
to remove the signal sequence, identified by SignalP, to enable cytoplasmic expression. 
As cell wall associated proteins are cleaved at the LPXTG motif, (Navarre and 
Schneewind, 1994) the C-terminal sequence was removed. A polyhistidine tag was 
added to the recombinant protein to enable nickel affinity purification. The C-terminus 
was selected for tag insertion, as in the native protein it is this site which tethers to the 
cell wall, therefore modification is less likely to cause perturbations to the folded 
structure. The DNA sequence was optimised for high efficiency expression in E. coli 
by GeneOptimizer® software (GeneArt, Life Technologies). The DNA sequence was 
edited to insert NcoI and XhoI restriction enzyme sites to enable insertion into a 
pET28a plasmid, causing the recombinant protein to be under control of IPTG 
induction. Further editing removed two internal NcoI sites, modifying the sequence to 
contain alternative codons that would not alter the translated amino acid sequence. 
The plasmid map and construct DNA sequence are shown in figure 4.6, the protein 
sequence is found in figure 4.7. Details on protein parameters can be found in table 
2.4, section 2.4.1. 
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Figure 4.6 Recombinant SAG1474 construct DNA sequence 
A: Plasmid map of the gene construct, produced in SnapGene Viewer. (GLS Biotech) 
B: DNA sequence encoding for SAG1474. NcoI and XhoI restriction enzymes were used to 
insert the construct DNA into pET28a, restriction sites shown in green. Codons were 
optimised for production in E. coli and two bases were altered to remove additional NcoI 
restriction sites (red). 
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4.4.2 Induction of SAG1474 
In order to investigate expression conditions for optimal SAG1474 production, small 
induction tests were performed. Each culture was grown at a constant temperature to 
an OD 600nm of 0.5, and induced with IPTG at various concentrations for various time 
points. Cell extracts were harvested, lysed by Bugbuster, and centrifuged to separate 
insoluble protein found in the pellet from soluble protein in the supernatant. The soluble 
and insoluble fractions were analysed by western blotting. An anti-polyhistidine tag 
antibody was used for SAG1474 detection, see figure 4.8. SAG1474 is predicted to be 
69.4 kDa. (Gasteiger et al., 2005) 
 
Figure 4.7 Recombinant SAG1474 protein 
A: Protein sequence encoding for SAG1474. The N terminal signal sequence and the region to 
the C terminus of the LPXTG motif have been removed and a histidine tag (orange) has been 
designed into the sequence. B: Representation of the SAG1474 protein construct. 
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Histidine-tagged protein was detected from cells induced with IPTG. There was no 
histidine-tagged product detected in the absence of IPTG, indicating the plasmid does 
not exhibit leaky expression in this system. A band corresponding to 85 kDa was 
detected in experiments B and C; the predicted molecular weight of SAG1474 is 
69.4 kDa. Aberrant protein mobility can arise from negatively charged amino acid 
Figure 4.8 Induction of SAG1474: western blots 
E. coli BL21 cells were transformed with pET28a-SAG1474. Cells were grown to 
an OD 600  nm of 0.5, before induction with IPTG. A: 37 °C, induced for one hour. B: 37 °C, 
induced for three hours. C: 20 °C, induced for 16 hours. Cells were lysed by Bugbuster and 
centrifuged to separate insoluble pellet from the soluble supernatant. Western blots 
were performed using an anti-his tag antibody for SAG1474 detection. Insufficient protein 
expression is achieved whilst growing at 37 °C. Growth at 20 °C, caused protein to be 
found solely in the insoluble fraction. Protein bands representing SAG1474 are indicated 
by a red box. 
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content, (Graceffa et al., 1992; Alves et al., 2004) proline residue content (Condemine 
and Shevchik, 2000) or result from the protein’s hydrophobicity. (Shirai et al., 2008) 
 
Western blots showed little protein expression when cells were cultured at 37 °C. There 
was an increase in SAG1474 detection at three hours in comparison to one hour, 
suggesting that induction over a longer time period may lead to further enhancement 
of protein production. However growth curves show cell growth is restricted by IPTG 
addition, indicating that extension of the induction time may not be viable, see figure 
4.9. Protein induction performed at 20 °C for 16 hours, caused SAG1474 to be found 
in the insoluble fraction. The insoluble fraction contains unfolded proteins, which have 
aggregated. It may not be possible to re-fold protein into the native conformation. As 
there is no solved structure for SAG1474 for comparison, it would be difficult to assess 
whether re-folding into the native formation was successful. Assuming the highest 
molecular weight band represents SAG1474, western blots show evidence of protein 
degradation with multiple protein bands of lower molecular weight observed. 
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Growth limitation upon SAG1474 expression suggests that SAG1474 is toxic. This is 
promising information as it may be functional in its putative role as an amidase, and 
therefore in its folded state. Amidases catalyse amide bond hydrolysis. In its native 
state as a cell wall associated protein, SAG1474 may function in breaking down 
peptidoglycan. This plays a role in cell wall growth and restructuring, cell division, and 
recycling cell wall components. (Scheffers and Pinho, 2005) As SAG1474 is largely 
unstudied, its precise target is unknown. It may lyse amide bonds in E. coli when 
produced recombinantly, thus causing toxicity. 
Figure 4.9 Growth curve following induction of SAG1474 with IPTG 
The optical density of cell cultures at 600 nm was followed at intervals of 30 minutes.  
There is a significant reduction in cell growth in cells induced with IPTG in comparison to 
non-induced cells. 
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4.4.3 Design of a SAG1474 fusion protein 
Induction of SAG1474 at high temperatures over a short period of time was unable to 
induce sufficient protein expression, and induction at low temperatures resulted in 
insoluble unfolded protein; therefore expression of this protein construct was deemed 
to be an unfeasible route to production. A protein tag was added to the SAG1474 
sequence to aid in protein folding, increase expression and reduce protein degradation. 
 
Maltose binding protein (MBP) is a 43 kDa solubility tag (Costa et al., 2014) which has 
been added to many proteins successfully. (Pryor and Leiting, 1997; Hang et al., 2016; 
Nguyen et al., 2016) MBP acts as a chaperone protein, preventing self-aggregation of 
the fusion partner by interaction with the hydrophobic cleft within MBP. (Kapust and 
Waugh, 1999; Costa et al., 2014) A commercially available plasmid, pMAL, includes 
the gene encoding for maltose binding protein, malE, adjacent to a multiple cloning 
site, allowing fusion partner insertion via the use of a selection of restriction sites. The 
construct is under the control of a strong promoter, PTac, therefore a fusion product will 
be strongly expressed. There are two variants of the pMAL plasmid, one of which 
directs proteins to the periplasmic space via a signal sequence. (New England BioLabs, 
2017b) The periplasm contains fewer proteases, (Baneyx and Mujacic, 2004) and 
therefore proteins within the periplasm are less susceptible to proteolytic degradation. 
Periplasmic expression may also aid purification. The periplasmic space contains 
fewer proteins, (Baneyx and Mujacic, 2004) therefore if the recombinant protein can 
be isolated from the periplasm without lysing the cell membrane, the protein 
preparation will contain fewer contaminants. The plasmid variant which directs fusion 
proteins to the periplasm was selected. A linker region between the gene encoding for 
MBP and SAG1474 was designed to include a TEV protease site. The protease site 
allowed for removal of MBP following expression. The plasmid map and construct DNA 
sequence can be found in figure 4.10. The protein sequence alongside a schematic of 
the protein construct can be seen in figure 4.11. Details on protein parameters can be 
found in table 2.4, section 2.4.1. 
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Figure 4.10 Recombinant SAG1474-MBP construct DNA sequence 
A: Plasmid map of the gene construct, produced in SnapGene Viewer. (GLS Biotech) 
B: DNA sequence encoding for SAG1474. AvaI and EcoRI restriction enzymes were used to 
insert the construct DNA into pMAL p5x, restriction sites shown in green. Codons were 
optimised for production in E. coli. 
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4.4.4 Induction of SAG1474-MBP 
A similar process was adopted for the evaluation of optimal conditions for 
SAG1474-MBP expression as for SAG1474. Induction test cultures were grown at 
37 °C and induced for various time points with a range of IPTG concentrations. 
Periplasmic extraction was performed and these samples, along with complete cell 
extracts, were analysed by western blotting, see figure 4.12. 
 
Figure 4.11 Recombinant SAG1474-MBP construct protein 
A: Protein sequence inserted into pMAL p5x encoding for production of SAG1474. A TEV 
protease cleavage site (green) and histidine tag (orange) have been designed into the 
sequence and the N terminal signal sequence and the region to the C terminus of the LPXTG 
motif have been removed. B: Representation of the SAG1474-MBP protein construct. 
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Figure 4.12 Induction of SAG1474-MBP: western blots 
E. coli BL21 cells were transformed with pMAL p5x-SAG1474-MBP. Cells were grown at 
37 °C to an OD 600 nm of 0.5, before induction with IPTG. A: induced for zero hours. B: 
induced for one hour. C: induced for two hours. D: induced for three hours. Periplasmic 
extraction was performed and analysed alongside whole cell extracts. Western blots were 
performed using an anti-his tag antibody for SAG1474 detection. Positive control (PC) in 
panel A is a cell extract induced with 2 mM IPTG for 1 hour at 37 °C, added to determine 
that western blotting procedure was successful. Protein bands representing SAG1474-MBP 
are indicated by a red box. 
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Similarly to SAG1474, the plasmid encoding SAG1474-MBP showed no leaky 
expression in the absence of IPTG. Protein bands were observed at 130 kDa, however 
prediction software estimates the molecular weight of SAG1474-MBP to be 115 kDa. 
(Gasteiger et al., 2005) Mass spectrometry confirmed protein identity as 
SAG1474-MBP, data not shown. Possible reasons for the deviation between observed 
and expected molecular weights are discussed in reference to SAG1474, see section 
4.4.2. 
 
Through analysis of whole cell extracts, maximal expression of SAG1474-MBP was 
observed following a two hour induction with 0.5 mM IPTG. At induction for two hours 
bands of lower molecular weight were detected at around 80-100 kDa, suggesting that 
a fraction of the total protein degrades at various sites within the protein. As the 
expected molecular weight of SAG1474 is 69.4 kDa, degradation may not fragment 
the SAG1474 protein. The low molecular weight band at 35 kDa can be removed via 
protein filtration with an appropriate molecular weight cut off, or via size exclusion 
chromatography. Degradation was increased when cells were induced for three hours. 
 
Periplasmic extraction was performed on all samples, however detection of histidine-
tagged protein was only achieved on one occasion. When repeated under identical 
conditions it was not possible to successfully extract protein from the periplasm. The 
SecYEG translocon is responsible for transportation of unfolded maltose binding 
protein to the periplasm. (Weiss et al., 1988) If the recombinant protein construct folds 
in the cytoplasm, transportation may not be achievable. Alternatively it is possible that 
the high expression rate exceeds the rate at which protein can be exported to the 
periplasm, thus creating a backlog of protein trapped in the cytoplasm. Although 
periplasmic extraction was unsuccessful, translocation to the periplasm may still have 
been beneficial due to the reduced protease concentration in comparison to the 
cytoplasm. Whole cell extracts were used for protein purification. SAG1474-MBP 
extracted from the whole cell is likely to exist as a mixed population of protein, the full 
length protein from the cytoplasm, and a signal sequence deficient variant extracted 
from the periplasm. (Beena et al., 2004) 
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As seen with induction of SAG1474, SAG1474-MBP expression causes a reduction in 
cellular growth, see figure 4.13. Toxicity is a sign that the putative amidase is active, 
and folded. A two hour induction with 0.5 mM IPTG was selected for large scale protein 
production.  
 
 
4.4.5 SAG1474-MBP purification 
A large scale growth of E. coli BL21 pMALp5xSAG1474-MBP was conducted by 
Newcastle University Protein and Proteome Analysis, following the optimised protocol 
devised by induction tests. Cells were harvested, lysed by Bugbuster and centrifuged 
Figure 4.13 Growth curve following induction of SAG1474-MBP with IPTG 
The optical density of cell cultures at 600 nm was followed at intervals of 30 minutes.  
There is a significant reduction in cell growth in cells induced with IPTG in comparison to 
non-induced cells. 
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to isolate the soluble protein fraction. Protein samples were purified by nickel affinity 
chromatography, utilising the nickel-binding properties of the polyhistidine tag. Eluates 
containing SAG1474-MBP were pooled and further purified by size exclusion 
chromatography see figure 4.14. A protein migrating at 130 kDa, the same value 
observed in induction tests was purified. A small sample injection volume and slow 
running speed (1 ml min-1) was used to enhance protein separation. This enabled the 
separation of SAG1474-MBP from the small amount of SAG1474, which was essential 
for protein characterisation via circular dichroism. A final yield ranging from 0.55-
1.1 mg SAG1474-MBP was purified per 1 g cell pellet. 
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Alternative methods of purification were considered and trialled. A TEV protease site 
was designed into the protein sequence to allow removal of MBP from SAG1474. 
Following nickel purification, samples were cleaved using TEV protease. The 
percentage of cleaved protein from total SAG1474 protein increased from around 30% 
to 80% following incubation with TEV protease, as determined by band densitometry, 
see figure 4.15. A GST affinity column was used to remove the GST-tagged TEV 
protease after proteolysis. This step caused an unexpected large loss of SAG1474 
protein, with little protein recovered during flow through or column cleaning (data not 
Figure 4.14 Purification of recombinant SAG1474-MBP 
SDS-PAGE gels show the purification process of recombinant SAG1474-MBP. E. coli BL21 
cells transformed with pMALp5xSAG1474 were grown at 37 °C to an OD 600 nm of 0.5 and 
induced with 0.5 mM IPTG for two hours. A: Cells were lysed by Bugbuster and 
centrifuged to isolate soluble protein which was purified by nickel chromatography. 
B: The sample was further purified using size exclusion chromatography. 
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shown). The cleaved sample, following GST-purification of TEV protease, exhibited 
degradation over a two week period, however the un-cleaved protein sample did not 
(data not shown). This may be due to low levels of protease remaining in the solution 
and acting non-specifically on the protein sample. Due to the instability, incomplete 
proteolysis and protein loss during protease removal, TEV protease cleavage was not 
performed in further protein purifications. Subsequent purification of the mixed protein 
population was attempted by ion exchange chromatography. A large amount of protein 
was lost whilst utilising a cationic exchange column (data not shown). For this reason 
size exclusion chromatography was selected in preference to ion exchange 
chromatography. 
 
The linker region of SAG1474-MBP was designed to be sufficiently long enough for 
MBP and SAG1474 to fold independently, in their native forms. A previous study has 
compared the X-ray crystallography structures obtained from free proteins and those 
bound to MBP. The structures were found to be very similar, with the average 
difference between atomic positions in the majority of proteins being around 1 Å. 
(Waugh, 2016) Previous studies have found proteins to be in their active state whilst 
existing as a MBP fusion product. (Smith and Kotin, 1998; Gholizadeh et al., 2010; 
Gholizadeh and Kohnehrouz, 2011) Therefore it is valid to structurally characterise 
SAG1474 in its SAG1474-MBP form. 
Figure 4.15 TEV protease cleavage of SAG1474-MBP 
SDS-PAGE gel showing the SAG1474-MBP protein sample before and after treatment 
with TEV protease. 
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4.4.6 Structural characterisation of SAG1474-MBP 
To assess antibody affinity to protein, the recombinant protein must be folded in its 
native state. Circular dichroism (CD) was utilised to assess the secondary and tertiary 
structure of SAG1474-MBP. The CD spectra of MBP was determined and subtracted 
from that of SAG1474-MBP to discover the structural characteristics of the SAG1474 
protein. 
 
Polarised light waves oscillate in single plane. When two polarised light waves, 
oscillating at an angle difference of 90 ° with respect to each other, are combined out 
of phase, the waves are circularly polarised. Circularly polarised light can be right or 
left handed. Chiral molecules absorb left-handed circularly polarised light to a different 
extent to right-handed circularly polarised light. All amino acids, except glycine, are 
chiral, with four distinct groups in an asymmetrical formation around a central carbon 
atom. 
 
4.4.6.1 Far UV circular dichroism 
Amino acids absorb light in the far UV region differently depending on their secondary 
structure. The CD spectrum of an α-helical protein shows minima at 222 nm and 
208 nm and a maxima at 193 nm. The CD spectrum of β-sheets shows a minima at 
218 nm and a maxima at 195 nm. The CD spectrum of an unstructured protein shows 
a minima at 195 nm, and little activity at over 210 nm. (Greenfield, 2006) The 
secondary structure of maltose binding protein consists of twice as much α-helical 
content as β-sheet; (Spurlino et al., 1991) the spectra observed reflected a species 
dominated by α-helices (maxima: 196 nm, minima: 209 nm and 222 nm), see figure 
4.16. A spectra indicative of an α-helical secondary structure was obtained for 
SAG1474 (maxima: 195 nm, minima: 209 nm and 222 nm). The structure of SAG1474 
is unknown, however the circular dichroism spectra can be compared to the structure 
predicted by I-TASSER and psipred. The predicted structure is dominated by α-helices 
and unstructured loops, with a small proportion of β-sheet structure, see table 3.7, 
section 3.5.5; these results concur. A variety of programmes were utilised to 
102 
 
deconvolute the spectra in order to determine proportions of α-helix and β-sheet 
content, however no predictions with high confidence levels were produced. This may 
be due to a lack of similarity to reference data. (Whitmore and Wallace, 2008) 
 
 
4.4.6.2 Near UV circular dichroism 
Tertiary structure can be probed with circular dichroism using wavelengths in the near 
UV region, with signals produced by aromatic residues. Phenylalanine causes a signal 
at 255-270 nm, tyrosine at 275-282 nm, tryptophan at 290-305 nm and disulphide 
bonds give rise to indistinct signals. When in a folded state, these residues are held in 
Figure 4.16 Circular dichroism study of SAG1474: Far UV 
A: Far UV spectra for SAG1474-MBP, MBP and SAG1474. Each wavelength scan was 
determined from an average of nine scans. The background CD spectrum from buffer 
(obtained by averaging the results from three scans) has been taken away. A far UV scan for 
SAG1474 has been calculated by subtracting the signal obtained for MBP from that of 
SAG1474-MBP. HT values did not exceed 800 V (data not shown), therefore protein 
concentration was acceptable. (Fung, n.d.)  
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an asymmetric (or chiral) formation. Unfolded proteins show a lack of uniformity across 
the population, therefore circularly polarised light is absorbed to different extents and 
a signal is not observed. (Kelly and Price, 2000) The near UV spectra for SAG1474-
MBP indicates that the protein has three dimensional structure. The spectra for 
SAG1474, calculated in the same way as for the far UV spectra, shows a peak at 253 
nm and 292 nm, and a trough at 280 nm, arising from phenylalanine, tryptophan and 
tyrosine residues, see figure 4.17. 
 
4.4.6.3 Melting temperature circular dichroism 
When proteins are heated, their absorption of circularly polarised light is altered due to 
the loss of folded structure. Unfolded proteins would show no change in CD absorption 
with increasing temperature. As SAG1474-MBP has a distinctly different CD 
Figure 4.17 Circular dichroism study of SAG1474: Near UV 
Near UV spectra for SAG1474-MBP, MBP and SAG1474. Each wavelength scan was 
determined from an average of nine scans. The background CD spectrum from buffer 
(obtained by averaging the results from three scans) has been taken away. A near UV 
scan for SAG1474 has been calculated by subtracting the signal obtained for MBP from 
that of SAG1474-MBP. HT values did not exceed 800 V (data not shown), therefore 
protein concentration was acceptable. (Fung, n.d.) 
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absorbance profile at 222 nm over a range of temperatures, the protein must be folded 
at low temperatures. Melting temperature, is defined as the temperature at which half 
of the structure exists in its unfolded form. The melting temperatures for SAG1474-
MBP and MBP were calculated to be 52 °C and 63 °C respectively. Circular dichroism 
graphs are found in figure 4.18. 
 
 
4.5 Antibody characterisation against folded protein 
 
The nine most promising antibodies were tested for binding to folded SAG1474-MBP. 
To confirm antibody affinity to SAG1474-MBP was dependent on binding in the 
SAG1474 region, MBP binding was used as a negative control. The limit of detection 
for each antibody was calculated by adding the mean of the MBP negative control to 
three times its standard deviation. The results can be seen in figure 4.19. ELISA results 
Figure 4.18 Circular dichroism study of SAG1474: Melting temperature 
A: Thermal melt spectra for SAG1474-MBP and MBP, measured at 222 nm. Temperature 
was increased at a rate of 2 °C min-1. HT values did not exceed 800 V (data not shown), 
therefore protein concentration was acceptable. (Fung, n.d.) 
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show peptide B antibodies exhibited the strongest binding to SAG1474-MBP, these 
antibodies showed reduced binding to MBP. Peptide A antibodies showed moderate 
peptide affinities, but limited protein binding, with antibody A1-69B-9-1-18 exhibiting 
no binding above the limit of detection. This could be due to peptides being not being 
surface exposed in the protein form or holding a different conformation. 
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Figure 4.19 Antibody binding to recombinant SAG1474-MBP protein 
ELISAs were performed to assess antibody binding to SAG1474-MBP protein (blue) and 
MBP (grey). The limit of detection (mean of the signal obtained from the negative control 
(MBP) + three times its standard deviation) is shown in black. Plates were coated with 
protein and incubated with the panel of antibodies at 2 µg ml-1, followed by incubation 
with HRP-linked anti mouse IgG antibody. Colorimetric change of TMB was measured at 
630 nm after 30 minutes. Error bars show standard deviation, n=3. 
* indicates a p value < 0.1, ** indicates a p value <0.05, as determined by a Mann 
Whitney U test. 
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4.6 Antibody characterisation against bacterial cells 
 
Antibodies with affinity for peptide B show the most promise and were investigated for 
binding to bacteria. A critical feature of an antibody for use in a diagnostic test is a lack 
of cross-reactivity. To assess this, antibody binding to a bacteria belonging to the same 
genus, Streptococcus pyogenes, was examined. SAG1474 has a homologue within 
S. pyogenes, AmiC, which functions as an amidase and has an amino acid identity and 
similarity to SAG1474 of 36% and 54% respectively. (Glaser et al., 2002) Therefore S. 
pyogenes is a suitable choice as a negative control. Ideally a diagnostic test would 
require as little processing as possible. An antibody that binds to non-lysed, or whole, 
cells would be beneficial to reduce the number of sample preparation steps. Antibody 
binding to lysed and whole cell S. agalactiae and S. pyogenes samples was 
investigated, see figure 4.20. S. agalactiae serotype III was utilised, as this is the one 
of the most prevalent serotypes in infectious disease. (Berg et al., 2000; Ippolito et al., 
2010; Soares et al., 2013; Vinnemeier et al., 2015) In this example S. pyogenes strain 
M5 Manfredo58 was used. 
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The signal obtained for antibody binding to lysed S. agalactiae cells is lower than to 
the peptide. When the proportion of target found in the coating material is considered, 
the result is expected. Wells which are coated in peptide-BSA contain a large number 
of target sequences, whereas the epitope makes up only a small proportion of the 
Figure 4.20 Antibody binding to lysed and whole cell S. agalactiae and S. pyogenes 
ELISA plates were coated with peptide and lysed and whole-cell group B streptococcal 
cells. Negative controls of lysed and whole-cell group A streptococcal cells and BSA were 
also coated onto ELISA wells. Wells were incubated with the panel of antibodies at 
2 µg ml-1, followed by incubation with HRP-linked anti mouse IgG antibody. Colorimetric 
change of TMB was measured at 630 nm after 30 minutes. Error bars show standard 
deviation. ELISA is able to distinguish between lysed group A and group B streptococcal 
cells. B4-3-5-8-25, B4-3-6-C10, B4-3-5-9-D9, B4-3-6-G10, B4-3-6-D9, B4-3-4-C9, n=8; B4-3-
6-B12, n=4; PBS, n=16. 
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SAG1474 protein which in turn makes up a small proportion within the S. agalactiae 
lysate. In a sandwich ELISA format SAG1474 would be captured on the plate, 
eliminating contaminating proteins, therefore enabling production of a higher signal. In 
respect to differentiating S. agalactiae and S. pyogenes, the antibodies perform well. 
However, the antibody was unable to bind whole cell S. agalactiae, producing a signal 
equivalent to that obtained with the BSA negative control. This experiment required a 
lysis step. Although a desirable feature, whole cell binding is not essential for 
diagnostics. 
 
4.6.1 Comparison of antibodies 
The seven antibodies were analysed to assess which is the most promising for the 
diagnosis of group B streptococcal disease. Expressing the signal obtained for 
S. agalactiae as a proportion to that obtained for S. pyogenes allows the ability of each 
antibody to discriminate between the target of interest and contaminating bacteria to 
be compared. The values calculated for each antibody are similar, ranging from 3.0-
4.0, see table 4.2. 
Antibody S. agalactiae signal as a proportion of 
S. pyogenes signal 
B4-3-4-C9 4.0 
B4-3-6-C10 3.7 
B4-3-5-8-25 3.7 
B4-3-5-9-D9 3.7 
B4-3-6-D9 3.5 
B4-3-6-G10 3.1 
B4-3-6-B12 3.0 
PBS 1.0 
 
B4-3-6-B12 has a decreased ability to detect lysed S. agalactiae cells over lysed 
S. pyogenes cells, which approaches statistical significance (p<0.1) in comparison to 
B4-3-5-9-D9 and B4-3-6-D9 antibodies, and is statistically significant (p<0.05) with 
respect to B4-3-5-8-25, B4-3-6-C10 and B4-3-4-C9. There are no statistical differences 
Table 4.2 Comparison of antibody binding to S. agalactiae and S. pyogenes 
The table shows ELISA signals derived from antibody binding to lysed S. agalactiae cells as 
a proportion to those obtained for binding to S. pyogenes. 
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between the remaining antibodies, determined by a Kruskal-Wallis test. As there is no 
outstanding antibody, all antibodies were considered for future work. 
 
4.6.2 Antibody characterisation against S. agalactiae serotypes 
The purpose of using IDRIS was to aid peptide selection by determining peptides found 
in all S. agalactiae strains and in no other bacteria. A panel of 10 strains representing 
distinct S. agalactiae serotypes was assessed for antibody binding, as well as three S. 
pyogenes strains, see figure 4.21. Antibodies show increased binding to all strains of 
S. agalactiae tested in comparison to those of S. pyogenes (p values <0.05, 
determined by a Mann-Whitney U test, GBS: n=10, GAS: n=3). Thus demonstrating 
the suitability of these antibodies to be used in a diagnostic test. This test also validates 
the use of IDRIS to select peptide tokens. 
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Figure 4.21 Assessment of antibody sensitivity and specificity  
10 strains of S. agalactiae and three strains of S. pyogenes were lysed and coated onto 
ELISA plates for analysis. Negative control wells were coated in BSA. Wells were 
incubated with the panel of antibodies at 2 µg ml-1, followed by incubation with HRP-
linked anti mouse IgG antibody. Colorimetric change of TMB was measured at 630 nm 
after 20 minutes. Error bars show standard deviation, n=3. Results show antibodies 
exhibit specificity in respect to binding S. agalactiae over S. pyogenes, and sensitivity to 
all strains of S. agalactiae tested. 
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4.7 Conclusions and future work 
 
Promising antibodies exhibiting target binding to peptide B (VNLEENSQV) were 
created. These antibodies are incapable of binding to the exterior of the cell, therefore 
whole cell diagnostics is not possible. A pair of antibodies, binding distinct regions of 
the same protein, is required to create an immuno-sandwich detection system. 
Antibodies generated against peptides A (VQTNDSNPT) and C (NMENLSQEERI) 
showed little to no binding. Therefore further antibodies need to be created in order to 
construct a functional diagnostic test. As specificity is ensured by the original antibody, 
the second antibody may be in the form of a monoclonal antibody or polyclonal 
antibody raised against the recombinant protein. 
 
Possible reasons for the lack of binding to whole cell S. agalactiae include epitope 
coverage by the cell wall or polysaccharide capsule. It is suggested that the capsule 
does not entirely cover the bacterial cell at all times, as the Sip protein evokes an 
immunoprotective response to GBS infection when injected in mice. (Brodeur et al., 
2000) It is possible that cells grown under laboratory conditions have a different 
morphology to those found in vivo, cell wall associated proteins may be exposed in 
patient samples. Alternatively the protein could be partially hidden, therefore producing 
antibodies against spatially distant sites of the protein may enable whole cell binding. 
 
The antibody signal generated by affinity to lysed S. agalactiae is higher than to 
recombinant SAG1474-MBP. As the protein constitutes a fraction of the cell lysate, and 
plates were coated at a concentration in excess of the maximal binding efficiency 
(2 µg ml-1), it was expected for the protein derived signal to be higher. It is possible that 
the target epitope is hidden through incorrect folding of the recombinant protein or 
concealment by the MBP moiety. Decreased binding may arise from partial or transient 
blocking of the binding site. As the recombinant protein contains a periplasmic 
signalling sequence, there may be two protein populations, one in the cytoplasm and 
one in the periplasm, which may be in two differentially folded states. As periplasmic 
extraction did not yield sufficient protein, whole cell protein extraction was performed, 
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and both populations harvested. Creation of a signal sequence deficient 
SAG1474-MBP construct, which remains within the cytoplasm, should enable a single 
population of protein to be extracted, which may be correctly folded. Future work may 
include the purification of native SAG1474 from S. agalactiae cells through affinity with 
the antibodies developed in this work. This would eliminate any effect that recombinant 
protein production and fusion with MBP causes, however the purification process will 
be limited by the levels found in the native cell. 
 
Additional work is needed to fully characterise antibody binding affinities to determine 
which of the seven antibodies raised against peptide B is best suited for group B 
streptococcal diagnostics. Surface plasmon resonance could be performed to analyse 
dissociation rates. Antibodies could be isotyped and sequenced to gain more 
information. Antibody specificity needs to be investigated further. A panel of bacteria 
which would be present in vaginal or rectal swabs should be investigated. Organisms 
which contain peptide sequences closely matching the immunogenic peptide should 
also be evaluated for antibody binding. To validate a diagnostic test, performance in 
patient samples must be studied. Initially, bacteria-spiked patient samples should be 
tested, followed by evaluating real patient samples. Ideally this would be performed 
blinded. 
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Chapter 5 RPA DNA amplification 
 
5.1 Introduction 
 
5.1.1 DNA amplification in diagnostic tests 
Molecular diagnostics is considered the gold standard for the detection of many 
infectious diseases. These techniques can exhibit high sensitivity alongside high 
specificity, and vastly reduce diagnosis times in comparison to traditional microbial cell 
culture. (Emmadi et al., 2011) The platform is adaptable, and tests for new disease 
targets can be developed rapidly as there is no reliance on the time-consuming 
production of affinity molecules, such as antibodies. (Lipman et al., 2005) This means 
molecular diagnostics can be readily mobilised on the emergence of new pathogens 
or genetic shifts. 
 
The most common molecular technique is PCR. PCR amplifies specific DNA using a 
thermostable polymerase, isolated from Thermus aquaticus. Template DNA is 
denatured, target-specific primers bind to the single stranded DNA and strand 
extension is performed by the polymerase. Each of the three stages, has a distinct 
optimum temperature, therefore the process is co-ordinated by temperature cycling. 
This process is typically repeated 25-35 times with DNA concentration doubling with 
each round of PCR. (Saiki et al., 1988) Simple PCR requires a separate readout step 
such as gel electrophoresis to visualise the results. Quantitative real time PCR 
incorporates the readout stage into the amplification process. Fluorescent dyes are 
used to monitor amplification, either binding non-specifically to the increasing amount 
of double stranded DNA or binding specifically to amplicons via targeted probes. 
(Saunders, 2009) PCR’s success is due to its high sensitivity. Quantitative PCR 
enables the detection of single molecules of DNA, with variations of the technique, 
such as digital PCR, enabling quantification of minority sequences in a sample. 
(Vogelstein and Kinzler, 1999) PCR is able to specifically identify related bacterial 
species, for instance 20 intestinal bacterial species were shown to cause no cross-
reactivity. (Ott et al., 2004) 
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Despite PCR’s dominance within DNA amplification, it does have considerable 
drawbacks relevant to the field of diagnostics, one of which is speed. Conventional 
PCR operates for a specified number of cycles, typically taking over one hour, with an 
additional 30 minutes per kb of DNA. (New England BioLabs, 2017a) Real time PCR 
reports the number of cycles required for the fluorescent signal to reach a level 
equivalent to a specified DNA concentration. Therefore a sample with a high 
concentration of template DNA will take a short amount of time to report a positive 
result, however a negative result can only be confirmed in a longer time period. 
(Saunders, 2009) The large expense of a thermocycler means PCR tends to be 
performed in centralised healthcare laboratories. (St John and Price, 2014) This 
increases the time from sample collection to result considerably. Its high price also 
means it is economically unviable for use in screening of low risk diseases or in 
developing countries. 
 
5.1.2 Isothermal DNA amplification 
Isothermal DNA amplification techniques are alternatives to PCR. As amplification is 
performed at a single temperature, expensive thermocyclers are not required and 
equipment costs are reduced. This makes DNA amplification accessible for wider 
healthcare applications and settings. 
 
There are many variations of isothermal DNA amplification, which can be classified 
into three major groups. The first group amplifies DNA exponentially, these methods 
are associated with high sensitivity. Techniques within the second group amplify DNA 
linearly, reducing the sensitivity, but maximising specificity. The final group amplify 
DNA linearly and feed the products into a cascade event to increase the signal, thus 
overcoming the limitations of linear techniques. Exponential DNA amplification 
techniques are the most studied methods. (Zhao et al., 2015) The properties of 
commonly used isothermal techniques are detailed in table 5.1. A rapid point-of-care 
test would ideally show large amplification of DNA at a low temperature over a short 
period of time. Recombinase polymerase amplification is able to amplify DNA over an 
extremely short period of time. This time frame is essential for point-of-care testing. 
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Name Type Amplification 
Efficiency 
Amplification 
Time 
/ mins 
Operating 
Temperature 
/ °C 
Reference 
RPA Exponential 1012 fold 
(104 fold every 
10 minutes) 
5-20 25-42 (Daher et al., 2016; 
TwistDx, 2016) 
LAMP Exponential 109-1010 fold 60 60-65 (Sahoo et al., 2016) 
HDA Exponential 107 fold 120 37-65 (Vincent et al., 2004; 
An et al., 2005) 
NASBA Exponential 109 fold 120 37 (Compton, 1991) 
HRCA Exponential 109 fold 90 65 (Lizardi et al., 1998; 
Hamidi et al., 2015) 
PGRCA Exponential 10 fold every 20 
minutes 
30-150 60 (Murakami et al., 
2009) 
ESDA Exponential 107 fold 120 37 (Walker et al., 1992) 
LRCA Linear 103 fold 30-60 37 (Nallur et al., 2001) 
LSDA Linear 20 fold 40 37 (Joneja and Huang, 
2011) 
 
5.1.3 Recombinase polymerase amplification 
RPA employs recombinases and polymerases to amplify short sequences (typically 
80-200 bp) of DNA in 5-20 minutes. It operates between 25 °C and 42 °C, and is 
capable of amplifying single copy numbers of DNA 1012 fold. It is the only isothermal 
technique which has been shown to operate using body heat, (Crannell et al., 2014; 
Daher et al., 2016) making it applicable to resource-limited settings. 
 
Recombinases are utilised in homologous recombination, playing a key role in DNA 
repair mechanisms. RecA is a well-studied example of a recombinase. Recombinase 
molecules polymerise along the two primers, creating a structure with a second DNA 
binding pocket into which the double stranded template binds. (Renkawitz et al., 2014) 
Table 5.1 Properties of isothermal DNA amplification techniques 
Common isothermal DNA amplification techniques were analysed for their suitability for 
use as point-of-care diagnostic tests. Amplification efficiency, amplification time and 
optimal temperature were considered. The techniques evaluated were RPA 
(recombinase polymerase amplification); LAMP (loop mediated isothermal 
amplification); HDA (helicase dependent amplification); NASBA (nucleic acid sequence 
based amplification); HRCA (hyper-branched rolling circle amplification); PGRCA (primer 
generation rolling circle amplification); ESDA (exponential strand displacement 
amplification); LRCA (linear rolling circle amplification); and LSDA (linear strand 
displacement amplification). 
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The RecA-primer nucleoprotein then searches for regions of homology within the 
double stranded DNA, it is proposed that this occurs by sliding in either direction along 
the filament. Once regions of homology are found, base pairing occurs and one strand 
of the template DNA is displaced, forming the D-loop. The displaced DNA is stabilised 
by single stranded DNA binding protein (SSB). ATP is generated by creatine kinase, 
and hydrolysed by RecA, causing RecA to dissociate from the DNA strand. A strand-
displacing polymerase can then enter and extend the DNA sequence. Parental strands 
separate, and polymerisation continues to the end of the DNA strand. DNA sequences 
are fed back into the system so amplicons are exponentially amplified. (Daher et al., 
2016) A schematic of the process is shown in figure 5.1. 
118 
 
 
 
Figure 5.1 Diagrammatic representation of recombinase polymerase amplification 
A protein mix of recombinase, polymerase and single stranded binding protein (SSB) 
facilitate the amplification of short regions of template DNA using two single stranded 
primers. Adapted from (Tröger et al., 2015). 
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TwistDx offer a number of commercially available variations of the RPA kit which allow 
detection through various means: agarose electrophoresis (basic kit), fluorescence 
(exo and fgp kits), and lateral flow assays (nfo kit). Kits are also available which include 
reverse transcriptase enzymes, to enable detection of RNA. (TwistDx, 2016) 
 
exo probes contain a fluorophore and quencher separated by a THF residue. Once 
DNA amplification is performed, probes can bind to the double stranded amplicon, in 
this form the exo enzyme is able to cleave the THF residue. This decouples the 
fluorophore and quencher. fgp probes contain a quencher and a fluorophore attached 
to the probe via a C-O-C linker. In its double stranded form, the linker can be attacked 
by the fgp enzyme, releasing the fluorophore. In both systems fluorescence is 
observed when released from the quencher and this can be measured in real time. 
 
The TwistDx nfo kit is compatible with lateral flow detection. In this system RPA is 
performed as usual, however one of the primers is labelled with a 5’ biotin. nfo probes 
contain a 5’ FAM protein and a 3’ modification that blocks DNA polymerisation, 
separated by a THF residue. When bound to the double stranded amplicon, nfo 
cleaves the THF residue, removing the polymerisation block and enabling RPA to 
extend this strand. The product from this second RPA reaction is an amplicon with a 
FAM protein attached at one end and a biotin label at the opposing end. Biotin is 
captured on a lateral flow strip, and a gold labelled anti-FAM antibody is used to detect 
the RPA product. This strategy has been employed to detect parasite infections, 
(Cordray and Richards-Kortum, 2015; Nair et al., 2015; Sun et al., 2016) zoonotic 
viruses (Wu et al., 2016; Yang et al., 2017) and bacterial infections. (Krolov et al., 2014) 
The technique can be combined with reverse transcription to detect RNA on lateral 
flow strips. (Yang et al., 2017) 
 
5.1.4 Hybridisation-based detection of RPA amplicon 
Fluorometric measurement of RPA reactions increases the cost of the technique, 
limiting the applications RPA can be utilised in. The nfo probe system incorporates 
RPA into a lateral flow assay, suitable for cheap point-of-care diagnostics. To decrease 
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the cost further, an antibody-free system which detects RPA amplicons via nucleic acid 
hybridisation on lateral flow assays has been devised. (Jauset-Rubio et al., 2016b) 
 
Target-specific primers are designed with 5’ single stranded overhang sequences. To 
ensure the full sequence is not amplified, a three-carbon spacer (C3) modification, 
which blocks polymerisation, is inserted between the primer and overhang regions. 
RPA creates an amplicon with a single stranded tail at either end. The complementary 
DNA sequence to one of the tails acts as the capture probe, which is coated in a line 
on the lateral flow strip. The complementary sequence to the second tail is covalently 
bonded to a gold nanoparticle and acts as the reporter probe. When the RPA product 
flows up the strip it is bound by hybridisation to the capture probe and is linked to signal 
detection by hybridisation to the reporter probe. This is shown diagrammatically in 
figure 5.2. 
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5.2 Recombinase polymerase amplification for the detection of S. agalactiae 
 
In previous studies RPA has been employed for the amplification and detection of 
S. agalactiae from vaginal, anal and blood samples. Fluorescent measurements of 
probes were used to observe amplification reactions. (Daher et al., 2014; Clarke et al., 
2016) There is currently no lateral flow-based RPA test for GBS. The aim of this project 
is to create a S. agalactiae detection system to be read on a lateral flow strip, based 
on the hybridisation of RPA products. 
Figure 5.2 Visualisation of tailed RPA detection 
A: Tailed-primer. The single stranded overhang (red) is separated from the primer sequence 
(blue) by a modification which blocks DNA polymerisation (black). B: Amplicon product. RPA 
extends the DNA (grey) from the primer sequence, creating a double stranded product, 
with 2 single stranded overhang sequences on opposing strands. C: RPA product binding to 
the lateral flow strip. Capture probe (green) is attached to the lateral flow strip. This 
hybridises to its complementary sequence, found in the forward primer overhang in the 
RPA amplicon. A gold nanoparticle (yellow) is conjugated to the reporter probe (orange) 
and this hybridises to its complementary sequence in the reverse primer overhang. Thus 
producing a readable signal. 
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5.2.1 Analysis of primers 
For a DNA amplification based diagnostic test, a primer pair which is found in all 
S. agalactiae strains, and in no other bacteria is required. Sequences of DNA that 
correspond to IDRIS tokens were considered. Although the IDRIS system is based on 
identification of distinctive protein targets, there is an increased chance that the 
corresponding DNA is also distinctive to S. agalactiae strains, in comparison to 
randomly selected sequences. 
 
Prior to the creation of tailed primers, a panel of non-tailed primers was designed, see 
table 5.2. It was previously advised that RPA primers should be 30-35 residues in 
length for optimum efficiency, (TwistDx, 2016) however recently it has been discovered 
that PCR primers, down to 18 nucleotides in length, are also suitable. (TwistDx, 2017) 
Therefore sequences of both lengths were selected for analysis. Primer sequences 
were computationally assessed to predict melting temperatures of folded primer 
structures and the change in Gibbs’ free energy (ΔG) associated with primer self-
dimers and hetero-dimers, and to determine amplicon length. The sequences of all 
currently sequenced S. agalactiae strains were aligned and conservation of primer 
sequences was assessed. The number of bases at which sequence variation occurred 
between strains was reported as DNA mismatches. 
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Name Token DNA 
mismatches 
Amplicon 
length 
Maximum 
Hairpin Tm 
/°C 
Maximum 
Self-dimer 
∆G 
/kcal mol-1 
Maximum 
Hetero-
dimer ∆G 
/kcal mol-1 
A Fwd Yes 0 142 31.2 -5.02 -6.6 
A Rev Yes 0 - 41.6 -7.31 - 
B Fwd Yes 1 191 37.5 -5.02 -6.14 
B Rev No 1 - 30.9 -8.74 - 
C Fwd Yes 1 191 37.3 -4.52 -6.14 
C Rev No 1 - 30.9 -3.14 - 
D Fwd Yes 1 267 32.3 -3.61 -5.47 
D Rev Yes 0 - 28.9 -6.84 - 
E Fwd* Yes 1 185 22.4 -6.34 -6.5 
E Rev* No 0 - 20.2 -3.61 - 
F Fwd* Yes 1 116 32 -6.34 -4.67 
F Rev* Yes 1 - 33.4 -4.85 - 
G Fwd No 1 131 47.6 -6.84 -6.94 
G Rev No 1 - 38.4 -3.55 - 
H Fwd No 0 176 37.3 -3.61 -5.19 
H Rev Yes 1 - 24.6 -5.02 - 
 
The two most promising primer pairs were pair E and F. Primer pair E had the lowest 
hairpin melting temperatures, and also showed favourable predicted ΔG values of 
primer dimerisation. It was proposed that this primer pair would function at low 
temperatures. Primer pair F had the shortest amplicon length and therefore had the 
potential to be amplified in the shortest time. Untailed versions of primer pair E and F 
were empirically evaluated in order to select one primer pair to develop into the tailed-
primer detection system. 
 
Table 5.2 Analysis of primer properties for amplification of GBS DNA 
The table compares the properties of several primer pairs which may affect RPA. Primer pair 
E was selected for its favourable thermal properties, with low hairpin melting temperatures 
and low ∆G values associated with formation of self- and hetero-dimers. Primer pair F was 
selected due to its short amplicon length predicted to enable amplification in a short period 
of time. Both primer pairs are well conserved with either 0 or 1 mismatches between all GBS 
strains currently sequenced. Both primer pairs also have at least 1 primer contained within 
an IDRIS token region, indicating its uniqueness to other bacteria and high specificity. 
Thermal properties were calculated with the following conditions: 0.5 µM oligo, 0 mM Na+, 
14 mM Mg2+, 0.24 mM dNTPs at 25 °C using IDT software. 
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DNA was extracted from Streptococcus agalactiae and a 2583 bp region was amplified 
by PCR. The PCR product was used as the RPA template. Unless specified, DNA from 
S. agalactiae serotype III was utilised, as this is the one of the most prevalent serotypes 
in infectious disease. (Berg et al., 2000; Ippolito et al., 2010; Soares et al., 2013; 
Vinnemeier et al., 2015) RPA was performed using primer pair E, see figure 5.3, and 
primer pair F, see figure 5.4, at various concentrations and for various time points. To 
analyse amplification, agarose electrophoresis was performed and gels were 
visualised through a 600 nm filter. 
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Figure 5.3 RPA of GBS DNA using primer pair E 
A: RPA: 37 °C, 20 minutes, 100 ng – 1pg. B: RPA: 25 °C, 20 minutes, 100 ng – 1pg. C: RPA: 
0-20 minutes, 1 pg. D: 25 °C, 0-20 minutes, 10 pg. No template DNA negative controls 
(NC) and TwistDx positive controls (PC) were used. RPA was performed and samples ran 
on 3% agarose gels. Gels were imaged with a Licor Odyssey Fc. RPA using primer pair E is 
able to amplify 1 pg DNA to a detectable level at 37 °C in 10 minutes, and 10 pg DNA at 
25 °C in 15 minutes.  
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Figure 5.4 RPA of GBS DNA using primer pair F 
A: RPA: 37 °C, 1 fg–2.7 ag, 0, 10 minutes. No template DNA negative control (NC) 10 
minutes, TwistDx positive control (PC) 10 minutes. B: RPA: 25 °C, 100 pg–100 fg, 0, 10, 20 
minutes. No template DNA negative control (NC) 10, 20 minutes, TwistDx positive control 
(PC) 20 minutes. RPA was performed and samples ran on 3% agarose gels. Gels were 
imaged on a Licor Odyssey Fc. RPA using primer pair F is able to amplify 10 ag DNA to a 
detectable level at 37 °C in 10 minutes, and 100 fg DNA in 20 minutes at 25 °C. 
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Using primer pair E, RPA was able to amplify 1 pg DNA to a detectable level at 37 °C 
in 10 minutes, and 10 pg of DNA at 25 °C in 15 minutes. When RPA was performed 
with primer pair E at 37 °C for 20 minutes, a faint band was observed in the no template 
control sample, indicating an amplification product was formed. This is likely to result 
from contamination from neighbouring reactions. False positive results were not 
observed in subsequent agarose gels. Using primer pair F, RPA was able to amplify 
10 ag DNA to a detectable level at 37 °C in 10 minutes, and 100 fg DNA in 20 minutes 
at 25 °C. 10 ag of DNA correlates to 3.8 copies of DNA, therefore the amplification is 
extremely sensitive. The prediction that primer pair E would be best suited to amplifying 
DNA at low temperatures was incorrect. It appears that despite the prediction that F 
primers would exist in hairpin structures at 25 °C, DNA amplification is still possible at 
this temperature. The amplicon size is the dominant feature to determine DNA 
amplification efficiency, even at low temperatures. It is suggested that DNA clean-up 
is performed prior to analysis on agarose gel, as RPA proteins may cause bands to 
appear smeared. (TwistDx, 2016) However as smearing was not observed, DNA 
clean-up was not performed. A further consideration is that a rapid point of care test 
procedure would not allow for DNA purification prior to analysis. The presence of 
proteins may account for the slight difference in observed mobility and the predicted 
mobility determined by the expected molecular weights, 185 bp using primer pair E 
and 116 bp using primer pair F. 
 
Amplification of DNA by primer pair F in 10 serotypes (1A, 1B, 2-9) was analysed at 
37 °C (shown in figure 5.5) and 25 °C (shown in figure 5.6). Consistent DNA 
amplification was achieved in all 10 strains at 37 °C. DNA was amplified in all serotypes 
at 25 °C, however there was a reduction in amplification of DNA extracted from 
serotypes 1A and 5. 
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Figure 5.5 RPA of GBS DNA using primer pair F in 10 serotypes at 37 °C 
A: RPA: 37 °C, 10 minutes, 10 fg template, no template DNA control. B: RPA: 37 °C, 
0 minutes, 10 fg template, TwistDx positive control amplified for 10 minutes. RPA was 
performed, and samples ran on 3% agarose gels. Gels were imaged on a Licor Odyssey Fc. 
RPA using primer pair F is able to amplify 10 fg DNA to a detectable level at 37 °C in 10 
minutes in all serotypes of GBS. 
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Figure 5.6 RPA of GBS DNA using primer pair F in all 10 serotypes at 25 °C 
A: RPA: 25 °C, 20 minutes, 1 pg template, no template DNA control, TwistDx positive 
control. B: RPA: 37 °C, 0 minutes, 1 pg template. RPA was performed, and samples ran on 
3% agarose gels. Gels were imaged on a Licor Odyssey Fc. RPA using primer pair F is able 
to amplify 1 pg DNA to a detectable level at 25 °C in 20 minutes in all serotypes of GBS. 
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5.2.2 Tailed-primer DNA amplification 
Primer pair F was selected for modification into tailed primers. Tail sequences were 
based on previously published sequences. (Jauset-Rubio et al., 2016a) These were 
added to primer pair F sequences and submitted to be computationally analysed for 
hairpin melting temperatures and primer dimer ΔG values. Any interaction which 
crossed the overhang-primer junction was discounted, due to likely disruption from the 
C3 spacer. Overhang sequences were edited to produce more favourable predictions. 
The final primer dimer ΔG values exceed -7 kcal mol-1, and hairpin melting 
temperatures are ≤31 °C. These results are shown in table 5.3. 
 
Name Sequence Maximum 
Hairpin Tm 
/°C 
Self-dimer 
∆G 
/kcal 
mol-1 
Hetero-
dimer ∆G 
/kcal 
mol-1 
Fwd 
(original) 
GTTTTCCCAGTCACGAC-C3- 
ACTACTAGACGCCAAGAAGCTATTGAAGAGG 
37 -6.34 -7.18 
Rev 
(original) 
TGTAAAACGACGGCCAGT-C3- 
TCACCACCTTTAATACTGTGCCCTAACC 
45.5 -9.28 - 
Fwd 
(final) 
GTAATCACAGACATGCC-C3-
ACTACTAGACGCCAAGAAGCTATTGAAGAGG 
31 -6.34 -6.85 
Rev 
(final) 
TGTAAAACGACGACCACT-C3-
TCACCACCTTTAATACTGTGCCCTAACC 
30.3 -4.85 - 
 
RPA performance using tailed primers was analysed through observation of TMB 
turnover by the HRP-conjugated reporter probe. Maleimide coated plates bound 
capture probe via a 3’ thiol group. RPA product was incubated with the plate and 
hybridised with the capture probe via an overhang sequence. HRP-conjugated reporter 
probe was introduced, and this hybridised to the RPA product via the second overhang. 
TMB was added, and HRP caused a colorimetric change to occur in TMB which was 
Table 5.3 Analysis of tailed primer properties. 
IDT software was used to predict the properties of tailed primers which may affect 
RPA. Sequences from primer pair F were combined with tails from previously 
published data. These were analysed for temperatures at which hairpins and self- and 
hetero-dimers form. Tail sequences were edited for more favourable predictions. 
Structures which bridge the C3 spacers were discounted as the conformation would 
disrupt inter/intra-molecular binding. The properties were calculated with the 
following conditions: 0.5 µM oligo, 0 mM Na+, 14 mM Mg2+, 0.24 mM dNTPs at 25 °C. 
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detected on a plate reader at 630 nm. The ELONA readout of the RPA was conducted 
to validate the detection system prior to moving to lateral flow format. 
 
RPA was executed at 37 °C for 10 and 20 minutes. Using a cut off limit of detection 
calculated by the mean of the negative (no DNA template) control plus three times its 
standard deviation, RPA was able to detect 1 pg DNA, corresponding to 380,000 
copies, after 10 minutes of amplification, see figure 5.7. After 20 minutes, the 
amplification efficiency increased 10 fold, with the system able to detect 100 fg (38,000 
copies), see figure 5.8. 
  
Figure 5.7 Concentration curve of RPA performed at 37 °C for 10 minutes 
RPA was performed and samples analysed by TMB turnover, determined using a Tecan 
Infinite 200. RPA hybridisation was carried out and the colorimetric change of TMB was 
measured after 5 minutes of incubation. No template DNA negative controls (NC) were 
used. 1 pg of template DNA, or 380,000 copies, generated a readable signal above the 
limit of detection. The line is fitted with a sigmoidal, Weibull 4 parameter equation in 
SigmaPlot, R2 = 0.9588. 
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When RPA was performed on tailed primers at 25 °C for 20 minutes no relationship 
between template concentration and absorbance was observed, see figure 5.9. Low 
temperatures appear to be unsuitable for amplification of DNA using tailed primers in 
this instance. This may be due to interactions between primers and template DNA 
being sterically hindered by the overhang sequences. 
Figure 5.8 Concentration curve of RPA performed at 37 °C for 20 minutes 
RPA was performed and samples analysed by TMB turnover, determined using a Tecan 
Infinite 200. RPA hybridisation was carried out and the colorimetric change of TMB was 
measured after 5 minutes of incubation. No template DNA negative controls (NC) were 
used. 100 fg of template DNA, or 38,000 copies, generated a readable signal above the 
limit of detection. The line is fitted with a sigmoidal, Weibull 4 parameter equation in 
SigmaPlot, R2 = 0.9598. 
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5.2.3 Strain sensitivity and specificity 
Amplification of DNA using tailed primers was performed on DNA extracted from 
S. agalactiae serotype III in the previously described experiments. To assess whether 
these tailed primers are suitable for a universal group B streptococcal test, DNA 
extracted from representative strains of all 10 serotypes of S. agalactiae was used as 
template material. DNA was also extracted from two strains of S. pyogenes, a related 
bacteria, to be used as negative controls. In previous experiments a short fragment of 
DNA was amplified by PCR for use as template material. In this experiment the 
extracted DNA was purified, but not amplified, and the total DNA content was used for 
recombinase polymerase amplification. This was essential as using short fragments of 
S. pyogenes would not qualify as a sufficient test of specificity as RPA could operate 
on a different region of S. pyogenes DNA. Additionally using the full DNA content 
introduces contaminating DNA, which may hinder the amplification of S. agalactiae 
Figure 5.9 Concentration curve of RPA performed at 25 °C for 20 minutes 
RPA was performed and samples analysed by TMB turnover, determined using a Tecan 
Infinite 200. RPA hybridisation was carried out and the colorimetric change of TMB was 
measured after 5 minutes of incubation. No template DNA negative controls (NC) were 
used. There is no clear correlation between template DNA concentration and observable 
signal. 
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DNA. This is a step closer towards the sample which would be used for a diagnostic 
test. Figure 5.10 shows the discriminative amplification of DNA from S. agalactiae over 
S. pyogenes DNA. As there is no signal observed for S. pyogenes in excess of the no 
template control, it can be inferred that no amplification has taken place. The signals 
obtained from GBS strains (n=10) were statistically different from those obtained for 
GAS strains (n=2) (p=0.0413, as determined by a Mann Whitney U test). 
 
 
 
Figure 5.10 RPA of DNA extracted from bacterial cell cultures 
DNA samples were extracted and purified from bacterial strains, including 10 serotypes of 
S. agalactiae and two strains of S. pyogenes. 3.65 x 105 copies of DNA was used as the 
template material, equivalent to the copy number found in 1 pg of DNA used in the earlier 
experiments. RPA was performed at 37 °C for 20 minutes and samples analysed by TMB 
turnover, determined using a Tecan Infinite 200. RPA hybridisation was carried out and the 
colorimetric change of TMB was measured after 5 minutes of incubation. No template DNA 
negative controls (NC) were used. The signals obtained from DNA extracted from 
S. pyogenes was equivalent to that of the no DNA template control. The signal from all 
strains of S. agalactiae was around twice the values obtained for S. pyogenes. 
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The previous experiment was performed on DNA extracted from bacterial samples 
using a DNA purification kit. To determine whether this is necessary RPA was also 
performed on lysed cell samples. Under these conditions, RPA discriminately amplified 
DNA from S. agalactiae strains and not from S. pyogenes strains, see figure 5.11. This 
indicates that time consuming DNA purification steps are not required, thus increasing 
the suitability to rapid testing. 
 
 
Figure 5.11 RPA directly from lysed cell cultures 
The lysates of two serotypes of S. agalactiae and two strains of S. pyogenes were used as 
RPA template material. RPA was performed and samples analysed by TMB turnover, 
determined using a Tecan Infinite 200. RPA hybridisation was carried out at 37 °C for 20 
minutes and the colorimetric change of TMB was measured after 5 minutes of 
incubation. No template DNA negative controls (NC) were used. The signals obtained 
from DNA extracted from S. pyogenes were equivalent to that of the no DNA template 
control. The signals from both strains of S. agalactiae were substantially higher than the 
values obtained for S. pyogenes. 
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5.3 Conclusions and future work 
 
At 37 °C RPA can amplify 38,000 copies of DNA to produce a positive reading on 
ELONA format in 20 minutes. This rapid amplification is essential for application to 
point of care testing at the point of labour for prevention of maternal to infant 
transmission. Further to this, RPA is able to amplify sequences within an example 
strain from all serotypes of S. agalactiae, which is promising for the detection of all 
clinical strains. In initial specificity tests, RPA shows no cross-reactivity in S. pyogenes. 
Specificity testing will be continued to include assessment of human DNA and DNA 
from bacteria found in rectal and vaginal patient samples. 
 
Future work will focus on the development of the on-plate format into lateral flow 
assays. By attaching a biotin label to the capture probe, the capture line can be formed 
on the lateral flow strip through interaction with streptavidin molecules coated onto the 
membrane. The HRP moiety on the reporter probe will be replaced by a gold particle 
which will be visible when multiple gold particles accumulate on the line. To confirm 
the lateral flow strip is functional, a control line consisting of the DNA sequence found 
in the reporter-side overhang will be added. This will bind to excess reporter probe and 
display a signal on the lateral flow strip. Conversion of the plate-based format into 
lateral flow detection has been achieved in a previous study. (Jauset-Rubio et al., 
2016b) The detection limit of the new system will need to be determined. To lower the 
limit of detection, excess forward primer-overhang may need to be mopped up prior to 
reaching the test line, as it may compete with amplicon binding. This could be achieved 
by hybridisation to a sequence complementary to the primer sequence. 
 
Additional work focusing on reducing sample preparation needs to be carried out. 
Current experiments utilise an hour-long lysis protocol prior to RPA detection, attempts 
to reduce this have not yet been conducted. Future work will also include the testing 
of patient samples spiked with S. agalactiae bacteria, followed by infected patient 
samples. 
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Chapter 6 Peptide aptamer 
 
6.1 Introduction 
 
In the previous work, antibodies were developed for antigen detection, however there 
are a number of other protein binding molecules which could be utilised, including 
peptide aptamers. This chapter investigates the use of a novel peptide aptamer 
scaffold, to be applied to the detection of S. agalactiae. 
 
6.2 Aptamers 
 
Peptide and oligonucleotide aptamers mimic antibody recognition; the short sequences, 
able to hold three-dimensional structures, show affinity to target molecules. Both, 
peptide and nucleic acid aptamers, exhibit some features which are favourable to 
antibodies and may find a role to complement antibodies. As there is no reliance on an 
in vivo immune response, aptamers can be generated against toxic or non-
immunogenic targets. (Menger et al., 2016; Ospina-Villa et al., 2016) Highly stable 
aptamers (Schmidt et al., 2004; Song et al., 2011; Song et al., 2012) and those which 
target molecules under non-physiological conditions (Radom et al., 2013), can be 
selected for. 
 
6.2.1 Peptide aptamers 
Peptide aptamers may be generated as free entities or as constructs incorporated into 
a protein scaffold. Peptide aptamer scaffolds, also known as non-immunoglobulin 
scaffolds or antibody mimetics, act to conformationally restrain aptamers, analogous 
to antibody constant regions providing a structure for the affinity-carrying CDR regions 
to be constrained within. The reported advantages are the presentation of structures 
that would not exist in the free aptamer, increased affinity for the target molecule, 
decreased entropy of binding (Ladner, 1995) and decreased susceptibility to cleavage. 
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(Stadler et al., 2014) Aptamers produced for the inhibition of cyclin dependent kinase 
2 activity are 1000 times more active constrained within E. coli thioredoxin A as 
opposed to as a free peptide, as indicated by half maximal inhibitory concentration 
data. (Cohen et al., 1998) Peptide aptamers offer increased target specificity in 
comparison to oligonucleotides; (McKeague and DeRosa, 2012; Mercier et al., 2017) 
there is the opportunity for any one of 20 amino acids to occupy each position in the 
sequence, as opposed to the four variants oligonucleotides possess. When 
considering that a binding site consists of several contributing monomers, there is 
scope for a large range of specificity. 
 
6.2.2 Nucleic acid aptamers 
Peptide aptamers should not be confused with nucleic acid aptamers. Single stranded 
oligonucleotide aptamers, DNA or RNA-based, possess regions of base pair self-
hybridisation which stabilise the aptamer into a unique conformation; common 
structures include pseudoknots, hairpins, and G-quadruplexes, (Radom et al., 2013) 
see figure 6.1. Nucleic acid aptamers have shown promise in the field of therapeutics, 
(Bunka et al., 2010; Mascini et al., 2012; Radom et al., 2013) being particularly suited 
to in vivo roles as they are unaffected by proteases found in the body. Degradation 
though nuclease activity is a significant problem, however nuclease resistivity can be 
established through the addition of antisense molecules or nucleotide modification. 
(Kusser, 2000) Locked nucleic acids have shown to have an increased half-life in the 
murine blood system. (Schmidt et al., 2004) Oligonucleotide aptamers exhibit high 
thermostability and are able to refold into their original structure following exposure to 
high temperatures; a significant advantage over proteins that often undergo irreversible 
denaturation. (Song et al., 2012) This would be beneficial in ensuring stability in 
diagnostic applications. 
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6.2.3 Designing a scaffold 
6.2.3.1 Peptide aptamer constraint 
When designing a scaffold, the site of aptamer insertion must be selected. Doubly 
constrained peptides, bound at both termini, are termed peptide aptamers, differing 
from singly constrained peptides, (Mascini et al., 2012) which are thought of as affinity 
tags. Aptamers are often inserted into scaffolds at sites utilised for binding activity. 
(Hoppe-Seyler et al., 2004; Woodman et al., 2005) In the native protein, binding sites 
are accessible to the solvent to allow ligand binding. Insertion of peptides into these 
regions ensures accessibility and the opportunity for potential ligands to bind. 
 
Aptamers may be inserted into a single loop, a region of secondary structure, or into 
multiple sites. Thioredoxin A is a scaffold protein to which aptamers are inserted in a 
single loop. This loop is highly constrained by disulphide bonds, enabling a high 
tolerance of peptide insertions, as they impose minimal impact on global protein 
structure. (Nygren and Skerra, 2004) Affibodies are derived from Staphylococcal 
protein A, which binds to the Fc portion of antibodies. Residues found to be involved 
Figure 6.1 Nucleic acid structures 
A: Hairpin structure. Visualised by RNAstructure, using results from Fold. (Reuter and 
Mathews, 2010) B: Pseudoknot structure. Visualised by RNAstructure, using results from 
ProbKnot. (Reuter and Mathews, 2010) C: G-quadruplex structure. Sequence predicted 
to hold a G-quadruplex structure by GRS mapper. (Kikin et al., 2006) 
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in this interaction, located across 2 helices, were selected for randomisation and 
affibodies showing affinity for desired targets were selected. Circular dichroism studies 
showed that protein structure was not disrupted, demonstrating the high stability of 
affibodies. (Nord et al., 1995) Anticalins are scaffolds derived from lipocalins. Four 
loops comprise the entrance to a β-barrel structure, aptamer sequences have been 
inserted into all loops causing significant changes in conformation in the flexible loop 
regions, but not disturbing the rigid secondary structure. (Nygren and Skerra, 2004) 
Affibodies and anticalin- and thioredoxin A- based scaffolds each follow a different 
strategy in selection of aptamer insertion sites, peptides are inserted into regions of 
different secondary structure and as continuous peptides or fragmented across 
multiple locations. In aptamer design an individual approach is likely to be required, 
based on the scaffold sequence and structure. 
 
6.2.3.2 Functional or non-functional scaffolds 
If scaffold structural and functional data is available, the insertion of aptamers may be 
purposefully designed to either retain or disrupt protein function. Typically scaffolds are 
selected for their non-functionality, and are designed to perform inhibitory roles in 
therapeutics (Nagel-Wolfrum et al., 2004) or solely as binding agents in diagnostic 
applications. (Evans et al., 2008; Davis et al., 2009; Ravalli et al., 2015; Ferrigno, 2016)  
 
In previous studies scaffold domains were fused with Fc antibody domains, effectively 
adding an effector function to the neutral scaffold. (Ronnmark et al., 2002) This product 
has implications for therapeutics in host-mediated responses, and also indicates the 
potential for a wide range of functions to be incorporated into recognition molecules. 
(Liu et al., 2017) Functional aptamers can be created through tagging with nuclear 
localisation sequences. (Colas et al., 2000) By transporting mislocated proteins to the 
correct compartment, proteins can become reactivated. Additionally this strategy could 
be utilised to translocate proteins to foreign localisations rendering them functionally 
inert. (Hoppe-Seyler et al., 2004) Ubiquitin ligases have been conjugated to peptide 
aptamers, thus the aptamer’s target becomes ubiquitinated. (Colas et al., 2000) This 
may be used to initiate protein degradation. (Hoppe-Seyler et al., 2004) 
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There are some examples of scaffolds that retain their native activity and utilise this for 
the visualisation of signals from molecule detection. GFP (green fluorescent protein) 
and β-lactamase, often used as reporter molecules for gene expression, have been 
modified into peptide aptamer scaffolds. (Abedi et al., 1998; Legendre et al., 2002; 
Rojas et al., 2004; Wang et al., 2014a) 
 
6.2.4 Aptamer scaffolds as diagnostic tools 
6.2.4.1 Surface adsorption 
Protein adsorption to a surface is often associated with conformational changes. 
(Nakanishi et al., 2001) Hydrophobic residues re-orientate themselves to maximise 
contact with a hydrophobic surface, reducing exposure to the hydrophilic solvent. 
(Hladilkova et al., 2016) Hydrophilic surface adhesion also causes conformational 
changes; a previous study has found α-helical content to reduce upon adsorption of α-
chymotrypsin to a hydrophilic surface. (Zoungrana et al., 1997) Changes in protein 
conformation may inhibit protein function. Stefin A is a cysteine protease inhibitor that 
exhibits high stability upon surface immobilisation. It was modified into an aptamer 
scaffold able to retain affinity for CDK2 (cyclin dependent kinase) upon adsorption to 
glass surfaces. Stefin A shows promise for use in microarrays to assess multiple 
biomarkers simultaneously. (Song et al., 2011) 
 
6.2.4.2 Specificity 
Aptamers have the capability to exhibit high binding partner specificity, essential for 
correct disease diagnosis. An anticalin molecule modified to show affinity for 
digoxigenin was found to possess no reactivity against ouabain which is functionally 
related to digoxigenin. (Schlehuber and Skerra, 2002) Ras is a key molecule in cell 
signalling pathways. There is a two amino acid difference in the sequence of two allelic 
variants, RasV12 and RasA15. Peptide aptamers have been developed which are able 
to differentially bind each variant. (Xu and Luo, 2002) 
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6.2.4.3 Compatible with label-free detection techniques 
For ease of implementation, an ideal aptamer would be compatible with the range of 
detection techniques currently used in diagnostic laboratories. Observation of antibody 
binding is often achieved through labelling, typically with fluorescence, radioactivity or 
enzymatic activity. (Hempen and Karst, 2006) Labelling imposes the risk of altering the 
conformation of the antibody, potentially reducing or eliminating its affinity for the 
desired epitope. An example of label-free detection systems is the use of reporter 
proteins as scaffolds. GFP has been investigated as an aptamer scaffold. 
Complementarity determining regions from antibodies recognising several toxins were 
inserted into the scaffold, each retained its affinity for its specific epitope. (Wang et al., 
2014a) Similarly, the use of β-lactamase as an aptamer scaffold has been investigated. 
A signal is obtained through studying the rate of breakdown of penicillin G and 
nitrocefin spectroscopically. Upon epitope binding, hydrolytic activity of the scaffold 
increases in respect to penicillin G, and decreases with respect to nitrocefin. (Legendre 
et al., 2002) 
 
6.2.4.4 The need for additional antigen detection molecules in diagnostics 
It is predicted that with the rise of personalised medicine the demand for aptamers will 
increase. The detection of biomarkers to aid prediction of a patient’s response to 
available treatments in addition to detection of disease-specific biomarkers will require 
the development of many novel detection molecules. Further to the previously 
discussed advantages aptamers offer over antibodies, such as suitability for use on 
surfaces and in label-free detection systems, low production costs are critical; 
aptamers provide this through high efficiency production and lack of animal 
involvement. (Song et al., 2011) In many diagnostic techniques two recognition 
molecules are required, one as a capture molecule and the other as a means of 
detection. Antibodies or aptamers could be used in either, or both of these roles. 
 
6.2.5 Production and screening of a peptide aptamer library 
There are several methods of achieving binding affinity. Aptamers can be created by 
the direct insertion of an amino acid sequence from one binding molecule to another. 
Complementarity determining regions of antibodies introduced to a superfolded GFP 
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variant provided the scaffold with a similar binding affinity as the native antibody. 
(Wang et al., 2014a) As there is no requirement for the generation of an aptamer library, 
molecular recognition tools are produced rapidly. This method of generation, however, 
does not enable novel epitopes to be targeted. Structures computationally predicted to 
bind the desired epitope may be designed. A research group produced proteins that 
exhibit 130 nM affinity for their binding partners, using directed evolution the affinity 
was increased to 180 pM. (Karanicolas et al., 2011) Site-directed mutagenesis can be 
used to rationally mutate binding sites; prior knowledge of the interaction is required. 
Alternatively, representative residues of several amino acid types (e.g. polar, 
negatively charged, and positively charged) may be inserted to each position of a 
sequence for an efficient method to scan for binding affinity. (Banta et al., 2013) Often 
a broad spectrum of aptamers is created with no sequence bias. Libraries of peptide 
aptamer scaffolds only contain variations in a small number of residues, but can 
comprise of 1015 molecules. (Banta et al., 2013) An aptamer should be large enough 
to include all amino acids that participate in binding the epitope, so the optimal 
arrangement can be selected. Aptamer length is limited by the likelihood that the 
insertion causes global protein misfolding of the scaffold and the feasibility of 
generating a library with sufficient coverage. (Nygren and Skerra, 2004) Affinity 
maturation is used to select for, refine and optimise binding affinity. (Banta et al., 2013) 
This process is similar to SELEX, (systematic evolution of ligands by exponential 
enrichment) which is employed for nucleic acid aptamers. (Ellington and Szostak, 1990; 
Tuerk and Gold, 1990) Positive discrimination of aptamers exhibiting target binding is 
used to select candidate aptamers. Multiple rounds of the process are carried out under 
differing conditions, enabling the production of a high affinity aptamer able to operate 
in a wide range of environments and functions, (Radom et al., 2013) see figure 6.2. 
Peptide aptamer library selection requires a technique that links the phenotype to its 
genetic material, phage display is often used. (Nygren and Skerra, 2004; Banta et al., 
2013) 
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In the context of designing an aptamer for use in GBS diagnostics, the complementary 
determining region of antibodies produced in the previous work could be inserted into 
a protein scaffold, or a novel peptide aptamer sequence could be selected for. 
 
Figure 6.2 Selection of peptide aptamers exhibiting target affinity 
Multiple rounds of peptide selection are performed under differing conditions to ensure 
aptamers are selected that show robust specificity for the desired target. Negative 
selection reduces non-specificity. Information from (Aghebati-Maleki et al., 2016) 
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6.3 Design of a reporter-based peptide aptamer 
 
6.3.1 Selection of reporter scaffold 
Several proteins were considered for the creation of a novel reporter scaffold including 
β-galactosidase proteins, HRP, alkaline phosphatase and luciferase proteins. 
β-galactosidases are enzymes able to hydrolyse the colorimetric substrate X-Gal 
resulting in a reporter signal. Penicillium ß-galactosidase is a large 120 kDa protein 
consisting of five domains, which, as a whole molecule, is too large for aptamer 
creation due to stability concerns. It is possible that the use of one domain as a scaffold 
may be achievable, however the active site is formed from regions within two domains 
(Rojas et al., 2004) and therefore a single domain would be non-functional. Alkaline 
phosphatase and HRP are two commonly utilised reporter proteins. However due to 
their large size, possession of disulphide bonds, (Coleman, 1992) and HRP being 
glycosylated, (Veitch, 2004) these molecules were not pursued as scaffolds, as simple 
bacterial production could not be exploited. Bioluminescent proteins were also 
considered. As background signal levels are zero, bioluminescence presents an 
advantage over fluorescent peptide aptamer scaffolds, such as GFP. Luciferases are 
bioluminescent proteins containing no post-translational modifications, however they 
do contain a high ratio of cysteine residues and therefore typically require low efficiency 
periplasmic expression to be produced. (Loening et al., 2006) 
 
6.3.2 Aequorin 
Aequorin, another bioluminescent protein, is relatively small compared to other 
reporter enzymes. According to previous literature, aequorin can be produced in in the 
cytoplasm of E. coli (Courchesne and Ozturk, 2003) and therefore it was selected to 
be assessed for aptamer creation. One limitation may be that it has a slow regeneration 
process so does not produce signal amplification like most enzyme systems. As 
aequorin has rapid activity, with signal production lasting for less than 10 seconds 
(Lewis et al., 2000), molecular detection and therefore diagnoses may be achieved 
within a very short time scale. Due to extremely low background signals, 
concentrations of 100 pM of aequorin have been utilised in in vitro assay development 
to produce high signal to noise ratios. (Deo et al., 2001) 
146 
 
 
Aequorin is a 21.7 kDa calcium-activated photoprotein that, in association with 
coelenterazine and oxygen, undergoes a conformational change causing light 
emission at a wavelength of 470 nm. Transfection into bacterial and mammalian cells 
has assisted the study of calcium cell signalling in living cells. (Jones et al., 2002; 
Bonora et al., 2013) Aequorin exhibits reasonable heat stability when in the presence 
of Ca2+, following incubation at 45 °C no structural changes are observed. (Inouye, 
2004)  
 
Aequorin is formed from four EF-hand domains, each consisting of a helix-loop-helix 
structure. Three of these domains contain Ca2+ binding sites; two binding events are 
required for full activity. Upon calcium binding EF-hand helices re-orientate themselves 
with respect to each other. (Head et al., 2000) Coelenterazine is oxidised and becomes 
unstable; carbon dioxide is released and an excited coelenteramide anion is formed. 
Light is released when this species returns to its ground state, (Jones et al., 1999) for 
a schematic of the reaction see figure 6.3. 
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Figure 6.3 Mechanism of aequorin light emission and regeneration 
Ca2+ binding triggers a conformational change within aequorin which causes 
coelenterazine to become oxidised. Carbon dioxide is released and the unstable 
coelenteramide ion is formed. Light is released when the cofactor relaxes to its ground 
state. The aequorin molecule is regenerated to its original form to enable the process to 
repeat. The regeneration process is much slower, taking several hours (Shimomura et al., 
1993) in comparison to calcium-induced light emission which takes around 10 seconds. 
(Lewis et al., 2000) Details on mechanism from (Jones et al., 1999), produced using 
(MolView, 2015). 
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6.4 Sequence design of peptide aptamer scaffold 
 
6.4.1 Site of aptamer insertion 
A short amino acid sequence, a FLAG tag (DYKDDDK), was inserted into the aequorin 
structure. The FLAG tag was designed in the 1980s to aid in protein identification and 
purification through antibody affinity. (Hopp et al., 1988) Insertion of the FLAG tag 
mimics a peptide aptamer, to assess whether molecular recognition could occur whilst 
the molecule retained functional activity. Binding of the protein to an anti-FLAG tag 
antibody would determine that the tag is exposed, essential to enable aptamer-epitope 
binding events to occur in future variants of the scaffold. 
 
Regions were analysed using structural and functional information to decide which 
would be most suitable for aptamer insertion, see table 6.1. To minimise the likelihood 
of structure and function disruption, the sequence was inserted into a loop rather than 
a sequence of secondary structure. Previous studies have mutated glycine residues 
involved in calcium binding to determine which sites are important for light emission. 
Loops within EF-hands 1 and 3 were found to be of significance, glycine mutation within 
EF-hand 4 did not affect bioluminescence. (Tsuji et al., 1986) Coelenterazine binding 
is co-ordinated by three tyrosine-histidine-tryptophan triads, which line the cofactor 
binding cavity. When several of these residues are mutated, protein activity is greatly 
reduced. (Head et al., 2000) As retaining bioluminescent function is essential for the 
intended reporting application, regions involved in cofactor and metal binding were 
avoided. 
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Region Structure 
type 
Domain Considerations for peptide insertion 
A Loop N-terminus Aptamer would not be doubly constrained. 
B Helix EF-hand 1 His16 is likely to interact with coelenterazine; light emission is 
dependent on the helix moving relative to the C-terminal loop, 
through disruption of the hydrogen bonding network; domain 
is involved in Ca2+ binding. 
C Loop EF-hand 1 Mutation of central glycine, which prevents Ca2+ binding, 
eliminates bioluminescence.* 
D Helix EF-hand 1 Domain is involved in Ca2+ binding. 
E Loop Loop Previous studies have inserted sequences here.** 
F Helix EF-hand 2 Helix forms coelenterazine binding cavity; His58 is involved in 
coelenterazine binding. 
G Loop EF-hand 2 None. 
H Helix EF-hand 2 Helix forms coelenterazine binding cavity; Tyr82 and Trp86 are 
involved in coelenterazine binding. 
I Loop Loop Loop brings regions H and J together, forming the 
coelenterazine binding cavity. 
J Helix EF-hand 3 Trp108 mutants result in reduced bioluminescence, likely due 
to loss of interaction with coelenterazine; domain involved in 
Ca2+ binding. 
K Loop EF-hand 3 Mutation of central glycine, which prevents Ca2+ binding, 
reduces bioluminescence.* 
L Helix EF-hand 3 Tyr132 is predicted to interact with coelenterazine and is 
involved in hydrogen bonding network; domain involved in Ca2+ 
binding. 
M Loop Loop Close proximity to C-terminus, conformational change of the C-
terminus is essential for light emission. 
N Helix EF-hand 4 Light emission is dependent on the helix moving relative to the 
C-terminal loop, through disruption of the hydrogen bonding 
network; domain involved in non-essential Ca2+ binding. 
O Loop EF-hand 4 Contains calcium binding glycine residue, calcium binding at 
this site is not essential for bioluminescence.* 
P Helix EF-hand 4 Light emission is dependent on the helix moving relative to the 
C-terminal loop through disruption of the hydrogen bonding 
network; proposed His169:coelenterazine hydrogen bond; 
domain involved in non-essential Ca2+ binding. 
Q Loop C-terminus Aptamer would not be doubly constrained; proposed 
Tyr184:coelenterazine hydrogen bond; C-terminal proline is 
reported to be essential for function*** 
 
 
 
 
 
Table 6.1 Analysis of sites in aequorin in which to insert a peptide aptamer. 
The peptide sequence of aequorin has been divided into regions based on the structure 
determined by X-ray crystallography produced by (Head et al., 2000), PDB code 1EJ3. The 
likelihood of disruption to protein structure and function following peptide insertion into 
each of these regions was analysed. Sites which are predicted to be involved with, or in 
close proximity to, essential binding activity were avoided. Information from: *(Tsuji et 
al., 1986); ** (Hamorsky et al., 2008); *** (Ellington and Szostak, 1990; Nomura et al., 
1991). Unless specified, data was obtained from (Head et al., 2000). 
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Regions E and G present no structural evidence to indicate that they would be 
unsuitable for the insertion of an amino acid sequence. BLAST searches were 
performed to assess sequence conservation of these regions between species 
(Altschul et al., 1990); if activity is retained whilst sequences are not conserved, this 
may indicate that sequences are not essential and may be suitable for aptamer 
insertion. However, both regions are highly conserved within aequorin molecules, and 
region E remains highly conserved within similar proteins obelin, clytin and mitrocomin. 
 
Previous studies have shown region E tolerates the insertion of peptides and maintains 
function; therefore this region was selected, see figure 6.4 for a model of the aequorin 
structure and site of sequence insertion. Glucose binding protein, a 32 kDa protein, 
has been inserted into aequorin at region E, splitting aequorin into two fragments to 
create a glucose sensor. The binding of glucose initiates a conformational change re-
forming the active site of aequorin, and enabling the bioluminescent reaction to occur. 
(Hamorsky et al., 2008) It was predicted that if this site can withstand this degree of 
perturbation, a wide variety of peptides could be inserted with bioluminescent function 
preserved. 
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6.4.2 Sequence optimisation 
All three cysteine residues were mutated to serine as this variant has shown increased 
bioluminescent activity in previous studies. ((Kurose et al., 1989; Lewis et al., 2000) 
Cysteine removal has also been found to improve protein stability as dimerisation is 
prevented. (Shrestha et al., 2002) Aequorin requires regeneration by replacing 
coelenteramide with coelenterazine, to enable future calcium-induced light emission. 
Cysteine bonds are predicted to be involved with this process as the regeneration time 
of cysteine mutants is much longer than that of the wild-type protein. (Kurose et al., 
1989) As regeneration of aequorin is a slow process, with 50% of aequorin re-
Figure 6.4 Structure of aequorin  
The three-dimensional structure of aequorin was obtained by X-ray crystallography, 
the structure is coloured by secondary structure (alpha helices red, β-sheets yellow, 
and unstructured loops green. The loop into which the FLAG tag was inserted into is 
shown in blue. PDB code 1EJ3 (Head et al., 2000) rendered in PyMOL. (Schrodinger, 
2015) 
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established in two hours, (Shimomura et al., 1993) it is not consequential in rapid 
diagnostics. The lack of disulphide bonds enable production in the cytoplasm, therefore 
no signal sequence was designed into the construct. A polyhistidine tag was added to 
the protein to enable purification via nickel affinity. It has been reported that a C-
terminal proline residue is essential for bioluminescence. (Nomura et al., 1991) A more 
recent study has found that sequence insertion to the C-terminus does not disrupt 
activity, (Deo et al., 2001) however due to conflicting data the C-terminus was avoided 
and an N-terminal histidine tag was inserted. 
 
Two DNA sequences were designed, one pseudo wild-type variant (Aequorin WT*) 
and one variant of aequorin containing the FLAG-tag sequence insertion (Aequorin 
FLAG). Codon usage was optimised for synthesis in E. coli using GeneOptimizer® 
software (GeneArt, Life Technologies), to maximise chances of high efficiency 
production. Figure 6.5 shows the construct plasmid map, and DNA and protein 
sequences. 
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Figure 6.5 Recombinant aequorin (WT* and FLAG) construct DNA and protein sequence. 
A: Plasmid map of the gene construct, produced in SnapGene Viewer. (GLS Biotech) NcoI 
and HindIII restriction enzymes were used to insert the construct DNA into pBAD HisA. B: 
Construct DNA sequence encoding for the two variants of recombinant aequorin. The 
pseudowildtype construct does not include the nucleic acids encoding for the FLAG tag 
(red). Restriction sites are shown in green. Codons were optimised for production in 
E. coli. C: Protein sequence for the two variants of recombinant aequorin. An N-terminal 
polyhistidine tag has been added (orange), and three cysteine residues have been 
mutated to serine residues (blue). The pseudowildtype variant does not include the FLAG 
tag (red). 
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6.5 Induction of aequorin WT* 
 
The plasmid constructs were inserted into the vector pBADHisA through use of 
restriction enzymes NcoI and HindIII. pBADHisA, containing an arabinose inducible 
operon, was selected as it has previously been used in successful aequorin production. 
(Rowe et al., 2010) pBADHisA-Aeq-WT* and pBADHisA-Aeq-FLAG were transformed 
into E. coli BL21 pLysS DE3 and E. coli LMG194 cells. BL21 is an expression strain 
often used for induction of the T7 promoter, it is not typically selected for arabinose-
based induction as it does not contain an araBAD deletion. The expression strain 
LMG194 lacks the araBAD operon, and is therefore unable to breakdown arabinose. 
This plasmid enables tight control of protein expression via arabinose. Protein 
expression in both strains was analysed. 
 
5 ml growth tests were cultured under various induction conditions to assess the 
optimal parameters (cell type, growth temperature, induction concentration, induction 
time, and lysis protocol) for aequorin expression. Cultures were grown at a single 
temperature between 37 °C and 20 °C to an OD 600 nm of 0.5, where aequorin 
expression was induced by the addition of L-arabinose at 0.2% and 0.02%. Cells were 
induced for between one and 20 hours, and harvested. Three lysis protocols were 
investigated: lysis by Bugbuster, sonication in solution containing 500 mM NaCl and 
sonication in solution containing 150 mM NaCl, see figure 6.6. 
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Figure 6.6 Induction and solubility test for Aequorin WT*: comparison of lysis protocols 
A: lysed by Bugbuster. B: lysed by sonication in 20 mM sodium phosphate 500 mM NaCl. 
C: lysed by sonication in 20 mM sodium phosphate 150 mM NaCl. E. coli cells were grown 
to an OD 600 nm of 0.5 and induced with arabinose for 3 hours at 37 °C. Cells were lysed 
and centrifuged to separate soluble proteins (supernatant) from insoluble proteins 
(pellet). These were analysed by SDS-PAGE and visualised by Coomassie staining. The red 
band highlights putative aequorin protein. 
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Samples were centrifuged to separate soluble and insoluble proteins. Soluble proteins 
are likely to be in a folded state, whereas unfolded proteins are likely to aggregate, 
forming inclusion bodies, and therefore will be non-functional. (Palmer and Wingfield, 
2004) The process of re-folding proteins adds complexity, and therefore does not lend 
itself to high efficiency production on a large scale. Additionally, proteins may not re-
fold into the correct conformation. Through studying protein production from induction 
at 37 °C for three hours, the optimal lysis protocol was determined to be chemical lysis 
by Bugbuster. This resulted in the most protein found in the soluble fraction. 
 
The previous induction at 37 °C for three hours was compared to that performed for 
one hour. A lower amount of total and soluble aequorin protein was expressed at one 
hour, see figure 6.7. 
 
 
 
Figure 6.7 Induction and solubility test for Aequorin WT*: comparison of time points 
E. coli cells were grown to an OD 600 nm of 0.5 and induced with arabinose at 37 °C for one 
hour, followed by lysis by Bugbuster. Cells were lysed and centrifuged to separate soluble 
proteins (supernatant) from insoluble proteins (pellet). These were analysed by SDS-
PAGE and visualised by Coomassie staining. The red band highlights putative aequorin 
protein. 
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In order to evaluate the effect of induction temperature, the previous results were 
compared to induction at 20 °C for 20 hours. Very little aequorin protein was expressed 
when incubated at the lower temperature, see figure 6.8. 
 
 
The presence of 22.6 kDa bands reflected expression of aequorin WT*. Aequorin WT* 
produced by BL21 cells cultured at 37 °C, induced for three hours at a concentration 
of 0.2% arabinose and lysed by Bugbuster, exhibited highest band density determined 
by SDS-PAGE analysis. Under the previously described conditions, around 40% of 
aequorin WT* was soluble. Although not optimal, it was preferable to purify the smaller 
amount of soluble aequorin WT*, than attempt to recover the larger proportion of 
insoluble protein for use in purification steps. 
Figure 6.8 Induction and solubility test for Aequorin WT*: comparison of induction 
temperatures 
E. coli cells were grown to an OD 600 nm of 0.5 and induced with arabinose at 20 °C for 20 
hours, followed by lysis by Bugbuster. Cells were lysed and centrifuged to separate soluble 
proteins (supernatant) from insoluble proteins (pellet). These were analysed by SDS-PAGE 
and visualised by Coomassie staining. The red band highlights putative aequorin protein. 
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To confirm that the induced protein observed is recombinant aequorin, western blotting 
was performed using an anti-histidine tag antibody see figure 6.9. A polyhistidine-
tagged protein was detected, which showed inducible behaviour under arabinose 
addition and corresponded to the correct predicted molecular weight. Thus supporting 
the conclusion that recombinant aequorin was expressed. 
 
6.6 Purification of aequorin WT* 
 
Proteins were expressed at the previously described conditions, cell debris and 
insoluble protein were removed by centrifugation following cell lysis and protein was 
purified by nickel chromatography. Soluble protein was added to a nickel column, 
which captured the protein via its polyhistidine tag. Nickel chromatography removed a 
number of contaminating proteins, however the eluate was an impure sample. The 
protein sample was further purified by ion exchange chromatography using a positively 
charged DEAE column. Aequorin WT* has an isoelectric point of 5.20, as predicted by 
ExPASy software. (Gasteiger et al., 2005) In a buffer with a pH higher than 5.20 the 
Figure 6.9 Confirmation induced protein is aequorin. 
To confirm the induced protein observed is aequorin WT*, SDS-PAGE gels were analysed 
by western blotting. An anti-histidine tag antibody was utilised for protein detection. 
BL21 cells were transformed to express aequorin WT* were cultured at 37 °C, and 
induced for three hours. Cells were lysed by Bugbuster and centrifuged to separate 
soluble (supernatant) and insoluble (pelleted) protein. An arabinose inducible histidine 
tag-containing protein was detected at the predicted molecular weight. 
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protein will have a negative charge, and be able to bind to the positively charged DEAE 
matrix. Nickel affinity chromatography followed by ion exchange chromatography 
increased sample purity to between 95-100%, as shown in figure 6.10. 
 
 
 
Figure 6.10 Purification of Aequorin WT* 
A: BL21 aequorin WT* cells were grown at 37 °C to an OD 600 nm of 0.5 and induced with 
0.2% arabinose for three hours. Cells were lysed with Bugbuster and purified on a nickel 
column. B: Protein was then loaded onto a DEAE column and purified by ion exchange. 
Figures are Coomassie stained SDS-PAGE gels. 
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6.7 Induction of aequorin FLAG 
 
Induction tests were performed for aequorin FLAG, varying the same parameters as 
for aequorin WT*, see figure 6.11. Aequorin FLAG expression is shown by a band at 
23.6 kDa. There is little aequorin protein expressed in the insoluble fraction under any 
condition examined and no detectable soluble protein produced. Purification was not 
attempted due to lack of protein expression. 
 
 
Figure 6.11 Induction and solubility test for Aequorin FLAG 
A: 37 °C, 3 hours. B: 30 °C 3 hours. C: 30 °C, 4 hours. D: 25 °C, 20 hours. E. coli cells were 
grown to an OD 600 nm of 0.5 and induced with arabinose under the stated conditions. 
Cells were lysed and centrifuged to separate soluble proteins (supernatant) from 
insoluble proteins (pellet). These were analysed by SDS-PAGE and visualised by 
Coomassie staining. No conditions studied produced soluble aequorin FLAG in significant 
amounts. 
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Although aequorin WT* is able to be produced and purified, there is a large decrease 
in the amount of protein expressed when the FLAG tag insert is added. As culture 
growth was not impeded by protein induction, as shown by growth curves, see figure 
6.12, it is unlikely that aequorin FLAG caused cell toxicity. The reduction in protein 
expression and solubility when the FLAG tag was inserted may be due to instability of 
the global protein structure, and possible degradation within the cell. 
 
 
 
Figure 6.12 Growth curve of cells expressing aequorin FLAG 
The growth of cells is unaffected by aequorin FLAG induction, as the growth curve is 
equivalent in cells with a high concentration of inducer (0.2% arabinose) and non-
induced cells. This indicates that the protein is non-toxic. 
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6.8 Conclusion 
 
It may be possible to select an insertion site which does not affect expression or 
solubility levels to as great an extent. However, as only 40% of the pseudo-native state 
protein is in its folded form, the protein may not be stable enough to withstand 
perturbations without significant restructuring. This does not lend itself to the creation 
of a platform library, which would require a large number of variants to be produced, 
and large scale production once a successful aptamer has been selected. For this 
reason research into developing aequorin into an aptamer scaffold was discontinued. 
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Chapter 7 Discussion 
 
7.1 Recent research in GBS diagnostics 
 
The gold-standard method for S. agalactiae detection, microbial culture, takes several 
days to provide results, whilst PCR can be prohibitively expensive. Strategies to 
improve diagnosis of group B streptococcus colonisation include optimising PCR, 
developing tests based on isothermal DNA amplification, improving sample 
preparation steps and collecting antibiotic susceptibility data. This section focuses on 
research published since 2014. 
 
7.1.1 Optimisation of PCR 
With the aim of optimising PCR sensitivity and specificity, studies have evaluated the 
effect of targeting alternative DNA sequences within S. agalactiae. PCR targeting the 
scpB gene was found to be more clinically sensitive than amplification of cfb. (Fouad 
et al., 2016) Whilst in another study sensitivity was found to be highest when amplifying 
16S rRNA in comparison with targets cfb, atr and scpB. (Mousavi et al., 2016) Recently 
a CAMP factor negative clinical isolate unable to be detected by GeneXpert was 
reported. (Savini et al., 2016) This highlights the importance of finding a universal 
target and shows the potential of IDRIS. 
 
7.1.2 Other methods of detection 
As previously discussed, isothermal DNA amplification offers advantages over PCR, 
such as reduced costs and often quicker completion times. A LAMP-based diagnostic 
test was found to be 10-100 times more sensitive than PCR and able to detect samples 
containing 10 cfu per ml, with 100% specificity. This was achieved after 40 minutes. 
(Yang et al., 2016) A further LAMP-based diagnostic test produced results after 60 
minutes of amplification. (Seok et al., 2017)) These times are consistent with 
intrapartum testing. 
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An RPA-based test which amplifies the gene encoding for CAMP factor was able to 
elicit a positive result from as few as 12 genome copies in 10-15 minutes. (Clarke et 
al., 2016) Another RPA test, directed against the same target, had a sensitivity of 96% 
and specificity of 100% with respect to RT-PCR. Results were complete within 20 
minutes, with positive results available after eight minutes (Daher et al., 2014) and 
therefore both are also suited to intrapartum testing. The tests utilise the TwistAmp exo 
system, and therefore require a fluorescent reader to interpret results. 
 
Another technique being evaluated for use in GBS diagnostics is mass spectrometry. 
Samples were cultured for 18-24 hours in selective broth before analysis, producing a 
quicker result in comparison to microbial culture but not enabling point-of-care testing. 
(Abrok et al., 2015) 
 
7.1.3 Alternative detection strategies 
LAMP-based amplification of S. agalactiae DNA has been performed on paper. 
Sample solutions travelled along wax printed fluidic channels to the reaction pad, which 
contained dry reagents. Using dry reagents ensures high stability in a wide range of 
conditions. During LAMP, pyrophosphate ions are produced, which bind magnesium 
and cause hydroxynapthol blue fluorescence to decrease. This reduction in 
fluorescence was the observable signal. (Seok et al., 2017) Paper-based amplification 
and detection decreases the complexity of the test, however the system requires a 
fluorescent reader. A LAMP-based S. agalactiae test which is able to be read visually 
was designed. In positive tests the solution changes colour from orange to green. This 
eliminates the need for fluorescence readers. (Yang et al., 2016) 
 
7.1.4 Sample preparation 
Efficiently obtaining DNA from bacterial samples can be used to lower the limit of 
detection of subsequent NAAT-based diagnostic tests without requiring a time 
consuming enrichment step. Including a mechanical bacterial cell lysis process prior to 
DNA extraction increased DNA yield 50-fold. (Burke et al., 2016) 
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7.1.5 Antibiotic susceptibility 
Whilst there have been no cases of penicillin resistance in the UK, resistance to 
clindamycin and erythromycin is increasing. (Lamagni et al., 2013) An ELISA was 
developed to simultaneously detect S. agalactiae presence and antibiotic susceptibility. 
Samples were incubated with antibiotics for up to nine hours prior to evaluation on an 
ELISA format. (Faro et al., 2016) This may be useful in cases of maternal penicillin 
allergy. 
 
7.1.6 Identification of multiple pathogens 
There are several pathogens which may cause an infant to present with suspected 
meningitis. In 2015 FDA approval was granted for the PCR-based Biofire Filmarray 
Meningitis/Encephalitis Panel, which analyses cerebrospinal fluid for the presence of 
14 pathogens, including S. agalactiae. (Arora et al., 2017) Incorporating GBS detection 
into a screening panel allows efficient identification of the causative agent to best 
inform treatment. 
 
7.1.7 Comparison to current work 
The two diagnostic tests in development in this project aim to provide rapid feedback 
to inform clinical decisions during labour. RPA- and LAMP-based tests developed in 
recent literature also exhibit short time frames (Daher et al., 2014; Clarke et al., 2016; 
Yang et al., 2016; Seok et al., 2017) consistent with this objective. The proposed 
antibody- and hybridisation-based lateral flow assays are visualised optically, 
presenting an advantage over fluorescence-based detection which requires a 
fluorescence reader for interpretation. Optical detection in solution has been achieved 
in LAMP-based S. agalactiae detection. (Yang et al., 2016) A process of optimising 
sample preparation may prove beneficial to improving test sensitivity. Alternative 
methods of improving GBS diagnostics which aim to provide extra information such as 
antibiotic susceptibility or presence of additional pathogens were not pursued within 
this project. 
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7.2 IDRIS as a useful tool 
 
IDRIS provides a significant advancement in the selection of bacterial group-distinctive 
peptides. The programme allows peptide selection, or shortlisting, with no prior 
knowledge of the protein. In this work the peptides utilised for antibody production, 
reside in a largely unstudied protein. Bioinformatic analysis performed by IDRIS was 
evaluated empirically. RT-PCR experiments showed the universal transcription of the 
selected protein across all serotypes and ELISA results showed expression of a 
selected peptide (peptide B) in all serotypes of the species of interest and no 
expression in a closely related species. In summary, data collected so far supports the 
use of this peptide as a target for GBS diagnostics. Without IDRIS to highlight the ability 
of the peptide to act as a biomarker for all S. agalactiae strains, it would not have been 
selected. 
 
IDRIS may also be useful in the search for GBS vaccine targets. Protein-based 
vaccines do not share the same serotype-specific limitations that capsular 
polysaccharide vaccines have, and may be preferential for vaccine development. 
(Nuccitelli et al., 2015) IDRIS is able to identify peptides found in all sequenced bacteria 
in a group of interest and identify those likely to be exposed on the cell surface, two 
key features for vaccine targets. 
 
7.3 ASSURED Diagnostics 
 
The term ASSURED, coined by the World Health Organisation, describes 
characteristics diagnostic tests should meet. Tests should be affordable, sensitive, 
specific, user friendly, robust and rapid, equipment-free and deliverable to those who 
need them. (Mabey et al., 2004) Levels of acceptable characteristics will be dictated 
by the intended use. The detection tools produced in this study are evaluated using 
these criteria. 
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7.3.1 Antibody for application to GBS diagnostics 
Future work will involve developing the ELISA assay into a lateral flow format following 
the production of a successful antibody against a second target on the protein. Lateral 
flow assays provide equipment-free and user friendly readouts, and are able to be 
deployed at the point of care. These diagnostic tests are low cost to manufacture and 
often do not require refrigerated storage, and are therefore relatively robust. Lateral 
flow assays provide rapid results within 5-30 minutes, (Koczula and Gallotta, 2016) 
which would enable point of care testing at the onset of labour. Intrapartum testing 
could be used in a universal screening programme or for testing individuals with 
appropriate clinical presentations. Public Health England has stated that rapid testing 
would be of particular use in cases of preterm births and premature membrane rupture. 
(Public Health England, 2015a) 
 
Initial results assessing bacterial sensitivity and specificity are promising, suggesting 
that the antibodies produced detect all S. agalactiae strains and no S. pyogenes strains. 
Additional work will include evaluating a panel of bacteria commonly found in rectal 
and vaginal swabs for cross reactivity. Testing patient samples will determine clinical 
sensitivity and specificity values. In lateral flow assays, gold conjugated detection 
molecules are typically used as reporter signals. As optical immunoassays previously 
developed for the detection of S. agalactiae have struggled with clinical sample 
sensitivity, (Baker, 1996; Daniels et al., 2009) ultrasensitive state of the art 
nanoparticles, could be used in replacement of gold particles.  (Bruno, 2014; Howes 
et al., 2014; Hu et al., 2017) 
 
7.3.2 RPA for application to GBS diagnostics 
RPA applied to a lateral flow format has many of the advantages previously described 
for antigen detection in lateral flow assays, such as ease of use and applicability to a 
point of care setting. In comparison to Cepheid’s GeneXpert GBS, the equipment 
demands are reduced, as amplification can be carried out at a constant temperature 
rather than requiring an expensive thermocycler. Individual Xpert GBS tests cost 
£38.80, (Jones et al., 2015) whereas RPA coupled to read-out on a lateral flow assay 
via hybridisation costs €1.15 per assay. This is also cheaper than antibody-based 
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detection of DNA (Jauset-Rubio et al., 2016b) and traditional screening, which is 
estimated to cost $4.76. (El Helali et al., 2012) 
 
In this work DNA amplification was performed for 20 minutes, and it is reported that 
colour visualisation, resulting from DNA hybridisation onto lateral flow strips, occurs 
within 30 seconds of sample addition. (Jauset-Rubio et al., 2016b) This time scale is 
much lower than that of Xpert GBS (Jones et al., 2015) and is consistent with point of 
care testing. Further work is required to investigate optimal sample preparation steps. 
 
The test in development is able to amplify DNA from all serotypes of S. agalactiae and 
produce no signal (above background) from strains of S. pyogenes. Initial specificity 
testing results are promising, however full analysis using an extended panel of bacteria 
and clinical samples is required before specificity can be assured. The test in its current 
ELONA format can detect 3.8 x 104 copies of DNA. Further sensitivity tests will be 
carried out in lateral flow format, initially with DNA and bacterial dilution series, followed 
by clinical samples. 
 
7.3.3 Aequorin as a peptide aptamer scaffold for application to GBS diagnostics 
Peptide insertion into aequorin caused decreased recombinant protein production and 
solubility; therefore research into the development of aequorin into a peptide aptamer 
scaffold was discontinued. Selection of an alternate scaffold with reporter function may 
enable the coupling of antigen detection directly to signal production. 
 
7.4 Conclusion 
 
The work on antibody- and RPA-based GBS diagnostics is promising, with both tests 
showing sensitivity to all serotypes of S. agalactiae and a lack of cross-reactivity to the 
related species S. pyogenes. Sensitivity and specificity assessment of the tests using 
clinical samples is required before full comparison can be made to currently available 
tests. Development of both systems to lateral flow formats is intended, with the 
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objective to produce rapid results in an inexpensive, simple process requiring little 
equipment which can be performed at the onset of labour. It is proposed that rapid, 
sensitive and specific testing would aid treatment of colonised mothers, resulting in 
fewer cases of early onset GBS disease, whilst reducing inappropriate antibiotic 
prescription. 
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